<?xml version="1.0" ?>
<document version="1.8" entity_encoding="single">
  <page number="1">
    <text>**CARDIOVASCULAR DISEASE AND DENTISTRY**

**DR JEE-YUN LEUNG**</text>
    <formatted_text>*Dr Jee-Yun Leung*</formatted_text>
  </page>
  <page number="2">
    <text>LEARNING OUTCOMES

2

• PART 1
• 1. Review common vascular, valvular, electrical, muscular and congenital cardiac conditions and their management (e.g. hypertension, coronary artery disease, rheumatic heart disease, infective endocarditis, arrhythmias, congenital structural defects, heart failure)
• 2. Describe potential oral findings associated with cardiac conditions
• 3. Describe the oral manifestations and manage the risks associated with common treatments used to manage cardiac conditions
• 4. Assess the associated risks of common dental procedures and modify dental treatment appropriately to safely provide care

• PART 2
• 5. Work a patient up prior to cardiac surgery
• 6. Manage angina or an acute coronary syndrome in dental practice</text>
    <formatted_text>#### Part 1

1. Review common vascular, valvular, electrical, muscular and congenital cardiac conditions and their management (e.g. hypertension, coronary artery disease, rheumatic heart disease, infective endocarditis, arrhythmias, congenital structural defects, heart failure)
2. Describe potential oral findings associated with cardiac conditions
3. Describe the oral manifestations and manage the risks associated with common treatments used to manage cardiac conditions
4. Assess the associated risks of common dental procedures and modify dental treatment appropriately to safely provide care

#### Part 2

5. Work a patient up prior to cardiac surgery
6. Manage angina or an acute coronary syndrome in dental practice</formatted_text>
    <audio_inserts count="2">
      <insert timestamp="00:11:59" confidence="4" anchor="Assess the associated risks of common dental procedures and modify dental treatm">

&gt; [!note] Lecturer — Cardiovascular Assessment
&gt; Cardiovascular conditions should be considered through their definitions and aetiology, general manifestations, and general medical management.
&gt; 
&gt; - Consider the oral manifestations of these conditions.
&gt; - Include dental management and associated treatment risks.
</insert>
      <insert timestamp="00:08:05" confidence="6" anchor="Manage angina or an acute coronary syndrome in dental practice">

&gt; [!note] Lecturer — Practical Dental Framework
&gt; Apply a practical framework to patients with cardiovascular disease in dental practice.
&gt; 
&gt; - Consider risk assessment and access to appropriate dental care.
&gt; - Consider the timing and setting of treatment, capacity and consent, and education and prevention.
&gt; - Plan pre-operative, peri-operative and post-operative care.
&gt; - Assess patients before cardiac surgery, including the balance between the risks and benefits of pre-operative dental treatment.
</insert>
    </audio_inserts>
    <images>
      <img order="0" bbox="589,327,898,752" bbox_format="xyxy_norm_1000" bbox_origin="top_left" bbox_space="page" type="clipart">
        <description>A cartoon illustration of a red heart character wearing glasses and holding an open yellow book.</description>
      </img>
    </images>
  </page>
  <page number="3">
    <text>**COMMON CARDIAC**
**CONDITIONS**

Hypertension, Coronary Artery Disease, Rheumatic Heart Disease,
Infective Endocarditis, Arrhytmias, Congenital Structural Defects, Heart
Failure</text>
    <formatted_text>- Hypertension
- Coronary Artery Disease
- Rheumatic Heart Disease
- Infective Endocarditis
- Arrhythmias
- Congenital Structural Defects
- Heart Failure</formatted_text>
  </page>
  <page number="4">
    <text>WHO INTERNATIONAL CLASSIFICATION OF DISEASES - 11TH REVISION

*   11 Diseases of the circulatory system
    *   Hypertensive diseases
    *   Hypotension
    *   Ischaemic heart diseases
    *   Diseases of coronary artery
    *   Pulmonary heart disease or diseases of pulmonary circulation
    *   Pericarditis
    *   Acute or subacute endocarditis
    *   Heart valve diseases
    *   BC20 Chronic rheumatic heart diseases, not elsewhere classified
    *   Diseases of the myocardium or cardiac chambers
    *   Cardiac arrhythmia
    *   Heart failure
    *   Diseases of arteries or arterioles
    *   Diseases of veins
*   Disorders of lymphatic vessels or lymph nodes
*   Postprocedural disorders of circulatory system
*   Neoplasms of the circulatory system
*   Developmental anomalies of the circulatory system
*   Infections of the circulatory system
*   Symptoms, signs or clinical findings of the circulatory system
*   Cerebrovascular diseases
*   Functional vascular disorders of the skin
*   JB64.4 Diseases of the circulatory system complicating pregnancy, childbirth or the puerperium

**BE2Y Other specified diseases of the circulatory system**
**BE2Z Diseases of the circulatory system, unspecified**</text>
    <formatted_text>- 11 Diseases of the circulatory system
  - Hypertensive diseases
  - Hypotension
  - Ischaemic heart diseases
  - Diseases of coronary artery
  - Pulmonary heart disease or diseases of pulmonary circulation
  - Pericarditis
  - Acute or subacute endocarditis
  - Heart valve diseases
  - BC20 Chronic rheumatic heart diseases, not elsewhere classified
  - Diseases of the myocardium or cardiac chambers
  - Cardiac arrhythmia
  - Heart failure
  - Diseases of arteries or arterioles
  - Diseases of veins
- Disorders of lymphatic vessels or lymph nodes
- Postprocedural disorders of circulatory system
- Neoplasms of the circulatory system
- Developmental anomalies of the circulatory system
- Infections of the circulatory system
- Symptoms, signs or clinical findings of the circulatory system
- Cerebrovascular diseases
- Functional vascular disorders of the skin
- JB64.4 Diseases of the circulatory system complicating pregnancy, childbirth or the puerperium
- BE2Y Other specified diseases of the circulatory system
- BE2Z Diseases of the circulatory system, unspecified</formatted_text>
    <audio_inserts count="2">
      <insert timestamp="00:13:19" confidence="5" anchor="- BE2Y Other specified diseases of the circulatory system
- BE2Z Diseases of the">

&gt; [!note] Lecturer — WHO Classification
&gt; The WHO International Classification of Diseases provides a classification system for a broad range of diseases.
&gt;
&gt; - It is revised every 10 years to maintain its currency and utility.
&gt; - The classification helps different countries and health professionals use a common language when discussing diseases.
</insert>
      <insert timestamp="01:43:42" confidence="4" anchor="#### **Muscular (Cardiomyopathies)**

- Primary – genetic/inherited, acquired
- ">

&gt; [!note] Lecturer — Heart Failure
&gt; Heart failure may result from the progression or complication of other cardiovascular conditions. It involves impairment of the heart’s ability to pump blood sufficiently to meet the body’s demands.
</insert>
    </audio_inserts>
  </page>
  <page number="5">
    <text>TYPES OF CARDIAC CONDITIONS
5

**Vascular / Ischaemic**
• Hypertension
• Hypotension
• Ischaemic heart disease (Coronary artery disease) – angina, myocardiac infarction
• Thromboembolic complications of CVD

**Valvular**
• Rheumatic fever and Rheumatic heart disease
• Infective endocarditis
• Aortic and mitral valve stenosis, regurgitation and prolapse

**Electrical (Dysrhythmias)**
• Extrasystoles (ectopics)
• Tachycardia (including Atrial fibrillation)
• Bradycardias

**Muscular (cardiomyopathies)**
• Primary – genetic/inherited, acquired
• Secondary

**Congenital**
• Cyanotic
• Acyanotic

**Heart Failure**</text>
    <formatted_text>#### Vascular / Ischaemic

- Hypertension
- Hypotension
- Ischaemic heart disease (Coronary artery disease) – angina, myocardiac infarction
- Thromboembolic complications of CVD

#### Valvular

- Rheumatic fever and Rheumatic heart disease
- Infective endocarditis
- Aortic and mitral valve stenosis, regurgitation and prolapse

#### Electrical (Dysrhythmias)

- Extrasystoles (ectopics)
- Tachycardia (including Atrial fibrillation)
- Bradycardias

#### Muscular (Cardiomyopathies)

- Primary – genetic/inherited, acquired
- Secondary

#### Congenital

- Cyanotic
- Acyanotic

#### Heart Failure</formatted_text>
  </page>
  <page number="6">
    <text>&lt;h1&gt;VASCULAR / ISCHAEMIC&lt;/h1&gt;

Hypotension

Hypertension

Ischaemic heart disease (Coronary artery disease) – angina, myocardial infarction

Thromboembolic complications of CVD</text>
    <formatted_text>- Hypotension
- Hypertension
- Ischaemic heart disease (Coronary artery disease) – angina, myocardial infarction
- Thromboembolic complications of CVD</formatted_text>
  </page>
  <page number="7">
    <text>**HYPOTENSION - DEFINITIONS**

*   **Hypotension** (chronic arterial hypotension) = systolic BP &lt;100 mmHg
*   **Pre-syncope (“near-fainting”)** = condition in which a patient feels syncope is imminent
*   **Syncope (“fainting”)** = acute fall in blood pressure, resulting in transient global cerebral hypoperfusion, causing a loss of consciousness which usually leads to loss of postural tone and falling
    *   **Vasovagal syncope** = reaction to pain, or to anxiety and fear before, during or after a dental procedure
    *   **Orthostatic hypotension** = fall in blood pressure when standing up after sitting or lying down for an extended period of time in the dental chair</text>
    <formatted_text>- **Hypotension** (chronic arterial hypotension) = systolic BP &lt;100 mmHg
- **Pre-syncope (&quot;near-fainting&quot;)** = condition in which a patient feels syncope is imminent
- **Syncope (&quot;fainting&quot;)** = acute fall in blood pressure, resulting in transient global cerebral hypoperfusion, causing a loss of consciousness which usually leads to loss of postural tone and falling
  - **Vasovagal syncope** = reaction to pain, or to anxiety and fear before, during or after a dental procedure
  - **Orthostatic hypotension** = fall in blood pressure when standing up after sitting or lying down for an extended period of time in the dental chair</formatted_text>
  </page>
  <page number="8">
    <text>ORTHOSTATIC HYPOTENSION - AETIOLOGY
8

• **Cardiac conditions**: ability for heart to pump blood (e.g. abnormal heart rhythm, heart failure, MI)

• **Autonomic nervous system**: involved in returning BP to normal (e.g. Parkinson’s disease)

• **Long-term bed rest** (e.g. hospitalised, pregnancy)

• **Low blood volume** (e.g. dehydration, anaemia, injury)

• **Medications** (e.g. antihypertensives, antidepressants)

| Primary autonomic causes | Secondary autonomic causes | Non-autonomic causes |
| :--- | :--- | :--- |
| Familial dysautonomia (Riley–Day syndrome) | B vitamin deficiency | Hypovolaemia |
| Pure autonomic failure (idiopathic orthostatic hypotension) | Alcoholism | Ageing |
| Shy–Drager syndrome | Diabetes | Prolonged bed rest |
| Dopamine Beta-hydroxylase deficiency | Parkinsonism | Pregnancy |
| | Porphyria | Drugs (e.g. antihypertensives) |

Scully C. Scully’s medical problems in dentistry. 7th ed. Edinburgh: Churchill Livingstone/Elsevier; 2014

![Table 5.12 Causes of orthostatic hypotension](L1 Cardiovascular Disease and Dentistry_figures/img_bb2aa539514c843e.webp)</text>
    <formatted_text>- **Cardiac conditions**: ability for heart to pump blood (e.g. abnormal heart rhythm, heart failure, MI)
- **Autonomic nervous system**: involved in returning BP to normal (e.g. Parkinson's disease)
- **Long-term bed rest** (e.g. hospitalised, pregnancy)
- **Low blood volume** (e.g. dehydration, anaemia, injury)
- **Medications** (e.g. antihypertensives, antidepressants)

| Primary autonomic causes | Secondary autonomic causes | Non-autonomic causes |
| :--- | :--- | :--- |
| Familial dysautonomia (Riley–Day syndrome) | B vitamin deficiency | Hypovolaemia |
| Pure autonomic failure (idiopathic orthostatic hypotension) | Alcoholism | Ageing |
| Shy–Drager syndrome | Diabetes | Prolonged bed rest |
| Dopamine Beta-hydroxylase deficiency | Parkinsonism | Pregnancy |
| | Porphyria | Drugs (e.g. antihypertensives) |

*Scully C. Scully's medical problems in dentistry. 7th ed. Edinburgh: Churchill Livingstone/Elsevier; 2014*</formatted_text>
    <audio_inserts count="1">
      <insert timestamp="00:16:01" confidence="10" anchor="- **Medications** (e.g. antihypertensives, antidepressants)">

&gt; [!note] Lecturer — Orthostatic Physiology
&gt; Moving from lying flat to standing makes it more difficult for blood in the legs and feet to return to the heart, briefly reducing the blood available for the heart to send to the brain and other organs.
&gt;
&gt; - Carotid sinus and aortic arch receptors normally detect the blood pressure change and increase the force of cardiac contraction.
</insert>
    </audio_inserts>
    <images>
      <img order="0" bbox="453,377,903,592" bbox_format="xyxy_norm_1000" bbox_origin="top_left" bbox_space="page" type="table" path="L1 Cardiovascular Disease and Dentistry_figures/img_bb2aa539514c843e.webp" caption="Table 5.12 Causes of orthostatic hypotension">
        <description>A three-column table listing causes of orthostatic hypotension categorized into Primary autonomic causes, Secondary autonomic causes, and Non-autonomic causes. Specific entries include Familial dysautonomia, Pure autonomic failure, Shy-Drager syndrome, B vitamin deficiency, Diabetes, Parkinsonism, Hypovolaemia, Ageing, and Prolonged bed rest.</description>
      </img>
    </images>
  </page>
  <page number="9">
    <text>ORTHOSTATIC HYPOTENSION – GENERAL MANIFESTATIONS 9

*   **Early symptoms**: vertigo, dizziness, visual blurring, headache, syncope
*   **Later**: tachycardia, paleness, cold extremities, sweating</text>
    <formatted_text>- **Early symptoms**: vertigo, dizziness, visual blurring, headache, syncope
- **Later**: tachycardia, paleness, cold extremities, sweating</formatted_text>
  </page>
  <page number="10">
    <text>H Y P OT E NSIO N – GE N ER AL MA NAGE MENT

Printable figure

Syncope – patient with sudden loss of consciousness and tone:
• falls to floor
• may have brief twitching or jerking (may appear similar to an epileptic seizure, but much shorter duration)

Presyncope – patient who feels faint or light-headed and may also have:
• nausea
• anxiety
• pallor
• sweating
• tinnitus

Stop dental treatment.
If the patient is in the dental chair, tilt it to be horizontal.
Provide basic life support.

Stop dental treatment.
Tilt the dental chair to horizontal or ask the patient to lie (not sit) down.
Raise the patient’s legs.
Place pregnant patients onto their left side.
Monitor consciousness by talking to the patient.

Has the patient regained alertness (without drowsiness or confusion) within 2 minutes [NB1]?

Does recovery occur rapidly?

NO
YES
YES
NO

Keep the patient reclined and supervised until the symptoms are fully resolved.
Before discharging the patient:
• check that the patient can stand unassisted without symptoms returning
• consider referring for or seeking medical advice if the patient
– is an older person
– lost consciousness while lying down or seated
– recovers slowly
– has recurrent episodes
– had no obvious trigger for the fainting or near-fainting (eg, pain, anxiety, getting up quickly after prolonged reclining).
Advise the patient not to drive or leave the practice unaccompanied.

Call 000 if not already in contact.
Provide basic life support if required.
Consider other diagnoses [NB1].
Maintain treatment as advised by the 000 operator until the patient regains consciousness or assistance arrives.

NB1: Many people with chest pain do not have angina or a heart attack, but anyone with acute chest pain requires rapid medical evaluation for potentially life-threatening causes. The likelihood of angina or heart attack increases with the number of suggestive features.

NB2: Sublingual glyceryl trinitrate (GTN) dosing is a 400 microgram spray (or 300 to 600 microgram tablet) generally administered every 5 minutes to a maximum of 3 doses. Ask patients who use GTN to bring their GTN to their dental appointment so that it can be administered if chest pain occurs.

NB3: If symptoms (pain or other features that may indicate angina) last longer than the patient’s usual angina symptoms, urgent medical evaluation of a possible heart attack or other urgent condition is required.

![Figure 13.80 Management of presyncope and syncope in dental practice](L1 Cardiovascular Disease and Dentistry_figures/img_597b9e97b07b37b2.webp)</text>
    <formatted_text>#### Syncope – patient with sudden loss of consciousness and tone

- falls to floor
- may have brief twitching or jerking (may appear similar to an epileptic seizure, but much shorter duration)

Management: stop dental treatment. If the patient is in the dental chair, tilt it to be horizontal. Provide basic life support.

#### Presyncope – patient who feels faint or light-headed

May also have:

- nausea
- anxiety
- pallor
- sweating
- tinnitus

Management: stop dental treatment. Tilt the dental chair to horizontal or ask the patient to lie (not sit) down. Raise the patient's legs. Place pregnant patients onto their left side. Monitor consciousness by talking to the patient.

#### Recovery Pathway

Has the patient regained alertness (without drowsiness or confusion) within 2 minutes [NB1]? Does recovery occur rapidly?

**If YES:** Keep the patient reclined and supervised until the symptoms are fully resolved. Before discharging the patient:

- check that the patient can stand unassisted without symptoms returning
- consider referring for or seeking medical advice if the patient
  - is an older person
  - lost consciousness while lying down or seated
  - recovers slowly
  - has recurrent episodes
  - had no obvious trigger for the fainting or near-fainting (eg, pain, anxiety, getting up quickly after prolonged reclining).
- Advise the patient not to drive or leave the practice unaccompanied.

**If NO:** Call 000 if not already in contact. Provide basic life support if required. Consider other diagnoses [NB1]. Maintain treatment as advised by the 000 operator until the patient regains consciousness or assistance arrives.

#### Notes

- NB1: Many people with chest pain do not have angina or a heart attack, but anyone with acute chest pain requires rapid medical evaluation for potentially life-threatening causes. The likelihood of angina or heart attack increases with the number of suggestive features.
- NB2: Sublingual glyceryl trinitrate (GTN) dosing is a 400 microgram spray (or 300 to 600 microgram tablet) generally administered every 5 minutes to a maximum of 3 doses. Ask patients who use GTN to bring their GTN to their dental appointment so that it can be administered if chest pain occurs.
- NB3: If symptoms (pain or other features that may indicate angina) last longer than the patient's usual angina symptoms, urgent medical evaluation of a possible heart attack or other urgent condition is required.</formatted_text>
    <audio_inserts count="1">
      <insert timestamp="00:15:16" confidence="5" anchor="- may have brief twitching or jerking (may appear similar to an epileptic seizur">
- ==Falls associated with syncope may cause secondary injury, including dental trauma==</insert>
    </audio_inserts>
    <images>
      <img order="0" bbox="41,262,398,825" bbox_format="xyxy_norm_1000" bbox_origin="top_left" bbox_space="page" type="image" path="L1 Cardiovascular Disease and Dentistry_figures/img_597b9e97b07b37b2.webp" caption="Figure 13.80 Management of presyncope and syncope in dental practice"/>
    </images>
  </page>
  <page number="11">
    <text>H Y P E R T E N S I O N - D E F I N I T I O N

*   **Essential (primary) hypertension (95%):** High blood pressure for which a secondary cause cannot be found.
*   **Secondary hypertension (5%):** Systolic BP &gt;140mmHg and diastolic BP &gt;90mmHg with an identifiable cause.

National Heart Foundation of Australia – Classification of Blood Pressure

| Diagnostic category* | Systolic (mmHg) | Diastolic (mmHg) |
| :--- | :---: | :---: |
| Optimal | &lt;120 and | &lt;80 |
| Normal | 120–129 and/or | 80–84 |
| High-normal | 130–139 and/or | 85–89 |
| Grade 1 (mild) hypertension | 140–159 and/or | 90–99 |
| Grade 2 (moderate) hypertension | 160–179 and/or | 100–109 |
| Grade 3 (severe) hypertension | ≥180 and/or | ≥110 |
| Isolated systolic hypertension | &gt;140 and | &lt;90 |

*When a patient’s systolic and diastolic blood pressure levels fall into different categories, the higher diagnostic category and recommended actions apply.

![Table 2.1 Classification of clinic blood pressure levels in adults](L1 Cardiovascular Disease and Dentistry_figures/img_a9ecc20dbdaa4c90.webp)</text>
    <formatted_text>#### Hypertension Definition

- **Essential (primary) hypertension (95%):** High blood pressure for which a secondary cause cannot be found.
- **Secondary hypertension (5%):** Systolic BP &gt;140 mmHg and diastolic BP &gt;90 mmHg with an identifiable cause.

#### National Heart Foundation of Australia – Classification of Blood Pressure

| Diagnostic category* | Systolic (mmHg) | Diastolic (mmHg) |
| :--- | :---: | :---: |
| Optimal | &lt;120 and | &lt;80 |
| Normal | 120–129 and/or | 80–84 |
| High-normal | 130–139 and/or | 85–89 |
| Grade 1 (mild) hypertension | 140–159 and/or | 90–99 |
| Grade 2 (moderate) hypertension | 160–179 and/or | 100–109 |
| Grade 3 (severe) hypertension | ≥180 and/or | ≥110 |
| Isolated systolic hypertension | &gt;140 and | &lt;90 |

*When a patient's systolic and diastolic blood pressure levels fall into different categories, the higher diagnostic category and recommended actions apply.</formatted_text>
    <images>
      <img order="0" bbox="147,547,763,760" bbox_format="xyxy_norm_1000" bbox_origin="top_left" bbox_space="page" type="table" path="L1 Cardiovascular Disease and Dentistry_figures/img_a9ecc20dbdaa4c90.webp" caption="Table 2.1 Classification of clinic blood pressure levels in adults">
        <description>Table: A classification chart for clinic blood pressure levels in adults, organizing diagnostic categories (from Optimal to Isolated systolic hypertension) against their corresponding Systolic and Diastolic mmHg ranges.</description>
      </img>
    </images>
  </page>
  <page number="12">
    <text>HYPERTENSION - AETIOLOGY

| Essential hypertension | Secondary hypertension |
| :--- | :--- |
| • Genetic predisposition | • Renal disease (80%) |
| • High basal metabolic index | • Endocrine conditions: pregnancy, Cushing syndrome, corticosteroids, hyperaldosteronism, acromegaly |
| • Sympathetic overactivity (40% have raised catecholamines and noradrenaline) | • Cerebral disease: cerebral oedema (mainly strokes, head injuries or tumours) |
| • High alcohol, salt intake | • Coarctation of aorta |
| | • Sleep apnoea |
| | • Drugs: oral contraceptive pill, HRT, corticosteroids, NSAIDs, sympathomimetics (decongestants, diet pills, cocaine), stimulants (amphetamine) cyclosporine / tacrolimus, excess alcohol, SNRIs and MAOIs, haemopoietic drugs |

![](L1 Cardiovascular Disease and Dentistry_figures/img_42bdffbce5f92529.webp)</text>
    <formatted_text>| Essential hypertension | Secondary hypertension |
| :--- | :--- |
| Genetic predisposition | Renal disease (80%) |
| High basal metabolic index | Endocrine conditions: pregnancy, Cushing syndrome, corticosteroids, hyperaldosteronism, acromegaly |
| Sympathetic overactivity (40% have raised catecholamines and noradrenaline) | Cerebral disease: cerebral oedema (mainly strokes, head injuries or tumours) |
| High alcohol, salt intake | Coarctation of aorta |
| | Sleep apnoea |
| | Drugs: oral contraceptive pill, HRT, corticosteroids, NSAIDs, sympathomimetics (decongestants, diet pills, cocaine), stimulants (amphetamine), cyclosporine/tacrolimus, excess alcohol, SNRIs and MAOIs, haemopoietic drugs |</formatted_text>
    <images>
      <img order="0" bbox="79,324,871,739" bbox_format="xyxy_norm_1000" bbox_origin="top_left" bbox_space="page" type="table" path="L1 Cardiovascular Disease and Dentistry_figures/img_42bdffbce5f92529.webp">
        <description>A two-column table comparing the aetiology of essential hypertension and secondary hypertension. The left column lists factors such as genetic predisposition, high basal metabolic index, sympathetic overactivity, and high alcohol/salt intake. The right column details causes like renal disease, endocrine conditions, cerebral disease, coarctation of the aorta, sleep apnoea, and various drugs.</description>
      </img>
    </images>
  </page>
  <page number="13">
    <text>**HYPERTENSION - EPIDEMILOGY**

**Australian Institute of Health and Welfare**
*   39% of Australians &gt;18yo have hypertension (~7.2 million adults)
*   Of adults with hypertension
    *   80-82% of those &lt;54yo had uncontrolled hypertension
    *   65% had been dispensed antihypertensive medications
*   Hypertensive disease contributed to 13% of all Australian deaths in 2023

*   Nearly 1 in 20 (5%) Australian women aged 15-44 giving birth had new onset hypertension in pregnancy
*   24% of ATSI adults &gt;18yo had hypertension 2022-2023

&lt;u&gt;https://www.aihw.gov.au/reports/risk-factors/hypertension/contents/summary&lt;/u&gt;</text>
    <formatted_text>#### Australian Institute of Health and Welfare

- 39% of Australians &gt;18yo have hypertension (~7.2 million adults)
- Of adults with hypertension:
  - 80–82% of those &lt;54yo had uncontrolled hypertension
  - 65% had been dispensed antihypertensive medications
- Hypertensive disease contributed to 13% of all Australian deaths in 2023
- Nearly 1 in 20 (5%) Australian women aged 15–44 giving birth had new onset hypertension in pregnancy
- 24% of ATSI adults &gt;18yo had hypertension 2022–2023

https://www.aihw.gov.au/reports/risk-factors/hypertension/contents/summary</formatted_text>
  </page>
  <page number="14">
    <text>HYPERTENSION – GENERAL MANIFESTATIONS

| Primary | Complications |
| :--- | :--- |
| Usually asymptomatic | Arteriosclerosis&lt;br&gt;Cerebrovascular disease (stroke)&lt;br&gt;Peripheral vascular disease&lt;br&gt;Hypertensive retinopathy&lt;br&gt;Hypertensive heart disease&lt;br&gt;Hypertensive renal disease&lt;br&gt;Hypertensive crisis |
| Advanced cases: headache, blurred vision, tinnitus, fatigue, dizziness, angina | |

![](L1 Cardiovascular Disease and Dentistry_figures/img_6d4d24cd3a5e8550.webp)</text>
    <formatted_text>| Primary | Complications |
| :--- | :--- |
| Usually asymptomatic | Arteriosclerosis |
| Advanced cases: headache, blurred vision, tinnitus, fatigue, dizziness, angina | Cerebrovascular disease (stroke) |
| | Peripheral vascular disease |
| | Hypertensive retinopathy |
| | Hypertensive heart disease |
| | Hypertensive renal disease |
| | Hypertensive crisis |</formatted_text>
    <audio_inserts count="1">
      <insert timestamp="00:21:33" confidence="15" anchor="| | Hypertensive renal disease |
| | Hypertensive crisis |">

&gt; [!note] Lecturer — Hypertension Damage
&gt; Prolonged, uncontrolled hypertension may affect myocardial structure, the coronary vasculature and the cardiac conduction system. Hypertensive renal disease results from chronic high blood pressure damaging the kidneys, while hypertensive crisis carries a high risk of complications involving blood vessels and other organs.
</insert>
    </audio_inserts>
    <images>
      <img order="0" bbox="121,303,791,752" bbox_format="xyxy_norm_1000" bbox_origin="top_left" bbox_space="page" type="table" path="L1 Cardiovascular Disease and Dentistry_figures/img_6d4d24cd3a5e8550.webp">
        <description>A two-column table comparing the primary manifestations of hypertension (usually asymptomatic, or headache, blurred vision, tinnitus, fatigue, dizziness, angina in advanced cases) with its complications (arteriosclerosis, cerebrovascular disease, peripheral vascular disease, and hypertensive retinopathy, heart disease, renal disease, or crisis).</description>
      </img>
    </images>
  </page>
  <page number="15">
    <text>HYPERTENSION – GENERAL MANAGEMENT

• **Identify and manage risk factors:** physical activity, smoking cessation, weight control, diet, alcohol intake, etc.

• Assess presence/absence of organ damage

• **Pharmacologic strategies:** most widely used first-line ACEIs and ARBs

Check eligibility for absolute CVD risk assessment

Eligible
Conduct absolute CVD risk assessment www.cvdcheck.org.au

Not eligible
Define risk based on clinical assessment of target organ damage, relevant comorbidities or known vascular disease

High risk &gt;15%
Moderate risk 10–15%
Low risk &lt;10%

Provide lifestyle advice

a. Start immediate drug treatment
b. Manage associated conditions
c. Review according to clinical context

Any of the following?
a. BP persistently ≥160/100mmHg
b. Family history of premature CVD
c. Aboriginal or Torres Strait Islander

Yes
Start drug treatment

No
Review BP

Is BP persistently ≥160/100 mmHg?

Yes
Start drug treatment

No
If SBP = 140–159 mmHg, review BP after 2 months of lifestyle advice

SBP 140–159 mmHg or DBP 90–99 mmHg
Start drug treatment

SBP 130–139 mmHg or DBP 85–90 mmHg
Review BP in 6 months

Review according to clinical context

https://www.heartfoundation.org.au/for-professionals/hypertension

![Figure 6.1 Treatment strategy for patients with newly diagnosed hypertension](L1 Cardiovascular Disease and Dentistry_figures/img_9f88b9c6cddc2a6f.webp)</text>
    <formatted_text>- **Identify and manage risk factors:** physical activity, smoking cessation, weight control, diet, alcohol intake, etc.
- Assess presence/absence of organ damage
- **Pharmacologic strategies:** most widely used first-line ACEIs and ARBs

#### Absolute CVD Risk Assessment

Check eligibility for absolute CVD risk assessment:

- **Eligible:** Conduct absolute CVD risk assessment — www.cvdcheck.org.au
- **Not eligible:** Define risk based on clinical assessment of target organ damage, relevant comorbidities or known vascular disease

Risk categories:

- High risk &gt;15%
- Moderate risk 10–15%
- Low risk &lt;10%

#### Treatment Pathway

Provide lifestyle advice:

1. Start immediate drug treatment
2. Manage associated conditions
3. Review according to clinical context

Any of the following?

- BP persistently ≥160/100 mmHg
- Family history of premature CVD
- Aboriginal or Torres Strait Islander

- **Yes:** Start drug treatment
- **No:** Review BP

Is BP persistently ≥160/100 mmHg?

- **Yes:** Start drug treatment
- **No:** If SBP = 140–159 mmHg, review BP after 2 months of lifestyle advice

- SBP 140–159 mmHg or DBP 90–99 mmHg → start drug treatment
- SBP 130–139 mmHg or DBP 85–90 mmHg → review BP in 6 months
- Review according to clinical context

https://www.heartfoundation.org.au/for-professionals/hypertension</formatted_text>
    <images>
      <img order="0" bbox="481,236,887,785" bbox_format="xyxy_norm_1000" bbox_origin="top_left" bbox_space="page" type="diagram" path="L1 Cardiovascular Disease and Dentistry_figures/img_9f88b9c6cddc2a6f.webp" caption="Figure 6.1 Treatment strategy for patients with newly diagnosed hypertension">
        <description>A color-coded flowchart titled 'Figure 6.1 Treatment strategy for patients with newly diagnosed hypertension' outlines clinical decision pathways based on CVD risk assessment and blood pressure levels. The chart branches into High (&gt;15%), Moderate (10–15%), and Low (&lt;10%) risk categories, leading to specific recommendations such as immediate drug treatment, lifestyle advice review, or BP monitoring intervals.</description>
      </img>
    </images>
  </page>
  <page number="16">
    <text>HYPERTENSION – GENERAL MANAGEMENT

[Flowchart Text]
Antihypertensive drug treatment*

1. Starting drug treatment†
Start with low-moderate recommended dose of a first-line drug. If not well tolerated, change to a different drug class, again starting with a low-moderate recommended dose.

Lifestyle advice‡
Manage associated conditions

2. If target not reached after 3 months*
Add a second drug from a different pharmacological class at a low–moderate dose, rather than increasing the dose of the first drug. This maximises antihypertensive efficacy, while minimising adverse effects.

3. If target not reached after 3 months*
If both antihypertensive drugs have been well tolerated, increase the dose of one drug (excluding thiazide diuretics) incrementally to the maximal recommended dose before increasing the dose of the other drug.

4. If target not reached after 3 months*
If, despite maximal doses of at least two drugs, a third drug class may be started at a low–moderate dose. It is advisable to reassess for non-adherence, secondary hypertension and hypertensive effects of other drugs, treatment resistant state due to sleep apnoea, undisclosed use of alcohol or recreational drugs or high salt intake.

5. If blood pressure remains elevated, consider seeking specialist advice

*Maximum effect of drug likely to be seen in 4–6 weeks. If baseline blood pressure is severely elevated earlier reviews may be considered. For steps 1–4, review every 4-6 weeks for tolerance, efficacy and adverse effects. †All patients should receive lifestyle advice with follow-up based on clinical context.

| First drug | Second drug | Comment |
| :--- | :--- | :--- |
| **Effective combination** | | |
| ACE inhibitor or ARB* | plus | Calcium channel blocker | Particularly useful in presence of diabetes and/or lipid abnormalities&lt;sup&gt;124&lt;/sup&gt; |
| ACE inhibitor or ARB* | plus | Thiazide diuretic | Useful in presence of heart failure or post stroke |
| ACE inhibitor or ARB* | plus | Beta-blocker | Recommended post myocardial infarction or in patients with heart failure&lt;sup&gt;†&lt;/sup&gt; |
| Beta-blocker | plus | Dihydropyridine calcium channel blocker | Useful in presence of symptomatic coronary heart disease |
| Thiazide diuretic | plus | Calcium channel blocker | |
| Thiazide diuretic | plus | Beta-blocker | Not recommended in presence of glucose intolerance, metabolic syndrome or established diabetes |
| **Combinations to use with care** | | |
| Diltiazem | plus | Beta-blocker | Due to risk of heart block, but risk is less than with verapamil |
| ACE inhibitor or ARB | plus | Potassium-sparing diuretic | Due to risk of hyperkalaemia |
| **Combinations to avoid** | | |
| ACE inhibitor | plus | ARB | Increased risk of renal dysfunction&lt;sup&gt;120&lt;/sup&gt; |
| Verapamil | plus | Beta-blocker | Due to risk of heart block |

ACE, angiotensin-converting enzyme; ARB, angiotensin receptor blocker
*In head-to-head trials ACE inhibitors and ARB’s are equally effective in blood pressure reduction and prevention of cardiovascular events overall, however may have important differences in their efficacy, so that they are not interchangeable, in some clinical conditions.
†Carvedilol; bisoprolol (beta-1 selective antagonist); metoprolol extended release (beta-1 selective antagonist); nebivolol.&lt;sup&gt;125&lt;/sup&gt;

https://www.heartfoundation.org.au/for-professionals/hypertension

![Figure 6.2 Drug treatment strategy to reach blood pressure target](L1 Cardiovascular Disease and Dentistry_figures/img_3263ba8fc77e369f.webp)
![Table 6.2 Effective drug combinations](L1 Cardiovascular Disease and Dentistry_figures/img_d422e8c09b0c4822.webp)</text>
    <formatted_text>#### Antihypertensive Drug Treatment

1. **Starting drug treatment** — Start with low-moderate recommended dose of a first-line drug. If not well tolerated, change to a different drug class, again starting with a low-moderate recommended dose.

   Lifestyle advice; manage associated conditions.

2. **If target not reached after 3 months** — Add a second drug from a different pharmacological class at a low–moderate dose, rather than increasing the dose of the first drug. This maximises antihypertensive efficacy, while minimising adverse effects.

3. **If target not reached after 3 months** — If both antihypertensive drugs have been well tolerated, increase the dose of one drug (excluding thiazide diuretics) incrementally to the maximal recommended dose before increasing the dose of the other drug.

4. **If target not reached after 3 months** — If, despite maximal doses of at least two drugs, a third drug class may be started at a low–moderate dose. It is advisable to reassess for non-adherence, secondary hypertension and hypertensive effects of other drugs, treatment resistant state due to sleep apnoea, undisclosed use of alcohol or recreational drugs or high salt intake.

5. **If blood pressure remains elevated** — Consider seeking specialist advice.

&gt; *Maximum effect of drug likely to be seen in 4–6 weeks. If baseline blood pressure is severely elevated earlier reviews may be considered. For steps 1–4, review every 4–6 weeks for tolerance, efficacy and adverse effects. All patients should receive lifestyle advice with follow-up based on clinical context.*

#### Drug Combinations

| First drug | Second drug | Comment |
| :--- | :--- | :--- |
| **Effective combination** | | |
| ACE inhibitor or ARB* | plus Calcium channel blocker | Particularly useful in presence of diabetes and/or lipid abnormalities |
| ACE inhibitor or ARB* | plus Thiazide diuretic | Useful in presence of heart failure or post stroke |
| ACE inhibitor or ARB* | plus Beta-blocker | Recommended post myocardial infarction or in patients with heart failure† |
| Beta-blocker | plus Dihydropyridine calcium channel blocker | Useful in presence of symptomatic coronary heart disease |
| Thiazide diuretic | plus Calcium channel blocker | |
| Thiazide diuretic | plus Beta-blocker | Not recommended in presence of glucose intolerance, metabolic syndrome or established diabetes |
| **Combinations to use with care** | | |
| Diltiazem | plus Beta-blocker | Due to risk of heart block, but risk is less than with verapamil |
| ACE inhibitor or ARB | plus Potassium-sparing diuretic | Due to risk of hyperkalaemia |
| **Combinations to avoid** | | |
| ACE inhibitor | plus ARB | Increased risk of renal dysfunction |
| Verapamil | plus Beta-blocker | Due to risk of heart block |

ACE, angiotensin-converting enzyme; ARB, angiotensin receptor blocker

- \*In head-to-head trials ACE inhibitors and ARBs are equally effective in blood pressure reduction and prevention of cardiovascular events overall, however may have important differences in their efficacy, so that they are not interchangeable in some clinical conditions.
- †Carvedilol; bisoprolol (beta-1 selective antagonist); metoprolol extended release (beta-1 selective antagonist); nebivolol.

https://www.heartfoundation.org.au/for-professionals/hypertension</formatted_text>
    <images>
      <img order="0" bbox="41,246,327,780" bbox_format="xyxy_norm_1000" bbox_origin="top_left" bbox_space="page" type="figure" path="L1 Cardiovascular Disease and Dentistry_figures/img_3263ba8fc77e369f.webp" caption="Figure 6.2 Drug treatment strategy to reach blood pressure target">
        <description>A vertical flowchart titled 'Figure 6.2 Drug treatment strategy to reach blood pressure target' outlining a five-step clinical protocol for antihypertensive therapy. The chart details sequential steps from starting drug treatment to seeking specialist advice, with parallel columns on the left indicating ongoing 'Lifestyle advice' and management of associated conditions.</description>
      </img>
      <img order="1" bbox="432,323,888,670" bbox_format="xyxy_norm_1000" bbox_origin="top_left" bbox_space="page" type="table" path="L1 Cardiovascular Disease and Dentistry_figures/img_d422e8c09b0c4822.webp" caption="Table 6.2 Effective drug combinations">
        <description>A clinical reference table categorizing antihypertensive drug pairings into three sections: 'Effective combination' (green header), 'Combinations to use with care' (yellow header), and 'Combinations to avoid' (red header). The columns list the first drug, second drug, and specific comments regarding their usage or risks, such as hyperkalaemia or heart block.</description>
      </img>
    </images>
  </page>
  <page number="17">
    <text>HYPERTENSION – ORAL MANIFESTATIONS

• No recognised oral manifestations from disease
• Hypertensive crisis – facial palsy may occur.
• Side-effects of antihypertensive drugs:

| Drug Class | Examples | Oral Side Effects |
| :--- | :--- | :--- |
| ACEI | Captopril, Ramipril | Burning mouth syndrome, angioedema, ulceration, dysguesia, dry mouth, lichenoid reactions, coughing, taste disturbances |
| ARB | Candesartan, Irbesartan, Losartan, Valsartan | Facial flushing, taste disturbances, dry mouth, increased gag reflex, lupoid reactions |
| β-adrenergic blockers | **β₁ selective (not bronchioles):** Atenolol, Bisoprolol , Metoprolol&lt;br&gt;&lt;br&gt;**Non-selective:** Propranolol | Dry mouth, lichenoid lesions, paraesthesia, taste changes |
| Calcium channel blockers | **Dihydropyridines** (vascular selective):&lt;br&gt;Amlodipine, Nifedipine, Nicardipine&lt;br&gt;&lt;br&gt;**Non-dihydropyridines** (heart rate lowering):&lt;br&gt;Phenylalkylamine class: Verapamil, Gallopamil&lt;br&gt;Benzothiazepine class: Diltiazem | Gingival hyperplasia (dihydropyridines), angioedema, facial flushing, xerostomia, metallic taste (diltiazem) |
| Diuretics | Hydrochlorothiazide, Furosemide, Spironolactone | Dry mouth |

![](L1 Cardiovascular Disease and Dentistry_figures/img_758f1d41c95fcbf0.webp)</text>
    <formatted_text>- No recognised oral manifestations from disease
- Hypertensive crisis – facial palsy may occur
- Side-effects of antihypertensive drugs:

| Drug Class | Examples | Oral Side Effects |
| :--- | :--- | :--- |
| ACEI | Captopril, Ramipril | Burning mouth syndrome, angioedema, ulceration, dysguesia, dry mouth, lichenoid reactions, coughing, taste disturbances |
| ARB | Candesartan, Irbesartan, Losartan, Valsartan | Facial flushing, taste disturbances, dry mouth, increased gag reflex, lupoid reactions |
| β-adrenergic blockers | β₁ selective (not bronchioles): Atenolol, Bisoprolol, Metoprolol; Non-selective: Propranolol | Dry mouth, lichenoid lesions, paraesthesia, taste changes |
| Calcium channel blockers | Dihydropyridines (vascular selective): Amlodipine, Nifedipine, Nicardipine; Non-dihydropyridines (heart rate lowering): Phenylalkylamine class — Verapamil, Gallopamil; Benzothiazepine class — Diltiazem | Gingival hyperplasia (dihydropyridines), angioedema, facial flushing, xerostomia, metallic taste (diltiazem) |
| Diuretics | Hydrochlorothiazide, Furosemide, Spironolactone | Dry mouth |</formatted_text>
    <images>
      <img order="0" bbox="64,366,892,827" bbox_format="xyxy_norm_1000" bbox_origin="top_left" bbox_space="page" type="table" path="L1 Cardiovascular Disease and Dentistry_figures/img_758f1d41c95fcbf0.webp">
        <description>A three-column table listing antihypertensive drug classes (ACEI, ARB, β-adrenergic blockers, Calcium channel blockers, Diuretics), their specific examples, and the associated oral side effects.</description>
      </img>
    </images>
  </page>
  <page number="18">
    <text>HYPERTENSION –ORAL MANAGEMENT - RISK ASSESSMENT

• General dental treatment possible if blood pressure is controlled
• Drug interactions and side effects
• Decrease endogenous catecholamine release: dental anxiety, “white coat syndrome”, manage pain
• Underlying disease or problems (cardiac/renal/endocrine)
• Avoid elective dental treatment if &gt;180/110 mmHg $\rightarrow$ refer for medical assessment
• Anaesthetic and sedation risks:

&lt;table&gt;
  &lt;tr&gt;
    &lt;th&gt;BP (Systolic/Diastolic)&lt;/th&gt;
    &lt;th&gt;Stage&lt;/th&gt;
    &lt;th&gt;ASA Grade&lt;/th&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td&gt;&amp;lt;140 and &amp;lt;90&lt;/td&gt;
    &lt;td&gt;-&lt;/td&gt;
    &lt;td&gt;I&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td&gt;140-159 and 90-99&lt;/td&gt;
    &lt;td&gt;1 Borderline/Mild&lt;/td&gt;
    &lt;td&gt;II&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td&gt;160-179 and 95-109&lt;/td&gt;
    &lt;td&gt;2 Moderate&lt;/td&gt;
    &lt;td&gt;III&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td&gt;&amp;gt;180 and &amp;gt;110&lt;/td&gt;
    &lt;td&gt;3 Severe&lt;/td&gt;
    &lt;td&gt;IV&lt;/td&gt;
  &lt;/tr&gt;
&lt;/table&gt;

![](L1 Cardiovascular Disease and Dentistry_figures/img_1a56475bbe540a61.webp)</text>
    <formatted_text>#### Risk Assessment

- General dental treatment possible if blood pressure is controlled
- Drug interactions and side effects
- Decrease endogenous catecholamine release: dental anxiety, &quot;white coat syndrome&quot;, manage pain
- Underlying disease or problems (cardiac/renal/endocrine)
- Avoid elective dental treatment if &gt;180/110 mmHg → refer for medical assessment
- Anaesthetic and sedation risks:

| BP (Systolic/Diastolic) | Stage | ASA Grade |
| :--- | :--- | :---: |
| &lt;140 and &lt;90 | – | I |
| 140–159 and 90–99 | 1 Borderline/Mild | II |
| 160–179 and 95–109 | 2 Moderate | III |
| &gt;180 and &gt;110 | 3 Severe | IV |</formatted_text>
    <images>
      <img order="0" bbox="207,568,711,712" bbox_format="xyxy_norm_1000" bbox_origin="top_left" bbox_space="page" type="table" path="L1 Cardiovascular Disease and Dentistry_figures/img_1a56475bbe540a61.webp">
        <description>A data table correlating blood pressure ranges (systolic/diastolic) with hypertension stages and corresponding ASA physical status classification grades.</description>
      </img>
    </images>
  </page>
  <page number="19">
    <text>HYPERTENSION – ORAL MANAGEMENT

Risk factor when evaluating peri-procedural bleeding risk

(Therapeutic Guidelines v4 2026 – Figure 13.73)

19

![Is the dental PROCEDURE likely to cause prolonged bleeding (see table classifying procedural bleeding risk)? NO -&gt; Treat using approach in this table. YES -&gt; Does the patient have any of the following MEDICAL CONDITIONS? a medical condition affecting haemostasis, signs of bleeding, bruising or jaundice, a personal or family history of prolonged bleeding after dental or other procedures. YES -&gt; Ask the medical practitioner or team for details of the medical history to clarify patient risk factors and ways to modify them (including review of medications). Create a management plan. Consider consultation with a specialist medical or dental team. Consider NB2: the level of risk, the treatment setting and access to specific haemostatic measures, access to after-hours care, especially for rural and remote patients. Referral may be appropriate for higher risk procedures or conditions requiring measures outside the practitioner's skill set. NO -&gt; Is the patient taking an ANITHROMBOTIC DRUG (including over-the-counter aspirin) NB3? YES -&gt; Is the antithrombotic drug for long-term (indefinite) use? YES -&gt; Defer nonurgent invasive dental procedures until antithrombotic therapy is complete. NO -&gt; Does the patient have AN ADDITIONAL FACTOR that heightens risk in conjunction with an antithrombotic, such as: uncontrolled hypertension (eg systolic blood pressure more than 160 mmHg), suboptimal anticoagulation control (eg fluctuating or high INR), age older than 85 years or frailty, other medication that can impair haemostasis? NO -&gt; Manage according to the type of antithrombotic drug being used (see advice on management of antithrombotics). Seek advice from a medical practitioner or a specialist dental team if uncertain about assessing or managing bleeding risk. NO -&gt; Is the patient taking any other medication that can impair haemostasis? YES -&gt; See advice for patients taking other medications. NO -&gt; Treat with standard approach.](L1 Cardiovascular Disease and Dentistry_figures/img_68b8ef44488ae199.webp)</text>
    <formatted_text>Risk factor when evaluating peri-procedural bleeding risk

*(Therapeutic Guidelines v4 2026 – Figure 13.73)*</formatted_text>
    <images>
      <img order="0" bbox="63,185,341,806" bbox_format="xyxy_norm_1000" bbox_origin="top_left" bbox_space="page" type="image" path="L1 Cardiovascular Disease and Dentistry_figures/img_68b8ef44488ae199.webp" caption="Is the dental PROCEDURE likely to cause prolonged bleeding (see table classifying procedural bleeding risk)? NO -&gt; Treat using approach in this table. YES -&gt; Does the patient have any of the following MEDICAL CONDITIONS? a medical condition affecting haemostasis, signs of bleeding, bruising or jaundice, a personal or family history of prolonged bleeding after dental or other procedures. YES -&gt; Ask the medical practitioner or team for details of the medical history to clarify patient risk factors and ways to modify them (including review of medications). Create a management plan. Consider consultation with a specialist medical or dental team. Consider [NB2]: the level of risk, the treatment setting and access to specific haemostatic measures, access to after-hours care, especially for rural and remote patients. Referral may be appropriate for higher risk procedures or conditions requiring measures outside the practitioner's skill set. NO -&gt; Is the patient taking an ANITHROMBOTIC DRUG (including over-the-counter aspirin) [NB3]? YES -&gt; Is the antithrombotic drug for long-term (indefinite) use? YES -&gt; Defer nonurgent invasive dental procedures until antithrombotic therapy is complete. NO -&gt; Does the patient have AN ADDITIONAL FACTOR that heightens risk in conjunction with an antithrombotic, such as: uncontrolled hypertension (eg systolic blood pressure more than 160 mmHg), suboptimal anticoagulation control (eg fluctuating or high INR), age older than 85 years or frailty, other medication that can impair haemostasis? NO -&gt; Manage according to the type of antithrombotic drug being used (see advice on management of antithrombotics). Seek advice from a medical practitioner or a specialist dental team if uncertain about assessing or managing bleeding risk. NO -&gt; Is the patient taking any other medication that can impair haemostasis? YES -&gt; See advice for patients taking other medications. NO -&gt; Treat with standard approach."/>
    </images>
  </page>
  <page number="20">
    <text>**HYPERTENSION – ORAL MANAGEMENT**

**Access:**
• Timing / Appointments: Short, minimally stressful, ideally late morning
• Positioning: orthostatic hypotension (ACEIs, ARBs)
• Setting: hospital if severe/uncontrolled hypertension and urgent dental care needed

**Education/Prevention**
• Common risk factor approach: smoking, alcohol, diet
• Antihypertensives: dry mouth management
• Calcium channel blockers (e.g. amlodipine) $\rightarrow$ gingiva enlargement
    • Minimise with good oral hygiene and perio debridement
    • Extensive enlargement $\rightarrow$ specialist periodontal and medical management</text>
    <formatted_text>#### Access

- **Timing/Appointments:** Short, minimally stressful, ideally late morning
- **Positioning:** orthostatic hypotension (ACEIs, ARBs)
- **Setting:** hospital if severe/uncontrolled hypertension and urgent dental care needed

#### Education/Prevention

- Common risk factor approach: smoking, alcohol, diet
- Antihypertensives: dry mouth management
- Calcium channel blockers (e.g. amlodipine) → gingiva enlargement
  - Minimise with good oral hygiene and perio debridement
  - Extensive enlargement → specialist periodontal and medical management</formatted_text>
  </page>
  <page number="21">
    <text>HYPERTENSION – ORAL MANAGEMENT

**Surgery**
• Check BP control prior to treatment
• Manage dental anxiety (exacerbates hypertension)
• Avoid NSAIDs = diuretic + either of:
    • Angiotensin converting enzyme inhibitor (e.g. perindopril)
    • Angiotensin II receptor blocker (e.g. candesartan)
    • $\rightarrow$ risk of acute kidney injury
• Sedation may be helpful to control stress/blood pressure
    • Pending nature and severity of underlying disease</text>
    <formatted_text>#### Surgery

- Check BP control prior to treatment
- Manage dental anxiety (exacerbates hypertension)
- Avoid NSAIDs = diuretic + either of:
  - Angiotensin converting enzyme inhibitor (e.g. perindopril)
  - Angiotensin II receptor blocker (e.g. candesartan)
  - → risk of acute kidney injury
- Sedation may be helpful to control stress/blood pressure
  - Pending nature and severity of underlying disease</formatted_text>
  </page>
  <page number="22">
    <text>HYPERTENSION – ORAL MANAGEMENT – VASOCONSTRICTORS IN LA

**How much adrenaline-containing LA can we use?**

• Profound anaesthesia for pain and anxiety control is important to ↓ endogenous catecholamine release

• LA with adrenaline:
  • Delays systemic absorption
  • Increases duration of anaesthesia
  • Provides local haemostasis
  • Reduces the dose required

• Poses a theoretical risk
  • Stimulates α and β adrenergic receptors (tachycardia, increase BP)
  • Irritates cardiac pacemakers cells (arrhythmias)

22</text>
    <formatted_text>#### How much adrenaline-containing LA can we use?

- Profound anaesthesia for pain and anxiety control is important to ↓ endogenous catecholamine release

LA with adrenaline:

- Delays systemic absorption
- Increases duration of anaesthesia
- Provides local haemostasis
- Reduces the dose required

Poses a theoretical risk:

- Stimulates α and β adrenergic receptors (tachycardia, increase BP)
- Irritates cardiac pacemaker cells (arrhythmias)</formatted_text>
    <audio_inserts count="1">
      <insert timestamp="00:28:56" confidence="7" anchor="- Irritates cardiac pacemaker cells (arrhythmias)">

&gt; [!note] Lecturer — Adrenaline Exposure
&gt; The systemic effects of vasoconstrictors depend on the dose and route of administration. Intravenous administration produces greater systemic effects, and the scientific evidence regarding a maximum safe dose remains limited.
</insert>
    </audio_inserts>
  </page>
  <page number="23">
    <text>**HYPERTENSION – ORAL MANAGEMENT – VASOCONSTRICTORS IN LA**

**How much adrenaline-containing LA can we use?**

*   Evidence regarding maximum safe dose of adrenaline is lacking
    *   &lt;u&gt;Malamed 2004&lt;/u&gt;: Most frequently quoted. Recommended max 0.04mg adrenaline per dental appt.
        *   ~2 cartridges containing 1:100,000 adr (0.018mg per 1.8ml cartridge, or 0.022mg per 2.2ml cartridge).
    *   &lt;u&gt;Tolas et al 1982, Cioffi et al 1985&lt;/u&gt;: Evaluated healthy pts following 2% lignocaine 1:100,000 adr injection
        *   After 1.8ml (1 cartridge): plasma levels incr 2-3x, no signif changes in BP or HR
        *   After 5.4ml (3 cartridges): plasma levels incr 5-6x, signif incr HR and BP
    *   &lt;u&gt;Godzieba et al 2014&lt;/u&gt;: systematic review of 11 RCTs
        *   Use of ≤4 cartridges of lignocaine with 1:100,000 adrenaline seems relatively safe for cardiovascular compromised patients
    *   &lt;u&gt;Serrera Figallo et al 2012&lt;/u&gt;: systematic review of RCTs
        *   Possible to use a dose between 1.8ml and 3.6ml on a general basis in patients with CVD

23</text>
    <formatted_text>#### How much adrenaline-containing LA can we use?

- Evidence regarding maximum safe dose of adrenaline is lacking:
  - **Malamed 2004:** Most frequently quoted. Recommended max 0.04 mg adrenaline per dental appointment.
    - ~2 cartridges containing 1:100,000 adrenaline (0.018 mg per 1.8 ml cartridge, or 0.022 mg per 2.2 ml cartridge)
  - **Tolas et al 1982, Cioffi et al 1985:** Evaluated healthy patients following 2% lignocaine 1:100,000 adrenaline injection
    - After 1.8 ml (1 cartridge): plasma levels increased 2–3x, no significant changes in BP or HR
    - After 5.4 ml (3 cartridges): plasma levels increased 5–6x, significant increase in HR and BP
  - **Godzieba et al 2014:** Systematic review of 11 RCTs
    - Use of ≤4 cartridges of lignocaine with 1:100,000 adrenaline seems relatively safe for cardiovascular compromised patients
  - **Serrera Figallo et al 2012:** Systematic review of RCTs
    - Possible to use a dose between 1.8 ml and 3.6 ml on a general basis in patients with CVD</formatted_text>
  </page>
  <page number="24">
    <text>**HYPERTENSION – ORAL MANAGEMENT – VASOCONSTRICTORS IN LA**

**How much adrenaline-containing LA can we use?**

• **Conclusion:**
  • Use of &gt;2 cartridges of vasoconstrictor-containing LA should be considered a relative rather than absolute contraindication.
  • Current consensus seems to favour judicious use of local anaesthetics containing vasoconstrictors to ensure profound anaesthesia

• **Recommendations:**
  • If supplementation with plain LA is required, use vasoconstricting LA first
  • Aspirating syringe
  • Intraligamentary injection contraindicated
  • Some report felypressin has fewer haemodynamic effects
  • ?Adrenaline-containing retraction cord astringent

24</text>
    <formatted_text>#### How much adrenaline-containing LA can we use?

**Conclusion:**

- Use of &gt;2 cartridges of vasoconstrictor-containing LA should be considered a relative rather than absolute contraindication.
- Current consensus seems to favour judicious use of local anaesthetics containing vasoconstrictors to ensure profound anaesthesia.

**Recommendations:**

- If supplementation with plain LA is required, use vasoconstricting LA first
- Aspirating syringe
- Intraligamentary injection contraindicated
- Some report felypressin has fewer haemodynamic effects
- ?Adrenaline-containing retraction cord astringent</formatted_text>
  </page>
  <page number="25">
    <text>HYPERTENSION – ORAL MANAGEMENT – VASOCONSTRICTORS IN LA

**Therapeutic Guidelines v4 2026**

• Local anaesthetics containing adrenaline = limited effect on BP elevation
• Avoid in patients with uncontrolled hypertension
    • Consider felypressin (Citanest® = prilocaine + felypressin)
    • Also avoid: MI in previous 6 months, unstable angina, uncontrolled arrhytmias, uncontrolled hyperthyroidism

25</text>
    <formatted_text>#### Therapeutic Guidelines v4 2026

- Local anaesthetics containing adrenaline = limited effect on BP elevation
- Avoid in patients with uncontrolled hypertension
  - Consider felypressin (Citanest® = prilocaine + felypressin)
  - Also avoid: MI in previous 6 months, unstable angina, uncontrolled arrhythmias, uncontrolled hyperthyroidism</formatted_text>
    <audio_inserts count="1">
      <insert timestamp="00:33:40" confidence="10" anchor="- Also avoid: MI in previous 6 months, unstable angina, uncontrolled arrhythmias">
- ==Felipressin is considered an alternative because it has minimal effects on the myocardium at the concentration used in dental cartridges==</insert>
    </audio_inserts>
  </page>
  <page number="26">
    <text>ISCHAEMIC HEART DISEASE (CORONARY ARTERY DISEASE) –
DEFINITION / EPIDEMIOL OGY

26

• **Definition**: Group of syndromes resulting from myocardial ischaemia – an imbalance between cardiac
blood supply (perfusion) and myocardial oxygen demand.

• **Classification / Aetiology**:

coronary ischaemic syndromes

stable angina

acute coronary
syndromes

STEMI

NSTEACS [NB1]

NSTEMI

unstable angina

NSTEACS = non-ST elevation acute coronary syndrome; NSTEMI = non-
ST elevation myocardial infarction; STEMI = ST elevation myocardial
infarction

NB1: NSTEACS can progress to STEMI and acute coronary occlusion can
occur without ST elevation, so ongoing monitoring is essential.

Dr Jee-Yun Leung

• **Stable angina**: chronic symptoms
  • Stable atherosclerotic plaque $\rightarrow$ Fixed
    coronary obstruction

• **ACS**: new or increasing ischaemic
  symptoms
  • Unstable atherosclerotic plaque or
    endothelial disruption $\rightarrow$
    transient/permanent thrombotic
    occlusion $\rightarrow$ ischemia and infarction

![Figure 3.2 Classification of coronary ischaemic syndromes](L1 Cardiovascular Disease and Dentistry_figures/img_abd906b2a2aec379.webp)
![](L1 Cardiovascular Disease and Dentistry_figures/img_434463e2b2204b59.webp)
![](L1 Cardiovascular Disease and Dentistry_figures/img_afcf427edf59260c.webp)</text>
    <formatted_text>- **Definition**: Group of syndromes resulting from myocardial ischaemia – an imbalance between cardiac blood supply (perfusion) and myocardial oxygen demand.

#### Classification / Aetiology

Coronary ischaemic syndromes divide into **stable angina** and **acute coronary syndromes**; the latter comprise STEMI and NSTEACS (NSTEMI and unstable angina).

- **Stable angina**: chronic symptoms
  - Stable atherosclerotic plaque → fixed coronary obstruction
- **ACS**: new or increasing ischaemic symptoms
  - Unstable atherosclerotic plaque or endothelial disruption → transient/permanent thrombotic occlusion → ischaemia and infarction

NSTEACS = non-ST elevation acute coronary syndrome; NSTEMI = non-ST elevation myocardial infarction; STEMI = ST elevation myocardial infarction

&gt; NB1: NSTEACS can progress to STEMI and acute coronary occlusion can occur without ST elevation, so ongoing monitoring is essential.</formatted_text>
    <images>
      <img order="0" bbox="53,424,305,648" bbox_format="xyxy_norm_1000" bbox_origin="top_left" bbox_space="page" type="diagram" path="L1 Cardiovascular Disease and Dentistry_figures/img_abd906b2a2aec379.webp" caption="Figure 3.2 Classification of coronary ischaemic syndromes">
        <description>A hierarchical flowchart classifying coronary ischaemic syndromes into stable angina and acute coronary syndromes. The acute coronary syndromes branch further into STEMI and NSTEACS, with the latter subdividing into NSTEMI and unstable angina.</description>
      </img>
      <img order="1" bbox="670,312,857,416" bbox_format="xyxy_norm_1000" bbox_origin="top_left" bbox_space="page" type="diagram" path="L1 Cardiovascular Disease and Dentistry_figures/img_434463e2b2204b59.webp">
        <description>A schematic diagram illustrating the mechanism of stable angina, showing a cross-section of an artery with a fixed yellow plaque obstructing blood flow. The top panel depicts the vessel at rest, while the bottom panel shows further narrowing of the lumen during increased demand or vasoconstriction.</description>
      </img>
      <img order="2" bbox="878,326,940,405" bbox_format="xyxy_norm_1000" bbox_origin="top_left" bbox_space="page" type="image" path="L1 Cardiovascular Disease and Dentistry_figures/img_afcf427edf59260c.webp"/>
    </images>
  </page>
  <page number="27">
    <text>ISCHAEMIC HEART DISEASE (CORONARY ARTERY DISEASE) – DEFINITION / AETIOLOGY
27

• Classification / Aetiology:

Figure 3.2 Classification of coronary ischaemic syndromes
coronary ischaemic syndromes
stable angina | acute coronary syndromes
STEMI | NSTEACS [NB1]
NSTEMI | unstable angina

NSTEACS = non–ST elevation acute coronary syndrome; NSTEMI = non–ST elevation myocardial infarction; STEMI = ST elevation myocardial infarction
NB1: NSTEACS can progress to STEMI and acute coronary occlusion can occur without ST elevation, so ongoing monitoring is essential.

Acute coronary syndromes:

• **Non-ST elevation acute coronary syndrome**
    • Unstable angina = without elevated cardiac biomarkers
    • Non-ST elevation myocardial infarction = pts with MI as determined by elevated cardiac biomarkers

• **ST-elevation myocardial infarction = medical emergency**

→ NSTEACs can progress to STEMI

Dr Jee-Yun Leung

&lt;!--CAPTIONS_JSON_START&gt;
{&quot;BOX_A&quot;: &quot;Figure 3.2 Classification of coronary ischaemic syndromes&quot;, &quot;BOX_B&quot;: &quot;&quot;, &quot;BOX_C&quot;: &quot;&quot;, &quot;BOX_D&quot;: &quot;&quot;, &quot;BOX_E&quot;: &quot;Non-ST&quot;, &quot;BOX_F&quot;: &quot;&quot;, &quot;BOX_G&quot;: &quot;ST&quot;}

![](L1 Cardiovascular Disease and Dentistry_figures/img_6965d3b02762ad92.webp)
![Figure 3.2 Classification of coronary isch](L1 Cardiovascular Disease and Dentistry_figures/img_cb91155f3309b1d1.webp)
![](L1 Cardiovascular Disease and Dentistry_figures/img_6955d161c9855d2f.webp)
![](L1 Cardiovascular Disease and Dentistry_figures/img_970aea6d5399f117.webp)
![](L1 Cardiovascular Disease and Dentistry_figures/img_ba391c78038336df.webp)
![](L1 Cardiovascular Disease and Dentistry_figures/img_a081e241306be3de.webp)
![ST](L1 Cardiovascular Disease and Dentistry_figures/img_80f80faac87ed9b3.webp)</text>
    <formatted_text>#### Classification of Coronary Ischaemic Syndromes

*Figure 3.2 Classification of coronary ischaemic syndromes*

Coronary ischaemic syndromes divide into **stable angina** and **acute coronary syndromes**; the latter comprise STEMI and NSTEACS (NSTEMI and unstable angina).

NSTEACS = non-ST elevation acute coronary syndrome; NSTEMI = non-ST elevation myocardial infarction; STEMI = ST elevation myocardial infarction

&gt; NB1: NSTEACS can progress to STEMI and acute coronary occlusion can occur without ST elevation, so ongoing monitoring is essential.

#### Acute Coronary Syndromes

- **Non-ST elevation acute coronary syndrome**
  - Unstable angina = without elevated cardiac biomarkers
  - Non-ST elevation myocardial infarction = pts with MI as determined by elevated cardiac biomarkers
- **ST-elevation myocardial infarction = medical emergency**

→ NSTEACS can progress to STEMI</formatted_text>
    <images>
      <img order="0" bbox="30,341,375,573" bbox_format="xyxy_norm_1000" bbox_origin="top_left" bbox_space="page" type="image" path="L1 Cardiovascular Disease and Dentistry_figures/img_6965d3b02762ad92.webp"/>
      <img order="1" bbox="34,350,265,575" bbox_format="xyxy_norm_1000" bbox_origin="top_left" bbox_space="page" type="diagram" path="L1 Cardiovascular Disease and Dentistry_figures/img_cb91155f3309b1d1.webp" caption="Figure 3.2 Classification of coronary isch">
        <description>A hierarchical flowchart titled 'Figure 3.2 Classification of coronary ischaemic syndromes'. It branches from the main category into 'stable angina' and 'acute coronary syndromes', with the latter subdividing into 'STEMI' and 'NSTEACS [NB1]', which further splits into 'NSTEMI' and 'unstable angina'.</description>
      </img>
      <img order="2" bbox="759,335,888,400" bbox_format="xyxy_norm_1000" bbox_origin="top_left" bbox_space="page" type="diagram" path="L1 Cardiovascular Disease and Dentistry_figures/img_6955d161c9855d2f.webp">
        <description>A schematic cross-section of a coronary artery showing a yellowish atherosclerotic plaque on the vessel wall with an overlying red thrombus causing significant narrowing (stenosis) of the lumen.</description>
      </img>
      <img order="3" bbox="902,310,975,408" bbox_format="xyxy_norm_1000" bbox_origin="top_left" bbox_space="page" type="figure" path="L1 Cardiovascular Disease and Dentistry_figures/img_970aea6d5399f117.webp">
        <description>This figure illustrates the pathological process of atherosclerosis within a coronary artery. It depicts a cross-section of the vessel with significant plaque accumulation (shown as red and white granular masses) narrowing the lumen, which restricts blood flow to the heart muscle.</description>
      </img>
      <img order="4" bbox="785,545,863,636" bbox_format="xyxy_norm_1000" bbox_origin="top_left" bbox_space="page" type="diagram" path="L1 Cardiovascular Disease and Dentistry_figures/img_ba391c78038336df.webp">
        <description>A schematic cross-section of a blood vessel showing partial occlusion. The lower portion of the lumen is filled with red material containing scattered white and green particles, representing plaque or thrombus buildup within the artery wall.</description>
      </img>
      <img order="5" bbox="851,498,910,562" bbox_format="xyxy_norm_1000" bbox_origin="top_left" bbox_space="page" type="figure" path="L1 Cardiovascular Disease and Dentistry_figures/img_a081e241306be3de.webp">
        <description>A small, low-resolution circular diagram depicting a cross-section of an artery. The vessel lumen is partially occluded by a red central mass and a yellow crescent-shaped area along the vessel wall.</description>
      </img>
      <img order="6" bbox="860,635,929,717" bbox_format="xyxy_norm_1000" bbox_origin="top_left" bbox_space="page" type="diagram" path="L1 Cardiovascular Disease and Dentistry_figures/img_80f80faac87ed9b3.webp" caption="ST">
        <description>A schematic cross-sectional diagram of a coronary artery featuring a lumen partially occluded by yellow plaque and a red thrombus or clot. The image is accompanied by the label 'ST', indicating its association with ST-elevation myocardial infarction within the slide's classification of ischaemic syndromes.</description>
      </img>
    </images>
  </page>
  <page number="28">
    <text>ISCHAEMIC HEART DISEASE (CORONARY ARTERY DISEASE) –
DEFINITION / AETIOLOGY

28

*Thygesen K, Alpert JS, Jaffe AS, Chaitman BR, Bax JJ, Morrow DA, et al. Fourth Universal Definition of Myocardial Infarction (2018). J Am Coll Cardiol 2018;72(18):2231-64*

**1) Type 1 myocardial infarction:**
1) Atherothrombotic coronary occlusion compromises myocardial blood flow

**2) Type 2 myocardial infarction:**
1) Secondary to an imbalance between myocardial oxygen supply and demand (arises from e.g. tachyarrhythmias, sustained bradyarrhythmias, anaemia, respiratory failure and hypotension)
2) Coronary artery spasm
3) Spontaneous coronary artery dissection
4) Coronary embolism</text>
    <formatted_text>*Thygesen K, Alpert JS, Jaffe AS, Chaitman BR, Bax JJ, Morrow DA, et al. Fourth Universal Definition of Myocardial Infarction (2018). J Am Coll Cardiol 2018;72(18):2231-64*

#### Type 1 Myocardial Infarction

1. Atherothrombotic coronary occlusion compromises myocardial blood flow

#### Type 2 Myocardial Infarction

1. Secondary to an imbalance between myocardial oxygen supply and demand (arises from e.g. tachyarrhythmias, sustained bradyarrhythmias, anaemia, respiratory failure and hypotension)
2. Coronary artery spasm
3. Spontaneous coronary artery dissection
4. Coronary embolism</formatted_text>
  </page>
  <page number="29">
    <text>ISCHAEMIC HEART DISEASE (CORONARY ARTERY DISEASE) –
AETIOLOGY

29

| | Risk factors for ischaemic heart disease |
| :--- | :--- |
| H | Heredity |
| A | Age (older) |
| S | Sex (male) |
| L | Lipidaemia |
| I | Increased weight (obesity) |
| P | Pressure (arterial hypertension) |
| I | Inactivity (sedentary lifestyle) |
| D | Diabetes |
| S | Smoking tobacco |

![Risk factors for ischaemic heart disease](L1 Cardiovascular Disease and Dentistry_figures/img_3131b4758ef3e86b.webp)</text>
    <formatted_text>#### Risk Factors for Ischaemic Heart Disease

- **H** – Heredity
- **A** – Age (older)
- **S** – Sex (male)
- **L** – Lipidaemia
- **I** – Increased weight (obesity)
- **P** – Pressure (arterial hypertension)
- **I** – Inactivity (sedentary lifestyle)
- **D** – Diabetes
- **S** – Smoking tobacco</formatted_text>
    <images>
      <img order="0" bbox="141,332,809,729" bbox_format="xyxy_norm_1000" bbox_origin="top_left" bbox_space="page" type="table" path="L1 Cardiovascular Disease and Dentistry_figures/img_3131b4758ef3e86b.webp" caption="Risk factors for ischaemic heart disease">
        <description>A two-column table titled 'Risk factors for ischaemic heart disease' that uses the mnemonic HASLIPIDS to list medical conditions. The left column contains the letters H, A, S, L, I, P, I, D, and S, while the right column provides their corresponding definitions: Heredity, Age (older), Sex (male), Lipidaemia, Increased weight (obesity), Pressure (arterial hypertension), Inactivity (sedentary lifestyle), Diabetes, and Smoking tobacco.</description>
      </img>
    </images>
  </page>
  <page number="30">
    <text>ISCHAEMIC HEART DISEASE (CORONARY ARTERY DISEASE) – DEFINITION / EPIDEMIOL OGY

30

Epidemiology:
• Leading cause of death globally: 13%
• Prevalence: 3% in Australia (higher amongst males)
• Significant decrease in age-standardised IHD mortality rates
    • 1960s: 7/10 MI’s fatal ; Today: 7/10 survive a MI
• CVD-related prescriptions increased 7-8 fold in this time

Dr Jee-Yun Leung

![Leading causes of death in 2021 globally](L1 Cardiovascular Disease and Dentistry_figures/img_5b074d2086b88886.webp)</text>
    <formatted_text>#### Epidemiology

- Leading cause of death globally: 13%
- Prevalence: 3% in Australia (higher amongst males)
- Significant decrease in age-standardised IHD mortality rates
  - 1960s: 7/10 MIs fatal; today: 7/10 survive an MI
- CVD-related prescriptions increased 7–8 fold in this time</formatted_text>
    <images>
      <img order="0" bbox="627,263,890,819" bbox_format="xyxy_norm_1000" bbox_origin="top_left" bbox_space="page" type="chart" path="L1 Cardiovascular Disease and Dentistry_figures/img_5b074d2086b88886.webp" caption="Leading causes of death in 2021 globally">
        <description>A dumbbell chart titled 'Leading causes of death in 2021 globally' ranking the top ten conditions by number of deaths. The chart compares mortality figures for the years 2000, 2019, and 2021 using dots on a horizontal axis scaled in millions, with color-coding to distinguish between communicable, noncommunicable, and injury-related causes.</description>
      </img>
    </images>
  </page>
  <page number="31">
    <text>ISCHAEMIC HEART DISEASE (CORONARY ARTERY DISEASE) –
GENERAL MANIFESTATIONS

31

high probability of ischaemia low

• central
• pressure
• squeezing
• gripping
• heaviness
• tightness
• exertional or stress-related
• retrosternal

• left-sided
• dull
• aching

• stabbing

• right-sided
• tearing
• ripping
• burning

• sharp
• fleeting
• shifting
• pleuritic
• positional

Source: Gulati M, Levy PD, Mukherjee D, Amsterdam E, Bhatt DL, Birtcher KK, et al. 2021 AHA/ACC/ASE/CHEST/SAEM/SCCT/SCMR Guideline for the Evaluation and Diagnosis of Chest Pain: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation 2021;144(22):e368-e454. URL

![Figure 13.81 Probability that chest pain is ischaemic in origin based on common descriptions of pain](L1 Cardiovascular Disease and Dentistry_figures/img_3289daba64bfa836.webp)</text>
    <formatted_text>Chest pain features range from a **high probability of ischaemia** to **low**:

- High probability of ischaemia
  - central
  - pressure
  - squeezing
  - gripping
  - heaviness
  - tightness
  - exertional or stress-related
  - retrosternal
- Intermediate
  - left-sided
  - dull
  - aching
  - stabbing
  - right-sided
  - tearing
  - ripping
  - burning
- Low probability
  - sharp
  - fleeting
  - shifting
  - pleuritic
  - positional

*Gulati M, Levy PD, Mukherjee D, Amsterdam E, Bhatt DL, Birtcher KK, et al. 2021 AHA/ACC/ASE/CHEST/SAEM/SCCT/SCMR Guideline for the Evaluation and Diagnosis of Chest Pain: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation 2021;144(22):e368-e454.*</formatted_text>
    <images>
      <img order="0" bbox="117,371,554,626" bbox_format="xyxy_norm_1000" bbox_origin="top_left" bbox_space="page" type="image" path="L1 Cardiovascular Disease and Dentistry_figures/img_3289daba64bfa836.webp" caption="Figure 13.81 Probability that chest pain is ischaemic in origin based on common descriptions of pain"/>
    </images>
  </page>
  <page number="32">
    <text>ISCHAEMIC HEART DISEASE (CORONARY ARTERY DISEASE) – GENERAL MANIFESTATIONS
32

| Stable Angina | Acute Coronary Syndromes (eg. MI) | Cardiac Arrest |
| :--- | :--- | :--- |
| • Episodic retrosternal chest discomfort (pain, ache or tightness) | • “Crushing” or heavy central chest pain (more severe) | • Sudden loss of consciousness |
| • May radiate to arms, neck, back, shoulder, jaw | • Shortness of breath, nausea, sweating, pale/clammy skin | • No pulse |
| • Commonly triggered by physical activity or emotional stress | • Decrease pulse &amp; BP, vomiting, “impending sense of doom” | • Not breathing |
| • Predictable, consistent over time | • May occur at rest | |
| • Lasts &lt;10min if provoking stimulus removed | • Lasts 20min to hours | |
| • Subsides with rest or GTN | • Not relieved by rest or GTN | |
| | *NB: Silent Angina = some may have no pain due to psychological factors persistently inhibiting pain perception (elderly) or autonomic neuropathy (diabetics)* | |

![](L1 Cardiovascular Disease and Dentistry_figures/img_2a3e9ecce1ac4961.webp)</text>
    <formatted_text>#### Stable Angina

- Episodic retrosternal chest discomfort (pain, ache or tightness)
- May radiate to arms, neck, back, shoulder, jaw
- Commonly triggered by physical activity or emotional stress
- Predictable, consistent over time
- Lasts &lt;10 min if provoking stimulus removed
- Subsides with rest or GTN

#### Acute Coronary Syndromes (e.g. MI)

- &quot;Crushing&quot; or heavy central chest pain (more severe)
- Shortness of breath, nausea, sweating, pale/clammy skin
- Decreased pulse &amp; BP, vomiting, &quot;impending sense of doom&quot;
- May occur at rest
- Lasts 20 min to hours
- Not relieved by rest or GTN

&gt; NB: Silent angina = some may have no pain due to psychological factors persistently inhibiting pain perception (elderly) or autonomic neuropathy (diabetics)

#### Cardiac Arrest

- Sudden loss of consciousness
- No pulse
- Not breathing</formatted_text>
    <images>
      <img order="0" bbox="70,266,855,805" bbox_format="xyxy_norm_1000" bbox_origin="top_left" bbox_space="page" type="table" path="L1 Cardiovascular Disease and Dentistry_figures/img_2a3e9ecce1ac4961.webp"/>
    </images>
  </page>
  <page number="33">
    <text>ISCHAEMIC HEART DISEASE: GENERAL MANAGEMENT

| Lifestyle | Pharmacological | Revascularisation |
| :--- | :--- | :--- |
| • ↓ Smoking | • Beta-blockers | • Coronary artery bypass grafting (CABG) |
| • Diet | • Calcium-channel blockers | • Percutaneous coronary intervention (PCI) = “coronary angioplasty and stent” |
| • ↓ Alcohol | • Nitrates | |
| • Physical Activity | • Nicorandil | |
| • Health weight | • ACE inhibitors | |
| • Psychosocial | • ARBs | |
| | • Antiplatelets | |
| | • Lipid-lowering drugs | |
| | • Ivabradine | |</text>
    <formatted_text>#### Lifestyle

- ↓ Smoking
- Diet
- ↓ Alcohol
- Physical activity
- Healthy weight
- Psychosocial

#### Pharmacological

- Beta-blockers
- Calcium-channel blockers
- Nitrates
- Nicorandil
- ACE inhibitors
- ARBs
- Antiplatelets
- Lipid-lowering drugs
- Ivabradine

#### Revascularisation

- Coronary artery bypass grafting (CABG)
- Percutaneous coronary intervention (PCI) = &quot;coronary angioplasty and stent&quot;</formatted_text>
    <audio_inserts count="1">
      <insert timestamp="00:47:10" confidence="10" anchor="- Percutaneous coronary intervention (PCI) = &quot;coronary angioplasty and stent&quot;">

&gt; [!note] Lecturer — Revascularisation Details
&gt; Revascularisation improves oxygen supply by relieving or bypassing the atherosclerotic obstruction.
&gt;
&gt; - Coronary artery bypass grafting may use the left internal mammary artery, saphenous vein or radial artery, attached above and below the obstruction.
&gt; - Coronary angioplasty uses a catheter and balloon to open the vessel, after which a stent remains in place to keep it open.
</insert>
    </audio_inserts>
  </page>
  <page number="34">
    <text>ISCHAEMIC HEART DISEASE: GENERAL MANAGEMENT

| Therapeutic goal | Pharmacological strategy |
| :--- | :--- |
| Inhibit progression atherosclerosis | Statins - ↓lipids |
| ↑coronary circulation | Nitrates&lt;br&gt;Ca channel blockers |
| ↓heart workload | B blockers |
| Prevent thrombus formation | Anti-thrombotic agents |

![](L1 Cardiovascular Disease and Dentistry_figures/img_8dfdda8e1b71e366.webp)</text>
    <formatted_text>| Therapeutic goal | Pharmacological strategy |
| :--- | :--- |
| Inhibit progression of atherosclerosis | Statins – ↓ lipids |
| ↑ coronary circulation | Nitrates; Ca channel blockers |
| ↓ heart workload | Beta blockers |
| Prevent thrombus formation | Anti-thrombotic agents |</formatted_text>
    <images>
      <img order="0" bbox="159,342,757,694" bbox_format="xyxy_norm_1000" bbox_origin="top_left" bbox_space="page" type="table" path="L1 Cardiovascular Disease and Dentistry_figures/img_8dfdda8e1b71e366.webp">
        <description>A two-column table mapping therapeutic goals for ischaemic heart disease to corresponding pharmacological strategies. Rows pair goals such as 'Inhibit progression atherosclerosis' with 'Statins - ↓lipids', '↑coronary circulation' with 'Nitrates / Ca channel blockers', '↓heart workload' with 'B blockers', and 'Prevent thrombus formation' with 'Anti-thrombotic agents'.</description>
      </img>
    </images>
  </page>
  <page number="35">
    <text>ISCHAEMIC HEART DISEASE: ORAL MANIFESTATIONS
35

• **Antihypertensive drugs**: as per previous section
• **Nicorandil**: *oral/skin/eye ulceration, facial flushing, lupoid lesions

• Possible association with **periodontitis** (growing evidence)
  • Direct pathway – bacteraemia
  • Indirect pathway – induces chronic systemic inflammatory state

• Possible association with **endodontic disease** (less investigated and inconclusive evidence)
  • apical periodontitis – comparable inflammatory and microbial profile (gram –ve anaerobes) to periodontal disease
  • pulp stones – similarity to calcified stones forming in coronary and renal arteries

• Rarely, **angina pain referred to lower jaw/teeth** mistakenly thought to be of dental origin (clue: onset with exertion)

![DIRECT Pathway: Invasion of Periodontopathic pathogens INDIRECT Pathway: Leakage of Inflammatory cytokines in the circulation. BLOOD VESSEL Vascular subendothelium Atheromatous plaque Blood vessel Atheromatous plaque formation Atheromatous plaque maturation](L1 Cardiovascular Disease and Dentistry_figures/img_1e76c6508c9a845a.webp)</text>
    <formatted_text>- **Antihypertensive drugs**: as per previous section
- **Nicorandil**: oral/skin/eye ulceration, facial flushing, lupoid lesions

#### Periodontitis

Possible association with **periodontitis** (growing evidence):
- Direct pathway – bacteraemia
- Indirect pathway – induces chronic systemic inflammatory state

#### Endodontic Disease

Possible association with **endodontic disease** (less investigated and inconclusive evidence):
- Apical periodontitis – comparable inflammatory and microbial profile (gram –ve anaerobes) to periodontal disease
- Pulp stones – similarity to calcified stones forming in coronary and renal arteries

#### Referred Pain

Rarely, **angina pain referred to lower jaw/teeth** mistakenly thought to be of dental origin (clue: onset with exertion)</formatted_text>
    <audio_inserts count="1">
      <insert timestamp="00:50:41" confidence="8" anchor="- Indirect pathway – induces chronic systemic inflammatory state">

&gt; [!note] Lecturer — Periodontitis Mechanisms
&gt; Proposed links between periodontitis and ischaemic heart disease include more than bacteraemia and chronic systemic inflammation.
&gt;
&gt; - Inflammatory mediators may promote a prothrombotic state.
&gt; - Antibodies produced in response to periodontal infection may cross-react with the heart.
&gt; - The association is emerging and is not equivalent in strength to the established association between diabetes and periodontitis.
</insert>
    </audio_inserts>
    <images>
      <img order="0" bbox="616,419,970,664" bbox_format="xyxy_norm_1000" bbox_origin="top_left" bbox_space="page" type="diagram" path="L1 Cardiovascular Disease and Dentistry_figures/img_1e76c6508c9a845a.webp" caption="DIRECT Pathway: Invasion of Periodontopathic pathogens INDIRECT Pathway: Leakage of Inflammatory cytokines in the circulation. BLOOD VESSEL Vascular subendothelium Atheromatous plaque Blood vessel Atheromatous plaque formation Atheromatous plaque maturation">
        <description>A schematic flowchart illustrating the proposed mechanisms linking periodontal disease to atherosclerosis. The top section depicts direct bacterial invasion and indirect cytokine leakage from a tooth into the circulation, while the bottom section shows a cross-section of a blood vessel wall with an 'Atheromatous plaque' in the vascular subendothelium, followed by a timeline of plaque formation and maturation.</description>
      </img>
    </images>
  </page>
  <page number="36">
    <text>**ISCHAEMIC HEART DISEASE: ORAL MANIFESTATIONS**
**36**

Periodontal Disease and Atherosclerotic Cardiovascular Disease: A Scientific Statement From the American Heart Association | Circulation

European Federation of Periodontology:
https://www.bsperio.org.uk/assets/downloads/EFP_cardiovascular-disease-gum-disease.pdf</text>
    <formatted_text>Periodontal Disease and Atherosclerotic Cardiovascular Disease: A Scientific Statement From the American Heart Association | Circulation

European Federation of Periodontology: https://www.bsperio.org.uk/assets/downloads/EFP_cardiovascular-disease-gum-disease.pdf</formatted_text>
  </page>
  <page number="37">
    <text>ISCHAEMIC HEART DISEASE: DENTAL MANAGEMENT – RISK ASSESSMENT 37

Careful medical history at first appointment. Ask about indicators of risk:
* History of chest pain at rest
* Triggers/frequency of episodes
* Carry GTN?
* How episodes are usually managed
* Number of anti-anginal medications
* Hx of CABG/stent placement with ongoing symptoms
* Hx of heart failure</text>
    <formatted_text>#### Risk Assessment

Careful medical history at first appointment. Ask about indicators of risk:

- History of chest pain at rest
- Triggers/frequency of episodes
- Carry GTN?
- How episodes are usually managed
- Number of anti-anginal medications
- Hx of CABG/stent placement with ongoing symptoms
- Hx of heart failure</formatted_text>
  </page>
  <page number="38">
    <text>## ISCHAEMIC HEART DISEASE: DENTAL MANAGEMENT – RISK ASSESSMENT

38

```mermaid
graph LR
    subgraph Timing_Flow [ ]
        direction LR
        Timing --&gt; Angina --&gt; Prior_to_cardiac_surgery[&quot;Prior to cardiac&lt;br&gt;surgery&quot;] --&gt; After_MI_or_Cardiac_Surgery[&quot;After MI or&lt;br&gt;Cardiac Surgery&quot;]
    end
```

* Risk of Vascular Events
* Appropriate setting
* Emergency Management
* Adrenaline
* Anxiety management
* Periodontitis

```mermaid
graph LR
    subgraph Endodontics_Flow [ ]
        direction LR
        Endodontics[&quot;?Endodontics&quot;] --&gt; Apical_Periodontitis[&quot;Apical Periodontitis&quot;] --&gt; Dental_Pulp_Stones[&quot;Dental Pulp Stones&quot;]
    end
```

```mermaid
graph LR
    subgraph Drug_Therapy_Flow [ ]
        direction LR
        Drug_Therapy[&quot;Drug Therapy&quot;] --&gt; Antihypertensive_drugs[&quot;Antihypertensive&lt;br&gt;drugs&quot;] --&gt; Antiplatelet_drugs[&quot;Antiplatelet drugs&quot;] --&gt; Lipid_lowering_drugs[&quot;Lipid-lowering&lt;br&gt;drugs&quot;]
    end
```

![](L1 Cardiovascular Disease and Dentistry_figures/img_3df2971a70072c78.webp)</text>
    <formatted_text>#### Risk Assessment – Key Considerations

- Timing: angina → prior to cardiac surgery → after MI or cardiac surgery
- Risk of vascular events
- Appropriate setting
- Emergency management
- Adrenaline
- Anxiety management
- Periodontitis
- ?Endodontics: apical periodontitis → dental pulp stones
- Drug therapy: antihypertensive drugs → antiplatelet drugs → lipid-lowering drugs</formatted_text>
    <images>
      <img order="0" bbox="92,261,825,785" bbox_format="xyxy_norm_1000" bbox_origin="top_left" bbox_space="page" type="diagram" path="L1 Cardiovascular Disease and Dentistry_figures/img_3df2971a70072c78.webp">
        <description>A flowchart diagram illustrating risk assessment factors for dental management of ischaemic heart disease. The chart is divided into four sections: a timing sequence (Angina, Prior to cardiac surgery, After MI or Cardiac Surgery), a grid of clinical considerations (Risk of Vascular Events, Appropriate setting, Emergency Management, Adrenaline, Anxiety management, Periodontitis), an endodontics pathway (?Endodontics -&gt; Apical Periodontitis -&gt; Dental Pulp Stones), and a drug therapy list (Antihypertensive drugs, Antiplatelet drugs, Lipid-lowering drugs).</description>
      </img>
    </images>
  </page>
  <page number="39">
    <text>**ISCHAEMIC HEART DISEASE: DENTAL MANAGEMENT**
**39**

**ACCESS**

*   **Access to clinic / Mobility:** Functional capacity (cardiopulmonary reserve)
*   **Appointments:** Short, minimally stressful appointments. Late morning appointments.
*   **Positioning:** Orthostatic hypotension (antihypertensives) $\rightarrow$ semi-supine and slowly upright
*   **Location / setting:** Hospital setting may be required for severe cardiac disease when emergency dental treatment required.
*   **Timing:**
    *   Patients with history of angina (or MI &gt;6 months earlier) can undergo dental treatment if medically stable
    *   Defer elective dental care if unstable angina
    *   Defer elective dental procedures for 6 months after MI, stent placement or CABG.
    *   Pain and infection within 6 months of above:
        *   provide adequate emergency treatment
        *   avoid use of adrenaline-containing LA
        *   consider specialist advice re: appropriate treatment and timing of procedures</text>
    <formatted_text>#### Access

- **Access to clinic / mobility**: functional capacity (cardiopulmonary reserve)
- **Appointments**: short, minimally stressful appointments; late morning appointments
- **Positioning**: orthostatic hypotension (antihypertensives) → semi-supine and slowly upright
- **Location / setting**: hospital setting may be required for severe cardiac disease when emergency dental treatment required

#### Timing

- Patients with history of angina (or MI &gt;6 months earlier) can undergo dental treatment if medically stable
- Defer elective dental care if unstable angina
- Defer elective dental procedures for 6 months after MI, stent placement or CABG
- Pain and infection within 6 months of the above:
  - provide adequate emergency treatment
  - avoid use of adrenaline-containing LA
  - consider specialist advice re: appropriate treatment and timing of procedures</formatted_text>
    <audio_inserts count="1">
      <insert timestamp="00:53:00" confidence="3" anchor="- **Location / setting**: hospital setting may be required for severe cardiac di">
- ==Patients may be connected to monitoring equipment, fluids or other devices that affect their ability to access a dental chair==</insert>
    </audio_inserts>
  </page>
  <page number="40">
    <text>ISCHAEMIC HEART DISEASE: DENTAL MANAGEMENT
40

**CAPACITY**
• Nil significant

**CONSENT**
• Nil significant

**EDUCATION/PREVENTION**
• Oral side effects of medications
• Possible association with periodontitis +/- endodontic disease</text>
    <formatted_text>#### Capacity

- Nil significant

#### Consent

- Nil significant

#### Education / Prevention

- Oral side effects of medications
- Possible association with periodontitis +/- endodontic disease</formatted_text>
  </page>
  <page number="41">
    <text>ISCHAEMIC HEART DISEASE: DENTAL MANAGEMENT
41

**SURGERY**

**Pre-operative**
• Instruct patients with angina to bring their medication (e.g. GTN spray or tablets), and have it readily accessible.
• Ensure GTN and oxygen readily available
• Monitor SpO$_2$, BP, HR

**Peri-operative**
• Use relaxation techniques and consider other measures for anxiety management
• Limit the duration of dental procedures
• **Bleeding**: may be on antithrombotics (see *Haematology – Bleeding Disorders* lecture)
• **LA** : Ensure effective analgesia $\rightarrow$ use of adrenaline (see *Hypertension*)
• **Sedation**: anxiety relief helpful (see *Hypertension*)

**Post-operative**
• Caution with NSAIDs</text>
    <formatted_text>#### Pre-operative

- Instruct patients with angina to bring their medication (e.g. GTN spray or tablets), and have it readily accessible
- Ensure GTN and oxygen readily available
- Monitor SpO₂, BP, HR

#### Peri-operative

- Use relaxation techniques and consider other measures for anxiety management
- Limit the duration of dental procedures
- **Bleeding**: may be on antithrombotics (see *Haematology – Bleeding Disorders* lecture)
- **LA**: ensure effective analgesia → use of adrenaline (see *Hypertension*)
- **Sedation**: anxiety relief helpful (see *Hypertension*)

#### Post-operative

- Caution with NSAIDs</formatted_text>
  </page>
  <page number="42">
    <text>ISCHAEMIC HEART DISEASE
– MANAGEMENT OF CHEST
PAIN IN DENTAL PRACTICE

**NB1:** Many people with chest pain do not have angina or a heart attack, but anyone with acute chest pain requires rapid medical evaluation for potentially life-threatening causes. The likelihood of angina or heart attack increases with the number of suggestive features.

**NB2:** Sublingual glyceryl trinitrate (GTN) dosing is a 400 microgram spray (or 300 to 600 microgram tablet) generally administered every 5 minutes to a maximum of 3 doses. Ask patients who use GTN to bring their GTN to their dental appointment so that it can be administered if chest pain occurs.

**NB3:** If symptoms (pain or other features that may indicate angina) last longer than the patient’s usual angina symptoms, urgent medical evaluation of a possible heart attack or other urgent condition is required.

Printable figure

Patient with chest pain and any of the following features suggestive of heart attack [NB1]:
• a prior diagnosis of angina or heart attack, or chest pain on exertion
• persistent central chest sensation of: pressure, squeezing, gripping, heaviness, or tightness
• radiation of the pain, pressure or tightness to the arms, neck, back or jaw
• breathlessness, nausea, vomiting, sweating or fatigue (these can be present in angina or heart attack without pain, especially in older patients, females and people with diabetes).

Does the patient use sublingual glyceryl trinitrate (GTN) as a spray or tablet for a known diagnosis of angina?

NO
Call 000.
Give oxygen by face mask if either:
• the patient is breathless or looks blue
• the pulse oximeter reading is less than 94% (if pulse oximetry is available).
Give 300 mg oral aspirin (non-enteric coated) if available, to chew or dissolve (unless the patient has a known aspirin allergy).
Recline the patient within their comfort range.
Have defibrillator ready; prepare for basic life support.

YES
Recline patient within their comfort range.
Administer sublingual GTN doses at intervals according to the patient’s usual regimen [NB2].

Are the symptoms (pain or other features) persisting for longer than the patient usually experiences them [NB3]?

YES
(Connects to &quot;Call 000&quot; box)

NO
Temporise any treatment that has been started.
Referral to general practitioner for review is reasonable.

![Figure 13.82 Management of chest pain in dental practice](L1 Cardiovascular Disease and Dentistry_figures/img_3970ca0b71c1d104.webp)</text>
    <formatted_text>&gt; **NB1:** Many people with chest pain do not have angina or a heart attack, but anyone with acute chest pain requires rapid medical evaluation for potentially life-threatening causes. The likelihood of angina or heart attack increases with the number of suggestive features.
&gt;
&gt; **NB2:** Sublingual glyceryl trinitrate (GTN) dosing is a 400 microgram spray (or 300 to 600 microgram tablet) generally administered every 5 minutes to a maximum of 3 doses. Ask patients who use GTN to bring their GTN to their dental appointment so that it can be administered if chest pain occurs.
&gt;
&gt; **NB3:** If symptoms (pain or other features that may indicate angina) last longer than the patient's usual angina symptoms, urgent medical evaluation of a possible heart attack or other urgent condition is required.

#### Patient with Chest Pain and Features Suggestive of Heart Attack [NB1]

- A prior diagnosis of angina or heart attack, or chest pain on exertion
- Persistent central chest sensation of: pressure, squeezing, gripping, heaviness, or tightness
- Radiation of the pain, pressure or tightness to the arms, neck, back or jaw
- Breathlessness, nausea, vomiting, sweating or fatigue (these can be present in angina or heart attack without pain, especially in older patients, females and people with diabetes)

#### Does the Patient Use Sublingual GTN for a Known Diagnosis of Angina?

**NO**

- Call 000.
- Give oxygen by face mask if either:
  - the patient is breathless or looks blue
  - the pulse oximeter reading is less than 94% (if pulse oximetry is available)
- Give 300 mg oral aspirin (non-enteric coated) if available, to chew or dissolve (unless the patient has a known aspirin allergy)
- Recline the patient within their comfort range
- Have defibrillator ready; prepare for basic life support

**YES**

- Recline patient within their comfort range
- Administer sublingual GTN doses at intervals according to the patient's usual regimen [NB2]

#### Are the Symptoms Persisting Longer than the Patient Usually Experiences Them [NB3]?

**YES** → Call 000

**NO**

- Temporise any treatment that has been started
- Referral to general practitioner for review is reasonable</formatted_text>
    <images>
      <img order="0" bbox="650,170,936,793" bbox_format="xyxy_norm_1000" bbox_origin="top_left" bbox_space="page" type="diagram" path="L1 Cardiovascular Disease and Dentistry_figures/img_3970ca0b71c1d104.webp" caption="Figure 13.82 Management of chest pain in dental practice">
        <description>A clinical flowchart titled 'Management of chest pain in dental practice' that guides practitioners through decision-making based on patient symptoms and history. The diagram uses connected boxes to direct the user from initial assessment criteria (such as prior angina diagnosis or radiation of pain) to specific actions, including calling emergency services (000), administering GTN, or referring to a general practitioner.</description>
      </img>
    </images>
  </page>
  <page number="43">
    <text>ISCHAEMIC HEART DISEASE –
MANAGEMENT OF CHEST PAIN IN DENTAL PRACTICE

If administering nitrates, recline the patient because blood pressure can be reduced by administration. To manage chest pain in a patient with a history of angina, use:

1 glyceryls trinitrate spray 400 micrograms sublingually, repeat every 5 minutes if pain persists, up to a total of 3 doses if tolerated

OR

1 glyceryls trinitrate tablet 300 to 600 micrograms sublingually, repeat every 5 minutes if pain persists, up to a total of 3 doses if tolerated.

To manage chest pain if angina or heart attack is suspected, provided no contraindication (eg aspirin allergy) is present, use:

aspirin (non-enteric coated) 300 mg orally, chewed or dissolved before swallowing.</text>
    <formatted_text>If administering nitrates, recline the patient because blood pressure can be reduced by administration. To manage chest pain in a patient with a history of angina, use:

1. Glyceryl trinitrate spray 400 micrograms sublingually, repeat every 5 minutes if pain persists, up to a total of 3 doses if tolerated

   OR

2. Glyceryl trinitrate tablet 300 to 600 micrograms sublingually, repeat every 5 minutes if pain persists, up to a total of 3 doses if tolerated

To manage chest pain if angina or heart attack is suspected, provided no contraindication (e.g. aspirin allergy) is present, use:

- Aspirin (non-enteric coated) 300 mg orally, chewed or dissolved before swallowing</formatted_text>
    <images>
      <img order="0" bbox="786,435,870,468" bbox_format="xyxy_norm_1000" bbox_origin="top_left" bbox_space="page" type="clipart">
        <description>A row of three dark circular icons containing white symbols: the first displays the text 'PBS', the second shows a stylized figure, and the third depicts a person with a heart symbol.</description>
      </img>
      <img order="1" bbox="787,572,870,605" bbox_format="xyxy_norm_1000" bbox_origin="top_left" bbox_space="page" type="clipart">
        <description>Three circular icons displayed in a row. The first icon contains the text 'PBS', the second depicts a silhouette of a pregnant woman, and the third shows a medical bag with a cross symbol.</description>
      </img>
      <img order="2" bbox="786,691,870,725" bbox_format="xyxy_norm_1000" bbox_origin="top_left" bbox_space="page" type="clipart">
        <description>Three circular icons arranged horizontally. The left icon contains the text &quot;PBS&quot; inside a pill shape, likely representing Pharmaceutical Benefits Scheme eligibility. The middle icon depicts a silhouette of a pregnant woman. The right icon shows a figure holding an object to their chest, possibly indicating a medical condition or emergency.</description>
      </img>
    </images>
  </page>
  <page number="44">
    <text>THROMBOEMBOLIC COMPLICATIONS OF CVD - AETIOLOGY

*   **Arterial thrombi**: platelet aggregation + fibrin + erythrocytes
*   **Venous thrombi**: slow &amp; turbulent blood flow, ↑ risk small emboli detaching &amp; blocking pulmonary arteries</text>
    <formatted_text>#### Aetiology

- **Arterial thrombi**: platelet aggregation + fibrin + erythrocytes
- **Venous thrombi**: slow &amp; turbulent blood flow, ↑ risk small emboli detaching &amp; blocking pulmonary arteries</formatted_text>
  </page>
  <page number="45">
    <text>THROMBOEMBOLIC COMPLICATIONS OF CVD – GENERAL MANIFESTATIONS AND MANAGEMENT

**Arterial thrombi**
*   TIA/stroke
*   Occlusion of coronary artery grafts
*   MI &amp; death in unstable angina
*   Systemic embolism with prosthetic heart valves/AF

**Venous thrombi**
*   DVT
*   Pulmonary embolism

**General management**
*   Antithrombotic agents: prevent thrombus formation (initiation)
*   Anticoagulants: prevent coagulation (clot formation)

**Dental management**
*   Antithrombotic drug use $\rightarrow$ bleeding (see *Haematology - Bleeding Disorders* lecture)

![](L1 Cardiovascular Disease and Dentistry_figures/img_7d2fe882804b87e4.webp)</text>
    <formatted_text>#### Arterial Thrombi

- TIA/stroke
- Occlusion of coronary artery grafts
- MI &amp; death in unstable angina
- Systemic embolism with prosthetic heart valves/AF

#### Venous Thrombi

- DVT
- Pulmonary embolism

#### General Management

- Antithrombotic agents: prevent thrombus formation (initiation)
- Anticoagulants: prevent coagulation (clot formation)

#### Dental Management

- Antithrombotic drug use → bleeding (see *Haematology – Bleeding Disorders* lecture)</formatted_text>
    <images>
      <img order="0" bbox="11,227,887,808" bbox_format="xyxy_norm_1000" bbox_origin="top_left" bbox_space="page" type="diagram" path="L1 Cardiovascular Disease and Dentistry_figures/img_7d2fe882804b87e4.webp">
        <description>This diagram categorizes thromboembolic complications into arterial and venous thrombi, listing associated conditions such as TIA/stroke for arterial issues and DVT for venous issues. It also outlines general management strategies using antithrombotic agents and anticoagulants, alongside specific dental management considerations regarding bleeding risks.</description>
      </img>
    </images>
  </page>
  <page number="46">
    <text>**VALVULAR**

Rheumatic fever and Rheumatic heart disease

Infective endocarditis

Aortic and mitral valve stenosis, regurgitation and prolapse</text>
    <formatted_text>- Rheumatic fever and rheumatic heart disease
- Infective endocarditis
- Aortic and mitral valve stenosis, regurgitation and prolapse</formatted_text>
  </page>
  <page number="47">
    <text>**RHEUMATIC FEVER AND RHEUMATIC HEART DISEASE**

DEFINITION

• Rheumatic Fever: An acute, immunologically-mediated, systemic inflammatory condition characterised by fever and arthritis 2-4 weeks after pharyngitis. Caused by certain strains of Group A beta-haemolytic streptococci (e.g. following impetigo and scabies).

EPIDEMIOLOGY

• &lt;span style=&quot;color: orange;&quot;&gt;1.o6 Acute rheumatic fever and rheumatic heart disease - AIHW Indigenous HPF&lt;/span&gt;

• RHD is a disease of disadvantage that is both preventable and treatable.

• First Nations people in Australia have one of the highest recorded rates of ARF and RHD in the world (119 per 100,000), with incidence rates increasing (50% increase 2012-2021)

• First Nations people accounted for 92% of the total number of ARF cases in Australia recorded over the 5-year period 2017–2021

• Otherwise rare disease in Western world, common in Indian subcontinent, Middle East, some Caribbean islands.</text>
    <formatted_text>#### Definition

- Rheumatic Fever: An acute, immunologically-mediated, systemic inflammatory condition characterised by fever and arthritis 2-4 weeks after pharyngitis. Caused by certain strains of Group A beta-haemolytic streptococci (e.g. following impetigo and scabies).

#### Epidemiology

- 1.06 Acute rheumatic fever and rheumatic heart disease - AIHW Indigenous HPF
- RHD is a disease of disadvantage that is both preventable and treatable.
- First Nations people in Australia have one of the highest recorded rates of ARF and RHD in the world (119 per 100,000), with incidence rates increasing (50% increase 2012-2021)
- First Nations people accounted for 92% of the total number of ARF cases in Australia recorded over the 5-year period 2017–2021
- Otherwise rare disease in Western world, common in Indian subcontinent, Middle East, some Caribbean islands.</formatted_text>
  </page>
  <page number="48">
    <text>RHEUMATIC FEVER AND RHEUMATIC HEART DISEASE

AETIOLOGY
• Group A streptococci
• RHD: repeated episodes of RF
• Autoimmune reaction: antibodies produced to fight streptococci cross react with enzymes of the heart

Streptococcus pyogenes
Pharyngitis or skin infection
Lymph Node
+ IL-10, TGF-B, TNF-a
Group A Strep/cross reactive antibodies and lymphocytes
Auto-inflammatory lesions affect the valves (mitral, aortic, tricuspid in order of frequency)

Image: Simpson MT, et al. Rheumatic Heart Disease in the Developing World. Structural Heart. 2023; 7(6): 100219

![Figure 2 Pathophysiology of RHD. RHD occurs as a sequela of GAS infection, especially pharyngitis. Social determinants of health and genetic predisposition play a role in repeated infection as well as in the progression to RHD. Cross-reactive antibodies and immune cells form in response to GAS infection and attack endothelial cells throughout the body; however, damage to the endothelial surface of the valves is not repaired effectively.](L1 Cardiovascular Disease and Dentistry_figures/img_3f569449e534e40b.webp)</text>
    <formatted_text>#### Aetiology

- Group A streptococci
- RHD: repeated episodes of RF
- Autoimmune reaction: antibodies produced to fight streptococci cross react with enzymes of the heart

#### Pathogenesis

Streptococcus pyogenes → pharyngitis or skin infection → lymph node (+ IL-10, TGF-β, TNF-α) → Group A Strep/cross reactive antibodies and lymphocytes → auto-inflammatory lesions affect the valves (mitral, aortic, tricuspid in order of frequency)

*Simpson MT, et al. Rheumatic Heart Disease in the Developing World. Structural Heart. 2023; 7(6): 100219*</formatted_text>
    <audio_inserts count="1">
      <insert timestamp="01:01:29" confidence="10" anchor="Streptococcus pyogenes → pharyngitis or skin infection → lymph node (+ IL-10, TG">

&gt; [!note] Lecturer — Rheumatic Carditis
&gt; All layers of the heart may potentially be affected, producing rheumatic carditis.
&gt;
&gt; - Vasculitis and inflammatory lesions may also involve the joints, skin and nervous system.
&gt; - Subendocardial inflammation occurs along valve closure lines, especially at the mitral and aortic valves.
&gt; - Minute fibrinous vegetations may form, and subsequent scarring, stiffening and distortion can cause permanent valve damage.
&gt; - Turbulent blood flow through damaged valves increases susceptibility to infective endocarditis.
</insert>
    </audio_inserts>
    <images>
      <img order="0" bbox="416,298,936,651" bbox_format="xyxy_norm_1000" bbox_origin="top_left" bbox_space="page" type="diagram" path="L1 Cardiovascular Disease and Dentistry_figures/img_3f569449e534e40b.webp" caption="Figure 2 Pathophysiology of RHD. RHD occurs as a sequela of GAS infection, especially pharyngitis. Social determinants of health and genetic predisposition play a role in repeated infection as well as in the progression to RHD. Cross-reactive antibodies and immune cells form in response to GAS infection and attack endothelial cells throughout the body; however, damage to the endothelial surface of the valves is not repaired effectively.">
        <description>This schematic diagram illustrates the pathophysiology of Rheumatic Heart Disease, tracing the progression from a Streptococcus pyogenes infection causing pharyngitis or skin infection to immune activation in lymph nodes. It depicts how Group A Strep triggers cross-reactive antibodies and lymphocytes, mediated by cytokines (IL-10, TGF-B, TNF-a), which subsequently cause auto-inflammatory lesions affecting the heart valves.</description>
      </img>
    </images>
  </page>
  <page number="49">
    <text>RHEUMATIC FEVER AND RHEUMATIC HEART DISEASE

GENERAL
MANIFESTATIONS

• Acute Rheumatic Fever
• Subacute/chronic
Rheumatic Fever

Acute rheumatic fever

Etiology
Previous GAS pharyngitis/tonsillitis
without antibiotic treatment

Peak incidence
5–15 years of age

Diagnosis
Evidence of a previous GAS infection
(e.g., throat culture, rapid antigen
detection test, antistreptolysin O,
antistreptococcal DNase B test)
Revised Jones criteria

Treatment
Antibiotic treatment of underlying
GAS infection
Symptomatic treatment of arthritis
and fever

Constitutional
High fever
Malaise
Fatigue

Skin
Erythema marginatum
Subcutaneous nodules

Joints
Migratory polyarthritis

Heart
Valvulitis
Pancarditis

CNS
1–8 months after infection
• Sydenham chorea
• Jerking
• Flinching

Untreated GAS pharyngitis/tonsillitis
Acute infection

Development of antibodies

Molecular mimicry

Type II hypersensitivity reaction
Latent period (2–4 weeks)

Inflammation and cell damage
Rheumatic fever onset

![](L1 Cardiovascular Disease and Dentistry_figures/img_f2175d39e20d657a.webp)
![Pathophysiology and disease course](L1 Cardiovascular Disease and Dentistry_figures/img_ac57550fb267d4c2.webp)</text>
    <formatted_text>#### General Manifestations

- Acute Rheumatic Fever
- Subacute/chronic Rheumatic Fever

#### Acute Rheumatic Fever

- **Etiology:** previous GAS pharyngitis/tonsillitis without antibiotic treatment
- **Peak incidence:** 5–15 years of age
- **Diagnosis:** evidence of a previous GAS infection (e.g., throat culture, rapid antigen detection test, antistreptolysin O, antistreptococcal DNase B test); Revised Jones criteria
- **Treatment:** antibiotic treatment of underlying GAS infection; symptomatic treatment of arthritis and fever

#### Clinical Features

- **Constitutional:** high fever, malaise, fatigue
- **Skin:** erythema marginatum, subcutaneous nodules
- **Joints:** migratory polyarthritis
- **Heart:** valvulitis, pancarditis
- **CNS:** 1–8 months after infection — Sydenham chorea, jerking, flinching

#### Pathogenesis

Untreated GAS pharyngitis/tonsillitis → acute infection → development of antibodies → molecular mimicry → Type II hypersensitivity reaction → latent period (2–4 weeks) → inflammation and cell damage → rheumatic fever onset</formatted_text>
    <images>
      <img order="0" bbox="538,279,930,673" bbox_format="xyxy_norm_1000" bbox_origin="top_left" bbox_space="page" type="figure" path="L1 Cardiovascular Disease and Dentistry_figures/img_f2175d39e20d657a.webp">
        <description>An anatomical illustration of a child demonstrating the multisystem manifestations of acute rheumatic fever. The figure uses pointers to link specific body areas to clinical findings, including high fever and malaise (Constitutional), erythema marginatum and subcutaneous nodules (Skin), migratory polyarthritis in the joints, valvulitis and pancarditis (Heart), and Sydenham chorea with jerking and flinching (CNS).</description>
      </img>
      <img order="1" bbox="359,712,926,774" bbox_format="xyxy_norm_1000" bbox_origin="top_left" bbox_space="page" type="diagram" path="L1 Cardiovascular Disease and Dentistry_figures/img_ac57550fb267d4c2.webp" caption="Pathophysiology and disease course">
        <description>A horizontal flowchart illustrating the pathophysiology of rheumatic fever, progressing from untreated GAS pharyngitis/tonsillitis through antibody development, molecular mimicry, and Type II hypersensitivity to inflammation and cell damage. The sequence is categorized below into three phases: acute infection, a latent period (2-4 weeks), and rheumatic fever onset.</description>
      </img>
    </images>
  </page>
  <page number="50">
    <text>RHEUMATIC FEVER AND RHEUMATIC HEART DISEASE

GENERAL MANIFESTATIONS

• Rheumatic Heart Disease
  • Valvular damage $\rightarrow$ regurgitation, stenosis $\rightarrow$ IE risk
  • Early heart disease: Heart murmur
  • Late effects: heart enlargement, cardiac failure
• Other:
  • Shortness of breath
  • Chest pain
  • Fatigue
  • Swollen legs and feet

Mitral valve
Aortic valve
Carditis

![Rheumatic heart disease](L1 Cardiovascular Disease and Dentistry_figures/img_54016cbcea1ff0d4.webp)
![Early stages: regurgitation](L1 Cardiovascular Disease and Dentistry_figures/img_71b7f377001e17ca.webp)
![Late stages: stenosis](L1 Cardiovascular Disease and Dentistry_figures/img_15f28f7241cda1cf.webp)</text>
    <formatted_text>#### General Manifestations

- **Rheumatic Heart Disease**
  - Valvular damage → regurgitation, stenosis → IE risk
  - Early heart disease: heart murmur
  - Late effects: heart enlargement, cardiac failure
- **Other:**
  - Shortness of breath
  - Chest pain
  - Fatigue
  - Swollen legs and feet

Mitral valve, aortic valve — carditis</formatted_text>
    <images>
      <img order="0" bbox="489,359,733,769" bbox_format="xyxy_norm_1000" bbox_origin="top_left" bbox_space="page" type="image" path="L1 Cardiovascular Disease and Dentistry_figures/img_54016cbcea1ff0d4.webp" caption="Rheumatic heart disease"/>
      <img order="1" bbox="762,353,842,462" bbox_format="xyxy_norm_1000" bbox_origin="top_left" bbox_space="page" type="diagram" path="L1 Cardiovascular Disease and Dentistry_figures/img_71b7f377001e17ca.webp" caption="Early stages: regurgitation">
        <description>A schematic cross-section of a heart valve showing two leaflets that are failing to coapt (close) completely, leaving a central gap. This visualizes the concept of valvular regurgitation, where blood leaks backward through the open valve.</description>
      </img>
      <img order="2" bbox="763,615,845,725" bbox_format="xyxy_norm_1000" bbox_origin="top_left" bbox_space="page" type="diagram" path="L1 Cardiovascular Disease and Dentistry_figures/img_15f28f7241cda1cf.webp" caption="Late stages: stenosis">
        <description>Anatomical diagram showing a cross-section of the heart with a focus on the mitral valve. The image illustrates the late stages of rheumatic heart disease, specifically depicting stenosis where the valve leaflets appear thickened and fused, narrowing the opening.</description>
      </img>
    </images>
  </page>
  <page number="51">
    <text>RHEUMATIC FEVER AND RHEUMATIC HEART DISEASE

| Diagnosis | Treatment | Prognosis |
| :--- | :--- | :--- |
| Physical examination | Antibiotic prophylaxis&lt;br&gt;(benzathine benzylpenicillin G) | • Acute phase last 6-12 weeks, definitive cure up to 6 months |
| History collection | Complications:&lt;br&gt;• Anticoagulants&lt;br&gt;• Balloon valvuloplasty&lt;br&gt;• Heart valve repair or replacement&lt;br&gt;• Heart failure management&lt;br&gt;• Lifestyle and prevention | • RF recurrence rate is high (50% in first 5 years) $\rightarrow$ prophylactic therapy with penicillin |
| Echocardiogram | | • Mortality rate: 0.5 per 100,000 |
| Electrocardiogram | | |
| Blood tests | | |

![](L1 Cardiovascular Disease and Dentistry_figures/img_5596a9a3d4c83a59.webp)</text>
    <formatted_text>#### Diagnosis

- Physical examination
- History collection
- Echocardiogram
- Electrocardiogram
- Blood tests

#### Treatment

- Antibiotic prophylaxis (benzathine benzylpenicillin G)
- Complications:
  - Anticoagulants
  - Balloon valvuloplasty
  - Heart valve repair or replacement
  - Heart failure management
  - Lifestyle and prevention

#### Prognosis

- Acute phase lasts 6-12 weeks, definitive cure up to 6 months
- RF recurrence rate is high (50% in first 5 years) → prophylactic therapy with penicillin
- Mortality rate: 0.5 per 100,000</formatted_text>
    <images>
      <img order="0" bbox="38,280,886,732" bbox_format="xyxy_norm_1000" bbox_origin="top_left" bbox_space="page" type="table" path="L1 Cardiovascular Disease and Dentistry_figures/img_5596a9a3d4c83a59.webp">
        <description>A three-column table outlining the clinical management of rheumatic fever and heart disease. The columns are labeled 'Diagnosis', 'Treatment', and 'Prognosis', listing specific medical procedures, medications, and outcome statistics for each category.</description>
      </img>
    </images>
  </page>
  <page number="52">
    <text>**INFECTIVE ENDOCARDITIS**

DEFINITION:
A rare, but dangerous, infection of the endocardial surface of the heart.
Predominantly affects one or more heart valves, especially where there is turbulent blood flow because of valve damage (typically left sided valves).

EPIDEMIOLOGY:
• Relatively uncommon illness with high morbidity and mortality
• 2010: Australian incidence 4.7 cases per 100 000 person-years
• In-hospital mortality variable – increases with age (up to 15% in 80-89 yos)</text>
    <formatted_text>#### Definition

A rare, but dangerous, infection of the endocardial surface of the heart. Predominantly affects one or more heart valves, especially where there is turbulent blood flow because of valve damage (typically left sided valves).

#### Epidemiology

- Relatively uncommon illness with high morbidity and mortality
- 2010: Australian incidence 4.7 cases per 100 000 person-years
- In-hospital mortality variable – increases with age (up to 15% in 80-89 yos)</formatted_text>
  </page>
  <page number="53">
    <text>**INFECTIVE ENDOCARDITIS - AETIOLOGY**

• Endothelial sites with turbulent blood flow
• $\rightarrow$ Platelet and fibrin deposits accumulate (non-thrombotic endocarditis)
• $\rightarrow$ sterile “vegetations” produced
• $\rightarrow$ can be readily infected if a subsequent bacteraemia occurs

Causative organisms: Streptococci viridans (oral) 50-60%, Enterococci (faecal strep) 10%, Staphylococci (skin) 20-30%, Others 10% (Gram negative bacilli – mainly HACEK group, fungi)</text>
    <formatted_text>#### Aetiology

- Endothelial sites with turbulent blood flow
  - → Platelet and fibrin deposits accumulate (non-thrombotic endocarditis)
  - → sterile &quot;vegetations&quot; produced
  - → can be readily infected if a subsequent bacteraemia occurs

#### Causative Organisms

- Streptococci viridans (oral) 50-60%
- Enterococci (faecal strep) 10%
- Staphylococci (skin) 20-30%
- Others 10% (Gram negative bacilli – mainly HACEK group, fungi)</formatted_text>
  </page>
  <page number="54">
    <text>**INFECTIVE ENDOCARDITIS - AETIOLOGY**

ASSOCIATION WITH DENTISTRY:

*   Dental procedures involving bleeding can initiate a bacteraemia that may lead to endocarditis (usually transient and &lt;15min, but occasionally up to 1 hour)

*   Most common types of bacteraemia in IE:
    *   S mutans and S sanguis (both Strep viridans) from dental plaque [40% of IE causative organisms due to complex attachment mechanisms enabling them to adhere to endocardium]
    *   Gram negative bacilli (HACEK group, including AA) occasionally implicated

*   Chance of dental extraction causing IE in patient with valvular disease may be as low as 1 in 3000, therefore bacteraemia not synonymous with IE (or would need antibiotic cover for brushing).

Dental treatment is not the only source of IE-bacteraemia

➔ Susceptible surface + high circulating bacterial loads</text>
    <formatted_text>#### Association with Dentistry

- Dental procedures involving bleeding can initiate a bacteraemia that may lead to endocarditis (usually transient and &lt;15min, but occasionally up to 1 hour)
- Most common types of bacteraemia in IE:
  - S mutans and S sanguis (both Strep viridans) from dental plaque [40% of IE causative organisms due to complex attachment mechanisms enabling them to adhere to endocardium]
  - Gram negative bacilli (HACEK group, including AA) occasionally implicated
- Chance of dental extraction causing IE in patient with valvular disease may be as low as 1 in 3000, therefore bacteraemia not synonymous with IE (or would need antibiotic cover for brushing).

Dental treatment is not the only source of IE-bacteraemia → susceptible surface + high circulating bacterial loads</formatted_text>
    <audio_inserts count="1">
      <insert timestamp="01:06:09" confidence="10" anchor="Dental treatment is not the only source of IE-bacteraemia → susceptible surface ">

&gt; [!note] Lecturer — Bacteraemia and Risk
&gt; Healthy ambulant patients do not generally develop infective endocarditis merely because bacteraemia occurs.
&gt;
&gt; - The condition may occur in edentulous patients, demonstrating that dentistry is not the only source.
&gt; - Risk depends on a susceptible surface, such as damaged endocardium, together with a high bacterial load in the circulation.
</insert>
    </audio_inserts>
  </page>
  <page number="55">
    <text>INFECTIVE ENDOCARDITIS - AETIOLOGY

*   **High risk of IE:** previous IE, prosthetic heart valves or valves repaired with prosthetic material, unrepaired cyanotic congenital heart disease, or some repaired congenital heart detects (up to 6 months after the procedure or lifelong if residual shunt or valvular regurgitation remains), +/- cardiac transplantation with cardiac valvulopathy.
*   **Moderate risk:** previous rheumatic fever, heart murmur, or evidence of native valve disease.

&lt;table&gt;
  &lt;tr&gt;
    &lt;th colspan=&quot;2&quot;&gt;Table 5.32 Main groups affected by infective endocarditis&lt;/th&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;th&gt;Aetiology&lt;/th&gt;
    &lt;th&gt;Approximate % of all cases of infective endocarditis&lt;/th&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td&gt;No obvious cardiac valve disease&lt;/td&gt;
    &lt;td&gt;40&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td&gt;Chronic rheumatic heart disease&lt;/td&gt;
    &lt;td&gt;30&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td&gt;Congenital heart disease&lt;/td&gt;
    &lt;td&gt;10&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td&gt;Prosthetic cardiac valves&lt;/td&gt;
    &lt;td&gt;10&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td&gt;Intravenous drug abuse&lt;/td&gt;
    &lt;td&gt;10&lt;/td&gt;
  &lt;/tr&gt;
&lt;/table&gt;

![Table 5.32 Main groups affected by infective endocarditis](L1 Cardiovascular Disease and Dentistry_figures/img_3f4d9c34d89f6067.webp)</text>
    <formatted_text>#### Risk Groups

- **High risk of IE:** previous IE, prosthetic heart valves or valves repaired with prosthetic material, unrepaired cyanotic congenital heart disease, or some repaired congenital heart defects (up to 6 months after the procedure or lifelong if residual shunt or valvular regurgitation remains), +/- cardiac transplantation with cardiac valvulopathy.
- **Moderate risk:** previous rheumatic fever, heart murmur, or evidence of native valve disease.

#### Table 5.32 Main groups affected by infective endocarditis

| Aetiology | Approximate % of all cases of infective endocarditis |
| :--- | :--- |
| No obvious cardiac valve disease | 40 |
| Chronic rheumatic heart disease | 30 |
| Congenital heart disease | 10 |
| Prosthetic cardiac valves | 10 |
| Intravenous drug abuse | 10 |</formatted_text>
    <images>
      <img order="0" bbox="248,603,653,761" bbox_format="xyxy_norm_1000" bbox_origin="top_left" bbox_space="page" type="table" path="L1 Cardiovascular Disease and Dentistry_figures/img_3f4d9c34d89f6067.webp" caption="Table 5.32 Main groups affected by infective endocarditis">
        <description>Table: A two-column data table listing the main aetiological groups associated with infective endocarditis and their approximate percentage of all cases. The rows detail specific conditions such as chronic rheumatic heart disease (30%), congenital heart disease (10%), prosthetic cardiac valves (10%), and intravenous drug abuse (10%).</description>
      </img>
    </images>
  </page>
  <page number="56">
    <text># INFECTIVE ENDOCARDITIS – GENERAL MANIFESTATIONS

| Variable (flu-like) symptoms | Septic emboli (20-45%) – Systemic manifestations | Cardiac manifestations | Immune complex formation from antigens’ resultant antibodies |
| :--- | :--- | :--- | :--- |
| Fever | • Infarcts brain ($\rightarrow$ stroke), limbs, spleen ($\rightarrow$ splenomegaly), *kidney ($\rightarrow$ haemuria), pulmonary. | Sepsis | Vasculitis |
| Weight loss | • Retinal necrosis and blindness | Tachycardia | Arthritis |
| Headache | • Coronary artery embolism | Hypotension | Renal damage |
| Malaise | • Mycotic aneurysms | Valve destruction | |
| Joint pain | • Focal glomerulonephritis | Murmur | |
| SOB/cough | | Pericarditis | |
| Chest pain (esp IVDUs) | | | |

Common signs: 90% fever, 85% heart murmurs

![](L1 Cardiovascular Disease and Dentistry_figures/img_30b10c8383948c0d.webp)
![Subconjunctival haemorrhages (2–5%) Cerebral emboli (15%) Roth's spots in fundi (rare, &lt; 5%) Petechial haemorrhages on mucous membranes and fundi (20–30%) Poor dentition Splenomegaly (30–40%, long-standing endocarditis only) Systemic emboli (7%) Nail-fold infarct Digital clubbing (10%, long-standing endocarditis only) Splinter haemorrhages (10%) Loss of pulses Petechial rash (40–50%, may be transient) Osler's nodes (5%) Haematuria (60–70%) Cardiac failure (40–50%) Conduction disorder (10–20%) 'Varying' murmurs (90% new or changed murmur)](L1 Cardiovascular Disease and Dentistry_figures/img_dafd735394fc0d22.webp)</text>
    <formatted_text>#### General Manifestations

| Variable (flu-like) symptoms | Septic emboli (20-45%) – systemic manifestations | Cardiac manifestations | Immune complex formation from antigens' resultant antibodies |
| :--- | :--- | :--- | :--- |
| Fever | Infarcts brain (→ stroke), limbs, spleen (→ splenomegaly), kidney (→ haematuria), pulmonary | Sepsis | Vasculitis |
| Weight loss | Retinal necrosis and blindness | Tachycardia | Arthritis |
| Headache | Coronary artery embolism | Hypotension | Renal damage |
| Malaise | Mycotic aneurysms | Valve destruction | |
| Joint pain | Focal glomerulonephritis | Murmur | |
| SOB/cough | | Pericarditis | |
| Chest pain (esp IVDUs) | | | |

Common signs: 90% fever, 85% heart murmurs</formatted_text>
    <images>
      <img order="0" bbox="35,325,501,583" bbox_format="xyxy_norm_1000" bbox_origin="top_left" bbox_space="page" type="table" path="L1 Cardiovascular Disease and Dentistry_figures/img_30b10c8383948c0d.webp">
        <description>A four-column table detailing the general manifestations of infective endocarditis. The columns categorize symptoms into variable (flu-like) symptoms, septic emboli systemic manifestations, cardiac manifestations, and immune complex formation results.</description>
      </img>
      <img order="1" bbox="516,287,965,749" bbox_format="xyxy_norm_1000" bbox_origin="top_left" bbox_space="page" type="image" path="L1 Cardiovascular Disease and Dentistry_figures/img_dafd735394fc0d22.webp" caption="Subconjunctival haemorrhages (2–5%) Cerebral emboli (15%) Roth's spots in fundi (rare, &lt; 5%) Petechial haemorrhages on mucous membranes and fundi (20–30%) Poor dentition Splenomegaly (30–40%, long-standing endocarditis only) Systemic emboli (7%) Nail-fold infarct Digital clubbing (10%, long-standing endocarditis only) Splinter haemorrhages (10%) Loss of pulses Petechial rash (40–50%, may be transient) Osler's nodes (5%) Haematuria (60–70%) Cardiac failure (40–50%) Conduction disorder (10–20%) 'Varying' murmurs (90% new or changed murmur)"/>
    </images>
  </page>
  <page number="57">
    <text>INECTIVE ENDOCARDITIS – GENERAL MANAGEMENT

| Treatment | Prognosis |
| :--- | :--- |
| • Hospital admission for early treatment | • 15-20% die during initial hospital admission; further 10-15% die over the following year |
| • Antibiotic therapy | • 40-45% require surgery during initial hospital admission; further 10% require surgery within 1 yr post-discharge |
| • Severe cases: valve replacement | • Good prognostic factors: young, penicillin-sensitive isolates, early tx |</text>
    <formatted_text>#### General Management

| Treatment | Prognosis |
| :--- | :--- |
| Hospital admission for early treatment | 15-20% die during initial hospital admission; further 10-15% die over the following year |
| Antibiotic therapy | 40-45% require surgery during initial hospital admission; further 10% require surgery within 1 yr post-discharge |
| Severe cases: valve replacement | Good prognostic factors: young, penicillin-sensitive isolates, early tx |</formatted_text>
    <audio_inserts count="2">
      <insert timestamp="01:08:23" confidence="7" anchor="Good prognostic factors: young, penicillin-sensitive isolates, early tx">

&gt; [!note] Lecturer — Endocarditis Antibiotics
&gt; Antibiotic choice is determined by the bacteriological findings and consultation with a microbiologist.
&gt;
&gt; - Penicillin with gentamicin may be used for two weeks when streptococci are the main causative organisms.
</insert>
      <insert timestamp="01:10:47" confidence="4" anchor="- Mitral valve prolapse: protrusion of the valves into the left atrium during sy">
- ==Valve disease does not automatically indicate antibiotic prophylaxis; assess the patient’s specific risk factors using the relevant guidelines==.</insert>
    </audio_inserts>
  </page>
  <page number="58">
    <text>AORTIC AND MITRAL VALVE STENOSIS, REGURGITATION AND PROLAPSE

*   **Aortic stenosis:** narrowing of the aortic valve; this generates an increased pressure in the left ventricle to maintain the blood volume per beat
*   **Aortic regurgitation:** blood propelled to the aorta during systole returns to the left ventricle during diastole due to a defective aortic valve
*   **Mitral valve stenosis:** Narrowing of the mitral valve that generates an increasing pressure in the left atrium of the heart
*   **Mitral valve regurgitation:** The blood propulsed to the left ventricle during systolic contraction returns into the left atrium during diastolic dilatation due to a valve closure defect
*   **Mitral valve prolapse:** Protrusion of the valves into the left atrium during systole. May exist in isolation, but sometimes associated with mitral regurgitation. May be associated with atrial septal defect, patent ductus arteriosus.

$\rightarrow$ DO NOT REQUIRE ANTIBIOTIC PROPHYLAXIS

![Superior vena cava, Aorta, Pulmonary artery, Atrial septum, Pulmonary valve, Aortic valve, Left atrium, Right atrium, Mitral valve, Tricuspid valve, Left ventricle, Right ventricle, Inferior vena cava](L1 Cardiovascular Disease and Dentistry_figures/img_aaf8f079f2544b48.webp)</text>
    <formatted_text>- **Aortic stenosis:** narrowing of the aortic valve; this generates an increased pressure in the left ventricle to maintain the blood volume per beat
- **Aortic regurgitation:** blood propelled to the aorta during systole returns to the left ventricle during diastole due to a defective aortic valve
- **Mitral valve stenosis:** narrowing of the mitral valve that generates an increasing pressure in the left atrium of the heart
- **Mitral valve regurgitation:** the blood propulsed to the left ventricle during systolic contraction returns into the left atrium during diastolic dilatation due to a valve closure defect
- **Mitral valve prolapse:** protrusion of the valves into the left atrium during systole. May exist in isolation, but sometimes associated with mitral regurgitation. May be associated with atrial septal defect, patent ductus arteriosus.

&gt; → DO NOT REQUIRE ANTIBIOTIC PROPHYLAXIS</formatted_text>
    <images>
      <img order="0" bbox="596,310,952,688" bbox_format="xyxy_norm_1000" bbox_origin="top_left" bbox_space="page" type="diagram" path="L1 Cardiovascular Disease and Dentistry_figures/img_aaf8f079f2544b48.webp" caption="Superior vena cava, Aorta, Pulmonary artery, Atrial septum, Pulmonary valve, Aortic valve, Left atrium, Right atrium, Mitral valve, Tricuspid valve, Left ventricle, Right ventricle, Inferior vena cava">
        <description>A labelled anatomical diagram of the human heart showing a coronal cross-section. Blue arrows indicate the direction of blood flow through the chambers and major vessels.</description>
      </img>
    </images>
  </page>
  <page number="59">
    <text># VALVE REPLACEMENT

*   **Tissue valve**
    *   Material: porcine, bovine, human
    *   Lifespan = 10-20 years
        *   Usually for older patients
    *   No turbulence = no anticoagulation required
        *   Unless required for other reason e.g. AF, DVT
    *   No noise

*   **Mechanical valve**
    *   Material: carbon, titanium
    *   Lifespan = highly durable, can last lifetime (30+ years)
        *   Usually for younger patients
    *   Turbulence = anticoagulation required
    *   Noisy

![Mechanical valve Biological valve](L1 Cardiovascular Disease and Dentistry_figures/img_90bc5ccfdf5cc993.webp)</text>
    <formatted_text>- **Tissue valve**
  - Material: porcine, bovine, human
  - Lifespan = 10-20 years
    - Usually for older patients
  - No turbulence = no anticoagulation required
    - Unless required for other reason e.g. AF, DVT
  - No noise

- **Mechanical valve**
  - Material: carbon, titanium
  - Lifespan = highly durable, can last lifetime (30+ years)
    - Usually for younger patients
  - Turbulence = anticoagulation required
  - Noisy</formatted_text>
    <audio_inserts count="1">
      <insert timestamp="01:11:49" confidence="6" anchor="- Lifespan = highly durable, can last lifetime (30+ years)
    - Usually for you">

&gt; [!note] Lecturer — Valve Selection
&gt; Valve replacement may be considered when medication does not adequately relieve symptoms.
&gt;
&gt; - Indications may include improving quality of life and the ability to exercise.
&gt; - The choice of valve balances durability, medical options and risks.
&gt; - Patients already taking warfarin for atrial fibrillation or deep vein thrombosis may be considered for a mechanical valve.
</insert>
    </audio_inserts>
    <images>
      <img order="0" bbox="525,299,947,584" bbox_format="xyxy_norm_1000" bbox_origin="top_left" bbox_space="page" type="diagram" path="L1 Cardiovascular Disease and Dentistry_figures/img_90bc5ccfdf5cc993.webp" caption="Mechanical valve Biological valve">
        <description>A side-by-side schematic comparison of heart valve replacements, showing a cross-section of the heart with an inset circular view for each type. The left panel depicts a 'Mechanical valve' with dark, rigid leaflets set in a blue sewing ring, while the right panel shows a 'Biological valve' with pale, flexible tissue cusps.</description>
      </img>
    </images>
  </page>
  <page number="60">
    <text>**VALVULAR HEART DISEASE – RISK ASSESSMENT**

• Bacteraemia to heart valves
• Oral hygiene
• Timing to perform dental treatment
• Anticoagulation
• Oral side effects of diuretics (e.g., furosemide), ACE inhibitors, and beta-blockers
• GA/sedation risks: myocarditis
• Concurrent antibiotic therapy</text>
    <formatted_text>#### Risk Assessment

- Bacteraemia to heart valves
- Oral hygiene
- Timing to perform dental treatment
- Anticoagulation
- Oral side effects of diuretics (e.g., furosemide), ACE inhibitors, and beta-blockers
- GA/sedation risks: myocarditis
- Concurrent antibiotic therapy</formatted_text>
  </page>
  <page number="61">
    <text>VALVULAR HEART DISEASE – DENTAL MANAGEMENT

DENTAL MANAGEMENT
• ACCESS:
  • Postpone elective dental care 6 months after episode of RF
  • RHD → IE or valve surgery = urgent management of dental infections (bacteraemia)
    • May be hospital in-patient setting
  • IVDUs: less reliable attendance unless in pain

• CAPACITY/CONSENT:
  • Nil significant

• EDUCATION/PREVENTION
  • Good oral hygiene most important factor in reducing risk in susceptible individuals
  • Preventive measures to avoid caries and periodontal disease
    • OHI for home maintenance, regular dental attendance, diet, etc
  • Patient educated to alert dental providers of RHD/IE history, and need for antibiotic prophylaxis</text>
    <formatted_text>#### Access

- Postpone elective dental care 6 months after episode of RF
- RHD → IE or valve surgery = urgent management of dental infections (bacteraemia)
  - May be hospital in-patient setting
- IVDUs: less reliable attendance unless in pain

#### Capacity/Consent

- Nil significant

#### Education/Prevention

- Good oral hygiene most important factor in reducing risk in susceptible individuals
- Preventive measures to avoid caries and periodontal disease
  - OHI for home maintenance, regular dental attendance, diet, etc
- Patient educated to alert dental providers of RHD/IE history, and need for antibiotic prophylaxis</formatted_text>
    <audio_inserts count="2">
      <insert timestamp="01:14:43" confidence="13" anchor="- Postpone elective dental care 6 months after episode of RF">
    - ==Elective dental care may need to be postponed for six months after infective endocarditis or valve surgery as well as rheumatic fever==.</insert>
      <insert timestamp="01:57:00" confidence="3" anchor="##### **Capacity/Consent**

- Nil significant">

&gt; [!note] Lecturer — Consent and Capacity
&gt; Consider the patient’s ability to consent and tolerate treatment.
&gt;
&gt; - The dental treatment plan should account for the urgency of the cardiac condition and the extent of treatment required.
</insert>
    </audio_inserts>
  </page>
  <page number="62">
    <text>VALVULAR HEART DISEASE – DENTAL MANAGEMENT

DENTAL MANAGEMENT

• SURGERY:
  • Antibiotic prophylaxis (see lecture *Antibiotic Prophylaxis and Dentistry*)
    • Liaise with Infectious Diseases physician if on concurrent antibiotics
  • Consult with physician re: anticoagulation (see lecture *Bleeding Disorders and Dentistry*)
  • LA: use adrenaline with caution, aspirating syringe (IV injection may precipitate arrhythmias)
  • Conscious sedation / GA: avoid when acute RF (myocarditis), hospital environment if required

• SPREAD
  • Infective endocarditis bacteraemia (antibiotic prophylaxis)
  • Possible antibiotic resistance issues</text>
    <formatted_text>#### Surgery

- Antibiotic prophylaxis (see lecture *Antibiotic Prophylaxis and Dentistry*)
  - Liaise with Infectious Diseases physician if on concurrent antibiotics
- Consult with physician re: anticoagulation (see lecture *Bleeding Disorders and Dentistry*)
- LA: use adrenaline with caution, aspirating syringe (IV injection may precipitate arrhythmias)
- Conscious sedation / GA: avoid when acute RF (myocarditis), hospital environment if required

#### Spread of Infection

- Infective endocarditis bacteraemia (antibiotic prophylaxis)
- Possible antibiotic resistance issues</formatted_text>
    <audio_inserts count="1">
      <insert timestamp="01:09:24" confidence="7" anchor="- Conscious sedation / GA: avoid when acute RF (myocarditis), hospital environme">
- ==Patients awaiting urgent valve surgery may require multiple extractions over a short period to become dentally fit==.</insert>
    </audio_inserts>
  </page>
  <page number="63">
    <text># ANTIBIOTIC PROPHYLAXIS

**Table 2.5 Indications for antibiotic prophylaxis for endocarditis**
Printable table

Antibiotic prophylaxis against infective endocarditis is recommended **only** for people who meet **both** of the following criteria:

*   are undergoing a &lt;u&gt;procedure associated with a high risk of a bacteraemia and subsequent infective endocarditis&lt;/u&gt;
*   have a &lt;u&gt;cardiac condition associated with an increased risk of developing infective endocarditis and the highest risk of adverse outcomes from endocarditis.&lt;/u&gt;

&lt;u&gt;Procedures for which endocarditis prophylaxis is recommended for patients with a cardiac condition listed below [NB1]&lt;/u&gt;

*   Dental procedures – only those involving manipulation of the gingival or periapical tissue or perforation of the oral mucosa (eg dental extractions, implant placement, biopsy, removal of soft tissue or bone, subgingival debridement, replanting avulsed teeth) [NB2] [NB3] [12] [33] [44].

**NB1:** Endocarditis prophylaxis is not recommended for procedures other than those covered in this topic. However, surgical prophylaxis may be indicated even if endocarditis prophylaxis is not – see &lt;u&gt;Surgical antibiotic prophylaxis recommendations for specific procedures&lt;/u&gt;.

**NB2:** For a list of dental procedures classified by invasiveness and their indications for endocarditis prophylaxis, see &lt;u&gt;Table 13.29&lt;/u&gt;.

**NB3:** Evidence on the risk of bacteraemia and subsequent infective endocarditis following supragingival debridement is conflicting. Pending further evidence, endocarditis prophylaxis is only recommended for supragingival debridement that involves manipulation of the gingival tissue [49] [50].

Cardiac conditions for which endocarditis prophylaxis is recommended for patients &lt;u&gt;undergoing a procedure listed above [NB5] [NB6] [12] [48] [56]&lt;/u&gt;

*   prosthetic cardiac valve, including transcatheter-implanted prosthesis or homograft
*   prosthetic material used for cardiac valve repair, such as annuloplasty rings and chords
*   previous infective endocarditis
*   ventricular assist devices [36] [56]
*   congenital heart disease **but only** if it involves:
    *   unrepaired cyanotic defects, including palliative shunts and conduits
    *   repaired defects with residual defects at or adjacent to the site of a prosthetic patch or device (which inhibit endothelialisation) [33] [48]
*   rheumatic heart disease [NB7].

**NB5:** Endocarditis prophylaxis is not recommended for patients with forms of valvular or structural heart disease not listed in this table, including patients with mitral valve prolapse, septal defects or cardiac implantable electronic devices.

**NB6:** Patients with a heart transplant who have developed cardiac valvulopathy may also be at high risk of adverse outcomes from endocarditis; consult the patient's cardiologist for specific recommendations.

**NB7:** Endocarditis prophylaxis was previously only recommended for rheumatic heart disease in Aboriginal and Torres Strait Islander peoples, or considered for people with rheumatic heart disease at significant socioeconomic disadvantage. However, studies have demonstrated that rheumatic heart disease is an independent risk factor for the development of and adverse outcomes from infective endocarditis [1] [3] [20].

Therapeutic Guidelines / Antibiotic / Infective endocarditis / Prevention of infective endocarditis [accessed July 2026]</text>
    <formatted_text>#### Table 2.5 Indications for antibiotic prophylaxis for endocarditis

Antibiotic prophylaxis against infective endocarditis is recommended **only** for people who meet **both** of the following criteria:

- are undergoing a procedure associated with a high risk of a bacteraemia and subsequent infective endocarditis
- have a cardiac condition associated with an increased risk of developing infective endocarditis and the highest risk of adverse outcomes from endocarditis.

#### Procedures for which endocarditis prophylaxis is recommended for patients with a cardiac condition listed below [NB1]

- Dental procedures – only those involving manipulation of the gingival or periapical tissue or perforation of the oral mucosa (eg dental extractions, implant placement, biopsy, removal of soft tissue or bone, subgingival debridement, replanting avulsed teeth) [NB2] [NB3] [12] [33] [44].

**NB1:** Endocarditis prophylaxis is not recommended for procedures other than those covered in this topic. However, surgical prophylaxis may be indicated even if endocarditis prophylaxis is not – see Surgical antibiotic prophylaxis recommendations for specific procedures.

**NB2:** For a list of dental procedures classified by invasiveness and their indications for endocarditis prophylaxis, see Table 13.29.

**NB3:** Evidence on the risk of bacteraemia and subsequent infective endocarditis following supragingival debridement is conflicting. Pending further evidence, endocarditis prophylaxis is only recommended for supragingival debridement that involves manipulation of the gingival tissue [49] [50].

#### Cardiac conditions for which endocarditis prophylaxis is recommended for patients undergoing a procedure listed above [NB5] [NB6] [12] [48] [56]

- prosthetic cardiac valve, including transcatheter-implanted prosthesis or homograft
- prosthetic material used for cardiac valve repair, such as annuloplasty rings and chords
- previous infective endocarditis
- ventricular assist devices [36] [56]
- congenital heart disease **but only** if it involves:
  - unrepaired cyanotic defects, including palliative shunts and conduits
  - repaired defects with residual defects at or adjacent to the site of a prosthetic patch or device (which inhibit endothelialisation) [33] [48]
- rheumatic heart disease [NB7].

**NB5:** Endocarditis prophylaxis is not recommended for patients with forms of valvular or structural heart disease not listed in this table, including patients with mitral valve prolapse, septal defects or cardiac implantable electronic devices.

**NB6:** Patients with a heart transplant who have developed cardiac valvulopathy may also be at high risk of adverse outcomes from endocarditis; consult the patient's cardiologist for specific recommendations.

**NB7:** Endocarditis prophylaxis was previously only recommended for rheumatic heart disease in Aboriginal and Torres Strait Islander peoples, or considered for people with rheumatic heart disease at significant socioeconomic disadvantage. However, studies have demonstrated that rheumatic heart disease is an independent risk factor for the development of and adverse outcomes from infective endocarditis [1] [3] [20].

*Therapeutic Guidelines / Antibiotic / Infective endocarditis / Prevention of infective endocarditis [accessed July 2026]*</formatted_text>
    <audio_inserts count="1">
      <insert timestamp="01:17:38" confidence="8" anchor="**NB7:** Endocarditis prophylaxis was previously only recommended for rheumatic ">

&gt; [!note] Lecturer — Guideline Changes
&gt; Therapeutic Guidelines have changed across versions in relation to rheumatic heart disease.
&gt;
&gt; - Rheumatic heart disease was omitted in one previous version.
&gt; - Rheumatic heart disease in First Nations and lower socioeconomic populations was included in a later version.
&gt; - Version 4 included rheumatic heart disease again.
&gt; - Intravenous drug use alone is not an indication for prophylaxis; the relevant cardiac or valvular condition must also be present.
&gt; - A pacemaker or implantable defibrillator alone is not an indication for surgical antibiotic prophylaxis.
</insert>
    </audio_inserts>
  </page>
  <page number="64">
    <text>**ELECTRICAL**
**(DYSRHYTHMIAS)**

Extrasystoles (ectopics)

Tachycardia (including Atrial fibrillation)

Bradycardias</text>
    <formatted_text>- Extrasystoles (ectopics)
- Tachycardia (including Atrial fibrillation)
- Bradycardias</formatted_text>
  </page>
  <page number="65">
    <text># DYSRHYTHMIAS

*   **Definition:** An alternation in the normal rhythm of the heartbeat.
*   **Epidemiology:** 15% of the population
*   **Aetiology:** disorders in heart automaticity (impulse formation) or conductivity (block or delay)

| Abnormal impulse generation | Abnormal impulse conduction |
| :--- | :--- |
| Sinus bradycardia &lt;60 bpm | AV Block – delay/failure conduction from atria to ventricles |
| Sinus tachycardia &gt;100bpm | |
| Atrial flutter | |
| Atrial fibrillation – acute/chronic | |
| Premature ventricular contractions | |
| Ventricular tachycardia | |
| Ventricular fibrillation | |
| Ventricular extrasystole | |

![](L1 Cardiovascular Disease and Dentistry_figures/img_e07c2945d1553a6e.webp)</text>
    <formatted_text>- **Definition:** An alteration in the normal rhythm of the heartbeat.
- **Epidemiology:** 15% of the population
- **Aetiology:** disorders in heart automaticity (impulse formation) or conductivity (block or delay)

| Abnormal impulse generation | Abnormal impulse conduction |
| :--- | :--- |
| Sinus bradycardia &lt;60 bpm | AV Block – delay/failure conduction from atria to ventricles |
| Sinus tachycardia &gt;100 bpm | |
| Atrial flutter | |
| Atrial fibrillation – acute/chronic | |
| Premature ventricular contractions | |
| Ventricular tachycardia | |
| Ventricular fibrillation | |
| Ventricular extrasystole | |</formatted_text>
    <audio_inserts count="1">
      <insert timestamp="01:28:48" confidence="5" anchor="- **Definition:** An alteration in the normal rhythm of the heartbeat.
- **Epide">
- ==Atrial fibrillation is the most common arrhythmia and affects approximately 1% of the general population.==</insert>
    </audio_inserts>
    <images>
      <img order="0" bbox="167,510,834,792" bbox_format="xyxy_norm_1000" bbox_origin="top_left" bbox_space="page" type="table" path="L1 Cardiovascular Disease and Dentistry_figures/img_e07c2945d1553a6e.webp"/>
    </images>
  </page>
  <page number="66">
    <text>DYSRHYTHMIAS - AETIOLOGY

**Causes**
• **Cardiac disease**
• **Drugs**: caffeine, alcohol, smoking, β-2-agonists, digoxin, dopamine, tricyclics, tobacco
• **Metabolic changes**: catecholamines, autonomic/endocrine disease, hyperthyroidism, fever, hypoxia, surgery, persistent vegetative neurological states
• **Electrolyte imbalance**: e.g. secondary to CKD
• **Respiratory**: COPD</text>
    <formatted_text>- **Cardiac disease**
- **Drugs:** caffeine, alcohol, smoking, β-2-agonists, digoxin, dopamine, tricyclics, tobacco
- **Metabolic changes:** catecholamines, autonomic/endocrine disease, hyperthyroidism, fever, hypoxia, surgery, persistent vegetative neurological states
- **Electrolyte imbalance:** e.g. secondary to CKD
- **Respiratory:** COPD</formatted_text>
    <audio_inserts count="1">
      <insert timestamp="01:29:24" confidence="5" anchor="- **Electrolyte imbalance:** e.g. secondary to CKD
- **Respiratory:** COPD">

&gt; [!note] Lecturer — Hyperthyroidism
&gt; Hyperthyroidism may cause dysrhythmias, and treating the thyroid disease may correct the cardiac problem.
</insert>
    </audio_inserts>
  </page>
  <page number="67">
    <text>**DYSRHYTHMIAS – GENERAL MANIFESTATIONS**

**Signs/symptoms**
• Most frequent symptom: Palpitations.
• Others: sickness, syncope, dyspnoea, anxiety, fatigue, chest pain, dizziness.
• May have no symptoms

**Classification:**
• Rate:
    • Tachycardia (fast rate &gt;100bpm)
    • Bradycardia (slow rate &lt;60bpm day, &lt;50bpm night)
    • Irregular
• Mechanism: automaticity, re-entry, fibrillation
• Origin: atrium, ventricle</text>
    <formatted_text>#### Signs/Symptoms

- Most frequent symptom: palpitations.
- Others: sickness, syncope, dyspnoea, anxiety, fatigue, chest pain, dizziness.
- May have no symptoms.

#### Classification

- **Rate:**
  - Tachycardia (fast rate &gt;100 bpm)
  - Bradycardia (slow rate &lt;60 bpm day, &lt;50 bpm night)
  - Irregular
- **Mechanism:** automaticity, re-entry, fibrillation
- **Origin:** atrium, ventricle</formatted_text>
    <audio_inserts count="2">
      <insert timestamp="00:51:28" confidence="3" anchor="- **Origin:** atrium, ventricle">
- ==Students are not expected to memorise every type, but should recognise the terms and understand that they may affect dental management.==</insert>
      <insert timestamp="01:30:50" confidence="4" anchor="- Cardioversion restores regular rhythm
- Pharmacological (chemical) cardioversi">
- ==Electrical cardioversion uses electrical shocks when medication is ineffective.==</insert>
    </audio_inserts>
  </page>
  <page number="68">
    <text>DYSRHYTHMIAS – GENERAL MANIFESTATIONS

Types of Arrhythmias

| Extrasystoles | Tachycardias |
| :--- | :--- |
| Premature beats | Sinus tachycardia |
| Atrial extrasystoles | Sinus node re-entrant tachycardia |
| Ventricular extrasystoles | Atrioventricular tachyarrhthmia |
| | Supraventricular tachycardia |
| **Inherited Disorders** | • Atrial flutter |
| Long QT syndrome | • *Atrial fibrillation |
| Brugada syndrome | • Paroxysmal AF |
| | • Persistent AF |
| **Bradycardias** | • Permanent AF |
| Sinus bradycardia | • Paroxysmal atrial tachycardia |
| Sinus arrest | • Paroxysmal supraventricular tachycardia |
| Atrioventricular block, bundle branch block, heart block | • Wolff-Parkinson-White syndrome |
| | Ventricular tachycardia |
| | Ventricular fibrillation |

![](L1 Cardiovascular Disease and Dentistry_figures/img_05a77d05f548ca26.webp)</text>
    <formatted_text>#### Types of Arrhythmias

| Extrasystoles | Tachycardias |
| :--- | :--- |
| Premature beats | Sinus tachycardia |
| Atrial extrasystoles | Sinus node re-entrant tachycardia |
| Ventricular extrasystoles | Atrioventricular tachyarrhythmia |
| | Supraventricular tachycardia |
| | • Atrial flutter |
| | • Atrial fibrillation |
| | • Paroxysmal AF |
| | • Persistent AF |
| | • Permanent AF |
| | • Paroxysmal atrial tachycardia |
| | • Paroxysmal supraventricular tachycardia |
| | • Wolff-Parkinson-White syndrome |
| | Ventricular tachycardia |
| | Ventricular fibrillation |
| **Inherited Disorders** | |
| Long QT syndrome | |
| Brugada syndrome | |
| **Bradycardias** | |
| Sinus bradycardia | |
| Sinus arrest | |
| Atrioventricular block, bundle branch block, heart block | |</formatted_text>
    <images>
      <img order="0" bbox="116,337,784,813" bbox_format="xyxy_norm_1000" bbox_origin="top_left" bbox_space="page" type="table" path="L1 Cardiovascular Disease and Dentistry_figures/img_05a77d05f548ca26.webp">
        <description>A two-column table listing various types of cardiac arrhythmias categorized under headings such as Extrasystoles, Inherited Disorders, Bradycardias, and Tachycardias.</description>
      </img>
    </images>
  </page>
  <page number="69">
    <text>DYSRHYTHMIAS – GENERAL MANAGEMENT

| Identify cause | If no underling cause | Treatments |
| :--- | :--- | :--- |
| May only need treatment for this | Treatment depends on type/severity of arrhythmia&lt;br&gt;Focus: controlling RATE and RHYTHM | Medications&lt;br&gt;Pharmacological cardioversion&lt;br&gt;Electric cardioversion&lt;br&gt;Pacemaking / Defibrillation&lt;br&gt;Surgery |</text>
    <formatted_text>| Identify cause | If no underlying cause | Treatments |
| :--- | :--- | :--- |
| May only need treatment for this | Treatment depends on type/severity of arrhythmia. Focus: controlling RATE and RHYTHM | Medications&lt;br&gt;Pharmacological cardioversion&lt;br&gt;Electric cardioversion&lt;br&gt;Pacemaking / Defibrillation&lt;br&gt;Surgery |</formatted_text>
  </page>
  <page number="70">
    <text>DYSRHYTMIAS – GENERAL MANAGEMENT

**Medications**
• Control abnormal heart rhythm: anti-arrhythmic drugs (Vaughan Williams Classification)
• Treat related hypertension/CAD/heart failure: adenosine, digoxin
• Reduce stroke risk: DOACs

| Class | Drug | Action |
| :--- | :--- | :--- |
| Class I | Membrane depressant drugs – quinidine, disopyramide | Sodium channel blockers – may slow conduction, delay recovery or reduce spontaneous discharge rate = VT or AF |
| Class II | Beta-adrenoceptor blocking drugs - propranolol | Anti-sympathetic nervous system. Decrease MI mortality, prevent recurrence of tachyarrhythmias |
| Class III | Drugs that prolong action potential | Potassium channel blockers. Amiodorone. Used for atrial flutter and AF |
| Class IV | Calcium-channel blockers – verapamil and diltiazem | Reduce ventricular rate in those with AF. |
| Other | Direct nodal inhibition - Adenosine and digoxin | Used for heart failure with AF |

![Antiarrhythmic drugs (Vaughan Williams classification)](L1 Cardiovascular Disease and Dentistry_figures/img_c1262d8e28b8e270.webp)</text>
    <formatted_text>#### Medications

- Control abnormal heart rhythm: anti-arrhythmic drugs (Vaughan Williams Classification)
- Treat related hypertension/CAD/heart failure: adenosine, digoxin
- Reduce stroke risk: DOACs

| Class | Drug | Action |
| :--- | :--- | :--- |
| Class I | Membrane depressant drugs – quinidine, disopyramide | Sodium channel blockers – may slow conduction, delay recovery or reduce spontaneous discharge rate = VT or AF |
| Class II | Beta-adrenoceptor blocking drugs – propranolol | Anti-sympathetic nervous system. Decrease MI mortality, prevent recurrence of tachyarrhythmias |
| Class III | Drugs that prolong action potential | Potassium channel blockers. Amiodarone. Used for atrial flutter and AF |
| Class IV | Calcium-channel blockers – verapamil and diltiazem | Reduce ventricular rate in those with AF |
| Other | Direct nodal inhibition – adenosine and digoxin | Used for heart failure with AF |</formatted_text>
    <images>
      <img order="0" bbox="426,517,855,815" bbox_format="xyxy_norm_1000" bbox_origin="top_left" bbox_space="page" type="table" path="L1 Cardiovascular Disease and Dentistry_figures/img_c1262d8e28b8e270.webp" caption="Antiarrhythmic drugs (Vaughan Williams classification)">
        <description>A five-row table categorizing antiarrhythmic medications according to the Vaughan Williams classification system. The columns list the drug Class (I through IV plus Other), specific Drug examples, and their physiological Action.</description>
      </img>
    </images>
  </page>
  <page number="71">
    <text>**DYSRHYTHMIAS – GENERAL MANAGEMENT**

**Cardioversion**
• Restores regular &lt;u&gt;rhythm&lt;/u&gt;
• Pharmacological (chemical) cardioversion
• Electrical cardioversion

**Cardiovascular Implantable Electronic Devices (CIEDs)**
• Permanent pacemakers
• External cardiac defibrillators
• Ventricular assistive devices (VAD)
• Implantable Cardioverter Defibrillator (ICD)

**Radiofrequency Ablation (Catheter Ablation)**</text>
    <formatted_text>#### Cardioversion

- Restores regular rhythm
- Pharmacological (chemical) cardioversion
- Electrical cardioversion

#### Cardiovascular Implantable Electronic Devices (CIEDs)

- Permanent pacemakers
- External cardiac defibrillators
- Ventricular assistive devices (VAD)
- Implantable Cardioverter Defibrillator (ICD)

#### Radiofrequency Ablation (Catheter Ablation)</formatted_text>
    <audio_inserts count="3">
      <insert timestamp="01:33:09" confidence="10" anchor="- External cardiac defibrillators
- Ventricular assistive devices (VAD)
- Implan">

&gt; [!note] Lecturer — Device Activation
&gt; Implantable cardioverter defibrillators may activate without significant warning.
&gt;
&gt; - Activation may cause the patient to flinch, bite down or move suddenly.
&gt; - Some devices may cause loss of consciousness when activated, although this is less likely with newer devices.
</insert>
      <insert timestamp="01:31:32" confidence="9" anchor="#### **Radiofrequency Ablation (Catheter Ablation)**">

&gt; [!note] Lecturer — Radiofrequency Ablation
&gt; Radiofrequency ablation uses radiofrequency energy to destroy cardiac tissue producing abnormal electrical signals. It may be used when medication is ineffective or cannot be tolerated.
</insert>
      <insert timestamp="01:32:53" confidence="2" anchor="- Consider:
  - Anticoagulation.
  - Oral side effects of medication.
  - The po">
- ==Assess the risk of sudden device activation and whether the patient may be injured by sudden movement.==</insert>
    </audio_inserts>
  </page>
  <page number="72">
    <text>DYSRHYTHMIAS – DENTAL MANIFESTATIONS

**Anti-arrhythmic drugs**
• Gingival swelling = verapamil/diltiazem (Ca-channel blockers), enalapril (ACE inhibitor)
• Lichenoid ulceration and oral ulceration related to agranulocytosis = some β-blockers
• Lupus-like reaction and mucosal ulcers due to agranulocytosis = procainamide
• Xerostomia = disopyramide</text>
    <formatted_text>#### Anti-arrhythmic Drugs

- Gingival swelling = verapamil/diltiazem (Ca-channel blockers), enalapril (ACE inhibitor)
- Lichenoid ulceration and oral ulceration related to agranulocytosis = some β-blockers
- Lupus-like reaction and mucosal ulcers due to agranulocytosis = procainamide
- Xerostomia = disopyramide</formatted_text>
  </page>
  <page number="73">
    <text>DYSRHYTHMIAS – RISK ASSESSMENT
73

• Anticoagulation (see *Bleeding Disorders* lecture)
• Oral side effects of drugs (see *Hypertension* section)
• CIED interference</text>
    <formatted_text>- Anticoagulation (see *Bleeding Disorders* lecture)
- Oral side effects of drugs (see *Hypertension* section)
- CIED interference</formatted_text>
  </page>
  <page number="74">
    <text>**DYSRHYTHMIAS – CARDIAC IMPLANTABLE ELECTRONIC DEVICES**

*   Patients with CIED can undergo most general dental treatment.
*   Surgical diathermy can interfere with some CEIDs (especially monopolar)
*   With modern CIEDs, interference from most other dental electronic and ultrasonic devices is usually not clinically significant
    *   Consult cardiologist if in doubt
*   CIED is not an indication for surgical nor IE antibiotic prophylaxis
*   LVADs increase risk of thrombotic events ∴ increased risk of post-op bleeding
    *   patients may be on antithrombotics
    *   LVAD-induced blood pressure changes</text>
    <formatted_text>- Patients with CIED can undergo most general dental treatment.
- Surgical diathermy can interfere with some CIEDs (especially monopolar).
- With modern CIEDs, interference from most other dental electronic and ultrasonic devices is usually not clinically significant.
  - Consult cardiologist if in doubt.
- CIED is not an indication for surgical nor IE antibiotic prophylaxis.
- LVADs increase risk of thrombotic events ∴ increased risk of post-op bleeding.
  - Patients may be on antithrombotics.
  - LVAD-induced blood pressure changes.</formatted_text>
  </page>
  <page number="75">
    <text>DYSRHYTMIAS – CARDIAC IMPLANTABLE ELECTRONIC DEVICES

Further info on interference (American Dental Association):
https://www.ada.org/resources/ada-library/oral-health-topics/cardiac-implanted-devices-and-electronic-dental-instruments

| Device | Reported Electromagnetic Interference: In-Vitro (laboratory testing) | Reported Electromagnetic Interference: In-Vivo (in people) |
| :--- | :--- | :--- |
| Ultrasonic dental scalers | | |
| Piezoelectric | None, $^{13}$ Minor to Severe$^{6, 11}$ | None,$^{1}$ Minor$^{13}$ |
| Magnetostrictive | None,$^{15}$ Minor$^{4}$ | Minor$^{10}$ |
| Electronic apex locators | None,$^{14, 21, 22}$ Minor$^{2, 6, 11}$ | Minor$^{8, 13}$ to Severe$^{8}$ |
| Electric pulp testers | None,$^{6, 14}$ Minor,$^{6, 11, 18}$ Severe$^{6, 11}$ | None,$^{10}$ Minor$^{13}$ |
| Electrosurgery instruments | None,$^{4}$ Minor$^{6, 11, 18}$ to Severe$^{6, 11, 14, 18}$ | N.A. |
| Curing lights | Minor,$^{18}$ Severe$^{4}$ | None$^{10}$ |
| Gutta percha devices | None,$^{18}$ Minor$^{2}$ | Minor$^{8}$ |
| Ultrasonic cleaning systems | Severe$^{4}$ | Minor$^{10}$ |
| Electric toothbrushes | None$^{4}$ | Minor (rare)$^{10}$ |
| Osseointegration tools | Minor to Severe$^{6, 11}$ | N.A. |

&quot;Minor&quot; refers to non-clinically significant interference (noise, telemetry); &quot;Severe,&quot; to clinically significant outcomes (i.e., pacing disturbances or shock); &quot;N.A.&quot; (Not Applicable), no studies available.

![Table 1. Tests of dental devices and reported electromagnetic interference.](L1 Cardiovascular Disease and Dentistry_figures/img_01f96558d4e9e198.webp)</text>
    <formatted_text>Further info on interference (American Dental Association):
https://www.ada.org/resources/ada-library/oral-health-topics/cardiac-implanted-devices-and-electronic-dental-instruments

| Device | Reported Electromagnetic Interference: In-Vitro (laboratory testing) | Reported Electromagnetic Interference: In-Vivo (in people) |
| :--- | :--- | :--- |
| Ultrasonic dental scalers | | |
| Piezoelectric | None,¹³ Minor to Severe⁶, ¹¹ | None,¹ Minor¹³ |
| Magnetostrictive | None,¹⁵ Minor⁴ | Minor¹⁰ |
| Electronic apex locators | None,¹⁴, ²¹, ²² Minor², ⁶, ¹¹ | Minor⁸, ¹³ to Severe⁸ |
| Electric pulp testers | None,⁶, ¹⁴ Minor,⁶, ¹¹, ¹⁸ Severe⁶, ¹¹ | None,¹⁰ Minor¹³ |
| Electrosurgery instruments | None,⁴ Minor⁶, ¹¹, ¹⁸ to Severe⁶, ¹¹, ¹⁴, ¹⁸ | N.A. |
| Curing lights | Minor,¹⁸ Severe⁴ | None¹⁰ |
| Gutta percha devices | None,¹⁸ Minor² | Minor⁸ |
| Ultrasonic cleaning systems | Severe⁴ | Minor¹⁰ |
| Electric toothbrushes | None⁴ | Minor (rare)¹⁰ |
| Osseointegration tools | Minor to Severe⁶, ¹¹ | N.A. |

&quot;Minor&quot; refers to non-clinically significant interference (noise, telemetry); &quot;Severe,&quot; to clinically significant outcomes (i.e., pacing disturbances or shock); &quot;N.A.&quot; (Not Applicable), no studies available.</formatted_text>
    <images>
      <img order="0" bbox="529,267,925,797" bbox_format="xyxy_norm_1000" bbox_origin="top_left" bbox_space="page" type="table" path="L1 Cardiovascular Disease and Dentistry_figures/img_01f96558d4e9e198.webp" caption="Table 1. Tests of dental devices and reported electromagnetic interference.">
        <description>Table: This data table lists various dental devices and summarizes reported electromagnetic interference findings from in-vitro (laboratory) and in-vivo (human) studies. It categorizes the severity of interference as None, Minor, Severe, or N.A. for items such as ultrasonic scalers, apex locators, and electrosurgery instruments.</description>
      </img>
    </images>
  </page>
  <page number="76">
    <text># DYSRHYTHMIAS – DENTAL MANAGEMENT
76

**Access**
*   Peak endogenous epinephrine levels in early morning $\rightarrow$ ideally appointments late morning or early afternoon
*   High risk patients – treated in hospital

**Education/Prevention:**
*   Oral side effects of medication

**Surgery**
*   Liaise with cardiologist if concerned about CIED interference
*   Pre-operative: anxiety management, check INR if warfarinated, defibrillator readily available
*   Peri-operative:
    *   Positioning: supine if pacemaker
    *   LA: adequate provision, judicious use of vasoconstrictor, avoid intravenous injection
    *   Sedation: oxygen saturation monitoring, may be helpful to minimise stress
*   Post-operative: haemostasis if anticoagulated</text>
    <formatted_text>#### Access

- Peak endogenous epinephrine levels in early morning → ideally appointments late morning or early afternoon
- High risk patients – treated in hospital

#### Education/Prevention

- Oral side effects of medication

#### Surgery

- Liaise with cardiologist if concerned about CIED interference
- Pre-operative: anxiety management, check INR if warfarinated, defibrillator readily available
- Peri-operative:
  - Positioning: supine if pacemaker
  - LA: adequate provision, judicious use of vasoconstrictor, avoid intravenous injection
  - Sedation: oxygen saturation monitoring, may be helpful to minimise stress
- Post-operative: haemostasis if anticoagulated</formatted_text>
    <audio_inserts count="1">
      <insert timestamp="02:03:26" confidence="2" anchor="- Post-operative: haemostasis if anticoagulated">

&gt; [!note] Lecturer — Anticoagulant Choice
&gt; Many patients now take a direct oral anticoagulant rather than warfarin.
</insert>
    </audio_inserts>
  </page>
  <page number="77">
    <text>**MUSCULAR**
**(CARDIOMYOPATHIES)**

Primary – genetic/inherited, acquired

Secondary</text>
    <formatted_text>- Primary – genetic/inherited, acquired
- Secondary</formatted_text>
  </page>
  <page number="78">
    <text>CARDIOMYOPATHIES

**Definition:** broad term for diseases of the heart muscle that result in reduced ability for the heart to pump blood to the rest of the body.

Aetiology

| Primary | Secondary |
| :--- | :--- |
| Genetic/Inherited | • Storage: haemochromatosis, Fabry disease |
| • Hypertrophic cardiomyopathy (HCM) | • Infiltrative: amyloidosis, Hurlers syndrome |
| • Dilated cardiomyopathy (DCM) | • Toxicity: alcohol, radiation |
| • Arrythmogenic R ventricular (ARVC) | • Nutrition: Beri-beri, Kwashiorkor |
| Acquired | • Autoimmune: SLE, RA |
| • Alcohol, chemotherapeutics (*most common acquired cause*) | • Neuromuscular: Friedrich’s ataxia |
| • Tako-tsubo cardiomyopathy | • Endocrine: Diabetes, thyroid disease, phaeochromocytoma |
| • Tachycardia induced | |
| • Muscular dystrophies | |

![](L1 Cardiovascular Disease and Dentistry_figures/img_d816a553ad1e5a36.webp)</text>
    <formatted_text>**Definition:** broad term for diseases of the heart muscle that result in reduced ability for the heart to pump blood to the rest of the body.

#### Aetiology

**Primary**

- Genetic/Inherited
  - Hypertrophic cardiomyopathy (HCM)
  - Dilated cardiomyopathy (DCM)
  - Arrythmogenic R ventricular (ARVC)
- Acquired
  - Alcohol, chemotherapeutics (*most common acquired cause*)
  - Tako-tsubo cardiomyopathy
  - Tachycardia induced
  - Muscular dystrophies

**Secondary**

- Storage: haemochromatosis, Fabry disease
- Infiltrative: amyloidosis, Hurlers syndrome
- Toxicity: alcohol, radiation
- Nutrition: Beri-beri, Kwashiorkor
- Autoimmune: SLE, RA
- Neuromuscular: Friedrich's ataxia
- Endocrine: Diabetes, thyroid disease, phaeochromocytoma</formatted_text>
    <images>
      <img order="0" bbox="49,408,865,785" bbox_format="xyxy_norm_1000" bbox_origin="top_left" bbox_space="page" type="table" path="L1 Cardiovascular Disease and Dentistry_figures/img_d816a553ad1e5a36.webp">
        <description>A two-column table titled 'Aetiology' that categorizes the causes of cardiomyopathies into 'Primary' and 'Secondary' groups. The Primary column lists Genetic/Inherited conditions (HCM, DCM, ARVC) and Acquired causes (Alcohol/chemotherapeutics, Tako-tsubo, etc.), while the Secondary column details systemic associations such as Storage, Infiltrative, Toxicity, Nutrition, Autoimmune, Neuromuscular, and Endocrine disorders.</description>
      </img>
    </images>
  </page>
  <page number="79">
    <text>CARDIOMYOPATHIES – GENERAL MANIFESTATIONS AND MANAGEMENT

| Signs/Symptoms | Management |
| :--- | :--- |
| • Oedema (pulmonary, peripheral – ankles &amp; legs, abdominal) | • Lifestyle changes: diet, exercise, stress, avoid tobacco/alcohol |
| • Thrombi/emboli/clot formation | • Medications: hypertension drugs, anti-arrhythmic drugs, oral anticoagulants. Often: beta blockers, potassium channel blockers. Other: CCBs (verapamil, diltiazem) +/- ACEIs, diuretics, digoxin. |
| • Exertional and paroxysmal nocturnal dyspnoea (SOB) | • Devices to correct arrhythmias: pacemakers, ICDs |
| • Arrhythmias | • Devices to improve blood flow: LVAD, cardiac resynchronisation therapy (CRT) |
| • Nausea | • Procedures: catheter ablation, heart transplant |
| • Chest pain | |
| • Palpitations | |
| • Fainting | |
| • Sudden cardiac death | |

![](L1 Cardiovascular Disease and Dentistry_figures/img_a97849a2f782a916.webp)</text>
    <formatted_text>#### Signs/Symptoms

- Oedema (pulmonary, peripheral – ankles &amp; legs, abdominal)
- Thrombi/emboli/clot formation
- Exertional and paroxysmal nocturnal dyspnoea (SOB)
- Arrhythmias
- Nausea
- Chest pain
- Palpitations
- Fainting
- Sudden cardiac death

#### Management

- Lifestyle changes: diet, exercise, stress, avoid tobacco/alcohol
- Medications: hypertension drugs, anti-arrhythmic drugs, oral anticoagulants. Often: beta blockers, potassium channel blockers. Other: CCBs (verapamil, diltiazem) +/- ACEIs, diuretics, digoxin.
- Devices to correct arrhythmias: pacemakers, ICDs
- Devices to improve blood flow: LVAD, cardiac resynchronisation therapy (CRT)
- Procedures: catheter ablation, heart transplant</formatted_text>
    <audio_inserts count="2">
      <insert confidence="1" anchor="Nausea
- Chest pain
- Palpitations
- Fainting
- Sudden cardiac death">
- ==Fatigue==</insert>
      <insert timestamp="01:38:57" confidence="6" anchor="Devices to improve blood flow: LVAD, cardiac resynchronisation therapy (CRT)
- P">

&gt; [!note] Lecturer — Cardiomyopathy Management
&gt; Cardiomyopathy may worsen over time, but treatment can slow progression and improve quality of life.
&gt;
&gt; - Management depends on the underlying cause and associated medical conditions.
&gt; - Dental management follows the general cardiovascular risk-assessment and access framework.
</insert>
    </audio_inserts>
    <images>
      <img order="0" bbox="86,325,856,766" bbox_format="xyxy_norm_1000" bbox_origin="top_left" bbox_space="page" type="table" path="L1 Cardiovascular Disease and Dentistry_figures/img_a97849a2f782a916.webp">
        <description>A two-column table listing the general signs and symptoms of cardiomyopathies on the left (e.g., oedema, arrhythmias, chest pain) alongside their corresponding management strategies on the right (e.g., lifestyle changes, medications, devices).</description>
      </img>
    </images>
  </page>
  <page number="80">
    <text/>
  </page>
  <page number="81">
    <text>**CONGENITAL HEART DISEASE**

**Definition**
*   Any congenital structural defects of the heart (including valve stenosis or septal defects) or adjacent great vessels that lead to malfunction (arrhythmias or flow problems). Can be alone or in combinations.

**Epidemiology**
*   Is the most common type of heart problem in children (1% live births). 20% also have other congenital anomalies.
*   Diagnosed in at least 1 in 180 births (1-2% of the population)</text>
    <formatted_text>#### Definition

- Any congenital structural defects of the heart (including valve stenosis or septal defects) or adjacent great vessels that lead to malfunction (arrhythmias or flow problems). Can occur alone or in combinations.

#### Epidemiology

- The most common type of heart problem in children (1% of live births); 20% also have other congenital anomalies.
- Diagnosed in at least 1 in 180 births (1–2% of the population).</formatted_text>
  </page>
  <page number="82">
    <text>**CONGENITAL HEART DISEASE**

**Aetiology**
*   Often unidentified, multifactorial, genetic, and environmental factors.
*   Acquired causes:
    *   maternal infections (Rubella, Cytomegalovirus)
    *   maternal drug use (alcohol, anticonvulsants, lithium, thalidomide, warfarin, other drugs
    *   maternal systemic disease (SLE, diabetes); maternal irradiation (rare).
*   Genetic syndromes with cardiac detects:
    *   Chromosomal: Downs, Edwards, Turners
    *   Hereditary: Ehlers-Danlos syndrome, Marfan syndrome, osteogenesis imperfecta, mucopolysaccharidosis, Holt-Oram syndrome, Noonan syndrome, Williams syndrome</text>
    <formatted_text>- Often unidentified, multifactorial — genetic and environmental factors.

#### Acquired Causes

- Maternal infections (Rubella, Cytomegalovirus)
- Maternal drug use (alcohol, anticonvulsants, lithium, thalidomide, warfarin, other drugs)
- Maternal systemic disease (SLE, diabetes); maternal irradiation (rare)

#### Genetic Syndromes with Cardiac Defects

- Chromosomal: Down syndrome, Edwards syndrome, Turner syndrome
- Hereditary: Ehlers-Danlos syndrome, Marfan syndrome, osteogenesis imperfecta, mucopolysaccharidosis, Holt-Oram syndrome, Noonan syndrome, Williams syndrome</formatted_text>
    <audio_inserts count="1">
      <insert timestamp="01:40:38" confidence="7" anchor="Hereditary: Ehlers-Danlos syndrome, Marfan syndrome, osteogenesis imperfecta, mu">
- ==Myler syndrome and other vascular or connective tissue disorders may also be associated with cardiac defects.==</insert>
    </audio_inserts>
  </page>
  <page number="83">
    <text>CONGENITAL HEART DISEASE – GENERAL MANIFESTATIONS

**Classification**
*   Cyanotic (R to L shunting): shunting deoxygenated blood from the right ventricle into the left side of the heart and the systemic circulation (bypassing the lungs)
*   Acyanotic (obstruction, or L to R shunting): blood contains enough oxygen but is pumped abnormally around body, forcing the heart to work harder

| Cyanotic | Acyanotic, no shunt | Acyanotic with shunt |
| :--- | :--- | :--- |
| • Tetralogy of Fallot | • Aortic stenosis | • Atrial septal defect |
| • Eisenmenger syndrome | • Bicuspid aortic valve | • Patent ductus arteriosus |
| • Pulmonary atresia | • Coarctation of the aorta | • Ventricular septal defect |
| • Pulmonary valve stenosis | • Dextrocardia | |
| • Total anomalous venous drainage | • Mitral valve prolapse | |
| • Transposition of the great vessels | | |
| • Tricuspid atresia | | |

![](L1 Cardiovascular Disease and Dentistry_figures/img_3c75eb613fad3250.webp)</text>
    <formatted_text>#### Classification

- **Cyanotic (R to L shunting):** shunting deoxygenated blood from the right ventricle into the left side of the heart and the systemic circulation (bypassing the lungs)
- **Acyanotic (obstruction, or L to R shunting):** blood contains enough oxygen but is pumped abnormally around the body, forcing the heart to work harder

| Cyanotic | Acyanotic, no shunt | Acyanotic with shunt |
| :--- | :--- | :--- |
| Tetralogy of Fallot | Aortic stenosis | Atrial septal defect |
| Eisenmenger syndrome | Bicuspid aortic valve | Patent ductus arteriosus |
| Pulmonary atresia | Coarctation of the aorta | Ventricular septal defect |
| Pulmonary valve stenosis | Dextrocardia | |
| Total anomalous venous drainage | Mitral valve prolapse | |
| Transposition of the great vessels | | |
| Tricuspid atresia | | |</formatted_text>
    <images>
      <img order="0" bbox="134,539,868,797" bbox_format="xyxy_norm_1000" bbox_origin="top_left" bbox_space="page" type="table" path="L1 Cardiovascular Disease and Dentistry_figures/img_3c75eb613fad3250.webp">
        <description>A three-column table classifying congenital heart diseases into Cyanotic, Acyanotic (no shunt), and Acyanotic with shunt categories. Specific conditions such as Tetralogy of Fallot, Aortic stenosis, and Atrial septal defect are listed under their respective headers.</description>
      </img>
    </images>
  </page>
  <page number="84">
    <text>**CONGENITAL HEART DISEASE – GENERAL MANIFESTATIONS**

**Complications**

• Arrhythmias

• Infective endocarditis

• Stroke (cerebral abscess)

• Pulmonary hypertension and oedema

• Polycythaemia/bleeding tendency/thrombotic tendency

• Heart failure</text>
    <formatted_text>#### Complications

- Arrhythmias
- Infective endocarditis
- Stroke (cerebral abscess)
- Pulmonary hypertension and oedema
- Polycythaemia / bleeding tendency / thrombotic tendency
- Heart failure</formatted_text>
  </page>
  <page number="85">
    <text>**CONGENITAL HEART DISEASE – ORAL MANIFESTATIONS**

*   delayed eruption of both dentitions
*   positional anomalies
*   enamel hypoplasia
*   gross vasodilatations in the pulps
*   cleft palate
*   fissure tongue
*   greater caries and periodontal disease (associated to poor oral hygiene and lack in dental attention).</text>
    <formatted_text>- Delayed eruption of both dentitions
- Positional anomalies
- Enamel hypoplasia
- Gross vasodilatations in the pulps
- Cleft palate
- Fissured tongue
- Greater caries and periodontal disease (associated with poor oral hygiene and lack of dental attention)</formatted_text>
    <audio_inserts count="2">
      <insert timestamp="01:42:49" confidence="9" anchor="Greater caries and periodontal disease (associated with poor oral hygiene and la">

&gt; [!note] Lecturer — Oral Disease Burden
&gt; Congenital heart disease may affect growth and development, and increased dental disease may have several contributing factors.
&gt;
&gt; - Multiple medical problems can compete with oral care.
&gt; - Competing appointments may reduce the priority given to oral hygiene.
&gt; - Treatment burnout may further contribute to increased caries and periodontal disease.
</insert>
      <insert timestamp="00:11:48" confidence="4" anchor="| | | Mitral valve disease |
| | | Hypertension |
| | | Cardiomyopathies |
| | |">
- ==Heart failure may result from the progression or complication of cardiovascular conditions, including ischaemic, valvular, muscular and congenital disease.==</insert>
    </audio_inserts>
  </page>
  <page number="86">
    <text/>
  </page>
  <page number="87">
    <text># CARDIAC FAILURE

**Definition:** When structural or functional impairment of the pumping action of the heart leads to blood output insufficient to meet the body’s demands $\rightarrow$ lack of tissue and organ perfusion

**Aetiology:** any structural or functional cardiac or non-cardiac disorder that impairs ability of heart to respond to physiological demands for CO

&lt;table&gt;
  &lt;tr&gt;
    &lt;th colspan=&quot;3&quot;&gt;Table 5.34 Main causes of heart failure&lt;/th&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;th&gt;Left-sided mainly&lt;/th&gt;
    &lt;th&gt;Right-sided mainly&lt;/th&gt;
    &lt;th&gt;Biventricular&lt;/th&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td&gt;Ischaemic heart disease&lt;/td&gt;
    &lt;td&gt;Chronic obstructive pulmonary disease&lt;/td&gt;
    &lt;td&gt;Ischaemic heart disease&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td&gt;Aortic valve disease&lt;/td&gt;
    &lt;td&gt;Pulmonary embolism&lt;/td&gt;
    &lt;td&gt;Aortic valve disease&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td&gt;Mitral valve disease&lt;/td&gt;
    &lt;td&gt;&lt;/td&gt;
    &lt;td&gt;Mitral valve disease&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td&gt;Hypertension&lt;/td&gt;
    &lt;td&gt;&lt;/td&gt;
    &lt;td&gt;Hypertension&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td&gt;&lt;/td&gt;
    &lt;td&gt;&lt;/td&gt;
    &lt;td&gt;Cardiomyopathies&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td&gt;&lt;/td&gt;
    &lt;td&gt;&lt;/td&gt;
    &lt;td&gt;Hyperthyroidism&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td&gt;&lt;/td&gt;
    &lt;td&gt;&lt;/td&gt;
    &lt;td&gt;Chronic anaemias&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td&gt;&lt;/td&gt;
    &lt;td&gt;&lt;/td&gt;
    &lt;td&gt;Arrhythmias&lt;/td&gt;
  &lt;/tr&gt;
&lt;/table&gt;

![Table 5.34 Main causes of heart failure](L1 Cardiovascular Disease and Dentistry_figures/img_1c97d88fbcbe1c37.webp)</text>
    <formatted_text>**Definition:** When structural or functional impairment of the pumping action of the heart leads to blood output insufficient to meet the body's demands → lack of tissue and organ perfusion.

**Aetiology:** Any structural or functional cardiac or non-cardiac disorder that impairs ability of heart to respond to physiological demands for CO.

#### Table 5.34 Main causes of heart failure

| Left-sided mainly | Right-sided mainly | Biventricular |
| --- | --- | --- |
| Ischaemic heart disease | Chronic obstructive pulmonary disease | Ischaemic heart disease |
| Aortic valve disease | Pulmonary embolism | Aortic valve disease |
| Mitral valve disease | | Mitral valve disease |
| Hypertension | | Hypertension |
| | | Cardiomyopathies |
| | | Hyperthyroidism |
| | | Chronic anaemias |
| | | Arrhythmias |</formatted_text>
    <images>
      <img order="0" bbox="262,536,743,797" bbox_format="xyxy_norm_1000" bbox_origin="top_left" bbox_space="page" type="table" path="L1 Cardiovascular Disease and Dentistry_figures/img_1c97d88fbcbe1c37.webp" caption="Table 5.34 Main causes of heart failure">
        <description>A three-column table categorizing the main causes of heart failure into 'Left-sided mainly', 'Right-sided mainly', and 'Biventricular'. The columns list specific conditions such as ischaemic heart disease, chronic obstructive pulmonary disease, and cardiomyopathies under their respective categories.</description>
      </img>
    </images>
  </page>
  <page number="88">
    <text>CARDIAC FAILURE – GENERAL MANIFESTATIONS

LEFT
sided HEART FAILURE
VS
RIGHT
sided HEART FAILURE

Left side of heart can't pump blood out of heart so blood backs up into the LUNGS

Right side of heart can't pump recieved blood to the lungs so blood backs up into the BODY

SYMPTOMS

• Pulmonary congestion:
○ Cough
○ Crackles
○ Pink-tinged sputum
○ Tachypnea
• Tachycardia
• Fatigue
• Cyanosis
• Exertional dyspnea

• Peripheral edema
• Ascites
• Enlarged liver &amp; spleen
• JVD
• Weight gain
• Increased peripheral venous pressure

![](L1 Cardiovascular Disease and Dentistry_figures/img_4543014b12ae9cbe.webp)
![](L1 Cardiovascular Disease and Dentistry_figures/img_86e0ff59120e8faa.webp)</text>
    <formatted_text>#### Left-sided vs Right-sided Heart Failure

- **Left-sided heart failure:** Left side of heart can't pump blood out of heart so blood backs up into the LUNGS
- **Right-sided heart failure:** Right side of heart can't pump received blood to the lungs so blood backs up into the BODY

#### Symptoms

- Pulmonary congestion:
  - Cough
  - Crackles
  - Pink-tinged sputum
  - Tachypnea
- Tachycardia
- Fatigue
- Cyanosis
- Exertional dyspnea

- Peripheral edema
- Ascites
- Enlarged liver &amp; spleen
- JVD
- Weight gain
- Increased peripheral venous pressure</formatted_text>
    <images>
      <img order="0" bbox="824,451,854,478" bbox_format="xyxy_norm_1000" bbox_origin="top_left" bbox_space="page" type="image" path="L1 Cardiovascular Disease and Dentistry_figures/img_4543014b12ae9cbe.webp"/>
      <img order="1" bbox="879,446,912,479" bbox_format="xyxy_norm_1000" bbox_origin="top_left" bbox_space="page" type="image" path="L1 Cardiovascular Disease and Dentistry_figures/img_86e0ff59120e8faa.webp"/>
    </images>
  </page>
  <page number="89">
    <text>CARDIAC FAILURE – GENERAL MANAGEMENT
89

&lt;table&gt;
  &lt;tr&gt;
    &lt;th&gt;Lifestyle changes&lt;/th&gt;
    &lt;th&gt;Pharmacologic&lt;/th&gt;
    &lt;th&gt;Devices&lt;/th&gt;
    &lt;th&gt;Surgical intervention&lt;/th&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td&gt;o Fluid &amp;amp; salt management (limit intake)&lt;/td&gt;
    &lt;td&gt;o Inotropes e.g. digoxin (AF)&lt;/td&gt;
    &lt;td&gt;o Pacemaker&lt;/td&gt;
    &lt;td&gt;o Revascularisation procedures (CABG)&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td&gt;o Minimise alcohol intake&lt;/td&gt;
    &lt;td&gt;o Diuretics e.g. thiazide&lt;/td&gt;
    &lt;td&gt;o Cardiac resynchronisation device&lt;/td&gt;
    &lt;td&gt;o Valve replacement / repair (due to valve damage: CHD, IE, MI)&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td&gt;o Gentle exercise&lt;/td&gt;
    &lt;td&gt;o ACE inhibitors&lt;/td&gt;
    &lt;td&gt;o ICD&lt;/td&gt;
    &lt;td&gt;o Heart transplantation (end stage)&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td&gt;&lt;/td&gt;
    &lt;td&gt;o β blockers&lt;/td&gt;
    &lt;td&gt;&lt;/td&gt;
    &lt;td&gt;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td&gt;&lt;/td&gt;
    &lt;td&gt;o Vasodilators&lt;/td&gt;
    &lt;td&gt;&lt;/td&gt;
    &lt;td&gt;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td&gt;&lt;/td&gt;
    &lt;td&gt;o Aldosterone antagonists&lt;/td&gt;
    &lt;td&gt;&lt;/td&gt;
    &lt;td&gt;&lt;/td&gt;
  &lt;/tr&gt;
&lt;/table&gt;

![](L1 Cardiovascular Disease and Dentistry_figures/img_40f1d4bfcdab7654.webp)</text>
    <formatted_text>| Lifestyle changes | Pharmacologic | Devices | Surgical intervention |
| --- | --- | --- | --- |
| Fluid &amp; salt management (limit intake) | Inotropes e.g. digoxin (AF) | Pacemaker | Revascularisation procedures (CABG) |
| Minimise alcohol intake | Diuretics e.g. thiazide | Cardiac resynchronisation device | Valve replacement / repair (due to valve damage: CHD, IE, MI) |
| Gentle exercise | ACE inhibitors | ICD | Heart transplantation (end stage) |
| | β blockers | | |
| | Vasodilators | | |
| | Aldosterone antagonists | | |</formatted_text>
    <images>
      <img order="0" bbox="32,325,907,691" bbox_format="xyxy_norm_1000" bbox_origin="top_left" bbox_space="page" type="table" path="L1 Cardiovascular Disease and Dentistry_figures/img_40f1d4bfcdab7654.webp"/>
    </images>
  </page>
  <page number="90">
    <text>**HEART FAILURE – DENTAL MANAGEMENT**

*   Do not undertake dental treatment unless medical practitioner advised HF is stable
*   Limit duration of dental procedures
*   Patient may be unable to lie horizontally
    *   Position dental chair with head higher than heart
    *   Comfortable position for sleeping $\rightarrow$ “how many pillows do you use when sleeping?”
*   Increased risk with sedation and GA $\rightarrow$ hospital environment with anaesthetist
*   Avoid NSAIDs if possible
    *   Especially if diuretic + (ACEI or A2RB) $\rightarrow$ risk of acute kidney injury
*   Diuretics + drugs with diuretic effect (e.g. dapagliflozin, empagliflozin) $\rightarrow$ dry mouth
*   May be candidate for heart transplant.
    *   Require dental assessment before being waitlisted
    *   Optimise oral health
    *   May seek hospital dental specialist for advice for pre-transplant dental treatment plan</text>
    <formatted_text>- Do not undertake dental treatment unless medical practitioner advised HF is stable
- Limit duration of dental procedures
- Patient may be unable to lie horizontally
  - Position dental chair with head higher than heart
  - Comfortable position for sleeping → &quot;how many pillows do you use when sleeping?&quot;
- Increased risk with sedation and GA → hospital environment with anaesthetist
- Avoid NSAIDs if possible
  - Especially if diuretic + (ACEI or A2RB) → risk of acute kidney injury
- Diuretics + drugs with diuretic effect (e.g. dapagliflozin, empagliflozin) → dry mouth
- May be candidate for heart transplant.
  - Require dental assessment before being waitlisted
  - Optimise oral health
  - May seek hospital dental specialist for advice for pre-transplant dental treatment plan</formatted_text>
    <audio_inserts count="2">
      <insert timestamp="01:46:20" confidence="7" anchor="- Especially if diuretic + (ACEI or A2RB) → risk of acute kidney injury">
- ==Severe heart failure patients should not be prescribed NSAIDs by a dentist.==</insert>
      <insert timestamp="01:46:59" confidence="8" anchor="- May be candidate for heart transplant.
  - Require dental assessment before be">
    - ==Use regular recalls and preventive management to optimise oral health and avoid delays if transplantation is required.==</insert>
    </audio_inserts>
  </page>
  <page number="91">
    <text/>
  </page>
  <page number="92">
    <text>**TYPES OF CARDIAC SURGERY**

*   Coronary angioplasty and stent (bare metal or drug-eluting) = Percutaneous coronary intervention (PCI)
    *   Improve blood flow through occluded coronary arteries
*   Coronary artery bypass grafting (CABG)
    *   Redirect blood flow around occluded coronary arteries
*   Valve replacement or Transcatheter aortic valve implantation (TAVI)
    *   Replace faulty or damaged heart valves
*   Congenital correction
    *   Repair abnormal or damaged structures
*   Pacemaker or Implantable Cardioverter Defibrillator (ICD) placement
    *   Implant devices to control heart beat or support function / blood flow
*   Cardiac Transplant
    *   Replace a damaged heart, severe heart failure

![](L1 Cardiovascular Disease and Dentistry_figures/img_a2491f164333ecea.webp)</text>
    <formatted_text>- **Coronary angioplasty and stent** (bare metal or drug-eluting) = Percutaneous coronary intervention (PCI)
  - Improve blood flow through occluded coronary arteries
- **Coronary artery bypass grafting (CABG)**
  - Redirect blood flow around occluded coronary arteries
- **Valve replacement or Transcatheter aortic valve implantation (TAVI)**
  - Replace faulty or damaged heart valves
- **Congenital correction**
  - Repair abnormal or damaged structures
- **Pacemaker or Implantable Cardioverter Defibrillator (ICD) placement**
  - Implant devices to control heart beat or support function / blood flow
- **Cardiac Transplant**
  - Replace a damaged heart, severe heart failure</formatted_text>
    <audio_inserts count="1">
      <insert timestamp="01:48:33" confidence="6" anchor="- **Coronary angioplasty and stent** (bare metal or drug-eluting) = Percutaneous">

&gt; [!note] Lecturer — Stent Placement
&gt; A catheter-mounted balloon widens the blocked artery, and a wire mesh stent remains in place to keep it open.
&gt; 
&gt; - Stents may be bare metal, drug-eluting, or non-drug-eluting.
</insert>
    </audio_inserts>
    <images>
      <img order="0" bbox="678,138,999,860" bbox_format="xyxy_norm_1000" bbox_origin="top_left" bbox_space="page" type="photo" path="L1 Cardiovascular Disease and Dentistry_figures/img_a2491f164333ecea.webp">
        <description>A clinical photograph showing a surgical procedure in progress, featuring surgeons in blue scrubs using instruments on a patient draped in green sterile cloth. A monitor displaying an internal view of the surgery is visible in the background along with various medical equipment.</description>
      </img>
    </images>
  </page>
  <page number="93">
    <text>**CARDIAC RISKS OF DENTAL TREATMENT**

*   Risk stratification guidelines: Peri-operative risks for CVD patients undergoing non-cardiac surgical procedures

*   H&amp;N surgery 1-5%, dental surgery / superficial surgery &lt;1%
    *   European Society of Cardiology (ESC) and European Society of Anaesthesiology (ESA) (Halvorsen et al., 2022)
    *   American College of Cardiology (ACC) and American Heart Association (AHA) (Thompson et al, 2024)

*   Smith et al 2014:
    *   Prophylactic dental extractions prior to cardiac surgery carries a **3% risk of death** and **8% risk of major adverse** outcome before cardiac operation

Smith MM, Barbara DW, Mauermann WJ, Viozzi CF, Dearani JA, Grim KJ. Morbidity and Mortality Associated with Dental Extraction Before Cardiac Operation. *Ann Thorac Surg*. 2014; 97: 838-44.

Dr Jee-Yun Leung
93</text>
    <formatted_text>- Risk stratification guidelines: Peri-operative risks for CVD patients undergoing non-cardiac surgical procedures
- H&amp;N surgery 1-5%, dental surgery / superficial surgery &lt;1%
  - European Society of Cardiology (ESC) and European Society of Anaesthesiology (ESA) (Halvorsen et al., 2022)
  - American College of Cardiology (ACC) and American Heart Association (AHA) (Thompson et al, 2024)
- Smith et al 2014:
  - Prophylactic dental extractions prior to cardiac surgery carries a **3% risk of death** and **8% risk of major adverse** outcome before cardiac operation

*Smith MM, Barbara DW, Mauermann WJ, Viozzi CF, Dearani JA, Grim KJ. Morbidity and Mortality Associated with Dental Extraction Before Cardiac Operation. Ann Thorac Surg. 2014; 97: 838-44.*</formatted_text>
    <audio_inserts count="1">
      <insert timestamp="01:49:51" confidence="12" anchor="- H&amp;N surgery 1-5%, dental surgery / superficial surgery &lt;1%
  - European Societ">

&gt; [!note] Lecturer — Cardiac Stress
&gt; Non-cardiac surgery can precipitate a cardiac event because major surgery stresses the cardiovascular system.
&gt; 
&gt; - Patients with limited cardiac reserve may be unable to increase cardiac output adequately in response to stress.
&gt; - Increased adrenaline and catecholamines may cause tachycardia, coronary vasoconstriction, platelet aggregation, coagulation, and an adverse oxygen supply-demand balance.
&gt; - General anaesthetic agents may act directly on the myocardium, decrease muscular tone, produce hypotension, and cause compensatory tachycardia.
&gt; - Dental extraction is generally less extensive than head and neck surgery.
</insert>
    </audio_inserts>
  </page>
  <page number="94">
    <text>“... raises the question whether
we should in fact get on with our
cardiac operations and deal with
the dental work at some other
time, if at all, or risk killing
patients with good intent!”

Unsworth-White 2014 (commentary of Smith et al 2014)

Unsworth-White MJ. Invited Commentary - Morbidity and Mortality Associated with Dental Extraction Before Cardiac Operation. Ann Thorac Surg .
2014;97,844.

2025
Dr Jee-Yun Leung
94</text>
    <formatted_text>&gt; &quot;... raises the question whether we should in fact get on with our cardiac operations and deal with the dental work at some other time, if at all, or risk killing patients with good intent!&quot;

Unsworth-White 2014 (commentary of Smith et al 2014)

*Unsworth-White MJ. Invited Commentary - Morbidity and Mortality Associated with Dental Extraction Before Cardiac Operation. Ann Thorac Surg. 2014;97,844.*</formatted_text>
    <audio_inserts count="1">
      <insert timestamp="01:51:21" confidence="6" anchor="&gt; &quot;... raises the question whether we should in fact get on with our cardiac ope">

&gt; [!note] Lecturer — Extraction Risk
&gt; Subsequent commentaries questioned whether the risks reported for prophylactic dental extractions were as high as originally stated.
&gt; 
&gt; - In some cases, it may be safer to proceed with cardiac surgery first and perform elective dental treatment later.
</insert>
    </audio_inserts>
    <images>
      <img order="0" bbox="770,552,841,617" bbox_format="xyxy_norm_1000" bbox_origin="top_left" bbox_space="page" type="clipart">
        <description>Two dark, slanted rectangular bars on a blue background.</description>
      </img>
    </images>
  </page>
  <page number="95">
    <text>Management of perioperative acute pain and infection (pus, swelling, cellulitis) needs to be a joint decision between the dentist and the physicians caring for the patient planned for cardiothoracic surgery.

**But when should we treat chronic, asymptomatic pathology?**

**Risks outweigh benefits**
X Ischaemic disease
(eg. CABG, PCI, stent, angioplasty)

X Rhythmic disease
(eg. ICD/pacemaker, ablation)

**Benefits may outweigh Risks**
? Valvular disease
(eg. replacement, repairs, TAVI)

? Infective endocarditis
(often leads to valvular surgery)

? Heart transplant (heart failure)

Dr Jee-Yun Leung</text>
    <formatted_text>Management of perioperative acute pain and infection (pus, swelling, cellulitis) needs to be a joint decision between the dentist and the physicians caring for the patient planned for cardiothoracic surgery.

**But when should we treat chronic, asymptomatic pathology?**

#### Risks Outweigh Benefits

- Ischaemic disease (eg. CABG, PCI, stent, angioplasty)
- Rhythmic disease (eg. ICD/pacemaker, ablation)

#### Benefits May Outweigh Risks

- Valvular disease (eg. replacement, repairs, TAVI)
- Infective endocarditis (often leads to valvular surgery)
- Heart transplant (heart failure)</formatted_text>
    <images>
      <img order="0" bbox="396,353,539,504" bbox_format="xyxy_norm_1000" bbox_origin="top_left" bbox_space="page" type="clipart">
        <description>A golden illustration of a balance scale, representing the weighing of risks versus benefits.</description>
      </img>
      <img order="1" bbox="45,514,89,569" bbox_format="xyxy_norm_1000" bbox_origin="top_left" bbox_space="page" type="clipart" caption="Ischaemic disease">
        <description>A bold black cross symbol (X) on a white background.</description>
      </img>
      <img order="2" bbox="46,637,89,693" bbox_format="xyxy_norm_1000" bbox_origin="top_left" bbox_space="page" type="clipart" caption="Rhythmic disease">
        <description>A large, bold black cross mark (X) on a white background.</description>
      </img>
      <img order="3" bbox="610,508,642,576" bbox_format="xyxy_norm_1000" bbox_origin="top_left" bbox_space="page" type="clipart" caption="Valvular disease">
        <description>A large, bold black question mark symbol on a white background.</description>
      </img>
      <img order="4" bbox="610,629,642,693" bbox_format="xyxy_norm_1000" bbox_origin="top_left" bbox_space="page" type="clipart" caption="Infective endocarditis">
        <description>A large, black question mark symbol.</description>
      </img>
      <img order="5" bbox="610,723,642,786" bbox_format="xyxy_norm_1000" bbox_origin="top_left" bbox_space="page" type="clipart" caption="Heart transplant (heart failure)">
        <description>A large, bold black question mark symbol.</description>
      </img>
    </images>
  </page>
  <page number="96">
    <text>ISCHAEMIC INDICATIONS – RISKS VS BENEFITS OF PRE-OP DENTAL TREATMENT

Potential benefits:

• **Decrease endogenous catecholamine** release (resulting in increased BP) if patient is in pain

• ?Reduce pre-operative **infection risk** or graft rejection
  • Limited literature regarding dental extractions prior to CABG or heart transplant surgery

→ **lack of clear evidence to support** the reduced risk of post-operative infection (*Meyer et al., 1999*)

96</text>
    <formatted_text>#### Ischaemic Indications – Potential Benefits of Pre-Op Dental Treatment

- Decrease endogenous catecholamine release (resulting in increased BP) if patient is in pain
- ?Reduce pre-operative infection risk or graft rejection
  - Limited literature regarding dental extractions prior to CABG or heart transplant surgery

→ **lack of clear evidence to support** the reduced risk of post-operative infection (*Meyer et al., 1999*)</formatted_text>
    <audio_inserts count="1">
      <insert timestamp="02:00:04" confidence="7" anchor="→ **lack of clear evidence to support** the reduced risk of post-operative infec">

&gt; [!note] Lecturer — Ischaemic Timing
&gt; When cardiac surgery is being performed for an ischaemic indication alone, restoring coronary perfusion through stenting or bypass may reduce cardiac risk.
&gt; 
&gt; - It may therefore be safer to defer elective dental treatment until after perfusion has been restored.
&gt; - Evidence that pre-operative dental treatment reduces infection risk in this setting is limited.
</insert>
    </audio_inserts>
  </page>
  <page number="97">
    <text>Management of perioperative acute pain and infection (pus, swelling, cellulitis) needs to be a joint decision between the dentist and the physicians caring for the patient planned for cardiothoracic

**But when should we treat chronic, asymptomatic pathology?**

**Risks outweigh benefits**

❌ Ischaemic disease
(eg. CABG, PCI, stent, angioplasty)

❌ Rhythmic disease
(eg. ICD/pacemaker, ablation)

Eberhard et al. Journal of Cardiothoracic Surgery 2013, 8:73
http://www.cardiothoracicsurgery.org/content/8/1/73

JCTS JOURNAL OF CARDIOTHORACIC SURGERY

RESEARCH ARTICLE Open Access

The oral cavity is not a primary source for implantable pacemaker or cardioverter defibrillator infections

Jörg Eberhard$^{1*}$, Nico Stumpp$^{1}$, Fadi Ismail$^{1}$, Ulrike Schnaidt$^{1}$, Wieland Heuer$^{1}$, Maximilian Pichlmaier$^{2}$, Christian Kühn$^{2}$, Axel Haverich$^{2}$ and Meike Stiesch$^{1}$

Abstract
Background: To test the hypothesis that the oral cavity is a potential source for implantable pacemaker and cardioverter defibrillators infections, the bacterial diversity on explanted rhythm heart management devices was investigated and compared to the oral microbiome.
Methods: A metagenomic approach was used to analyze the bacterial diversity on the surfaces of non-infected and infected pacemakers. The DNA from surfaces swaps of 24 non-infected and 23 infected pacemaker were isolated and subjected to bacterial-specific DNA amplification, single strand conformation polymorphism- (SSCP) and sequencing analysis. Species-specific primer sets were used to analyze for any correlation between bacterial diversity on pacemakers and in the oral cavity.
Results: DNA of bacterial origin was detected in 21 cases on infected pacemakers and assigned to the bacterial phylotypes *Staphylococcus epidermidis*, *Propionibacterium acnes*, *Staphylococcus aureus*, *Staphylococcus schleiferi* and *Staphylococcus*. In 17 cases bacterial DNA was found on pacemakers with no clinical signs of infections. On the basis of the obtained sequence data, the phylotypes *Propionibacterium acnes*, *Staphylococcus* and an uncultured bacterium were identified. *Propionibacterium acnes* and *Staphylococcus epidermidis* were the only bacteria detected in pacemaker (n = 25) and oral samples (n = 11).
Conclusions: The frequency of the coincidental detection of bacteria on infected devices and in the oral cavity is low and the detected bacteria are highly abundant colonizers of non-oral human niches. The transmission of oral bacteria to the lead or device of implantable pacemaker or cardioverter defibrillators is unlikely relevant for the pathogenesis of pacemaker or cardioverter defibrillators infections.
Keywords: Biofilm, Infection, Pacemaker, Defibrillator, Oral cavity

Dr Jee-Yun Leung

**Benefits may outweigh Risks**

Valvular disease
(eg. replacement, repairs, TAVI)

Infective endocarditis
(often leads to valvular surgery)

Heart transplant (heart failure)</text>
    <formatted_text>Management of perioperative acute pain and infection (pus, swelling, cellulitis) needs to be a joint decision between the dentist and the physicians caring for the patient planned for cardiothoracic surgery.

**But when should we treat chronic, asymptomatic pathology?**

#### Risks Outweigh Benefits

- Ischaemic disease (eg. CABG, PCI, stent, angioplasty)
- Rhythmic disease (eg. ICD/pacemaker, ablation)

#### Benefits May Outweigh Risks

- Valvular disease (eg. replacement, repairs, TAVI)
- Infective endocarditis (often leads to valvular surgery)
- Heart transplant (heart failure)

#### Supporting Evidence: Pacemaker/ICD Infections

*Eberhard et al. Journal of Cardiothoracic Surgery 2013, 8:73. http://www.cardiothoracicsurgery.org/content/8/1/73*

**The oral cavity is not a primary source for implantable pacemaker or cardioverter defibrillator infections** — Jörg Eberhard, Nico Stumpp, Fadi Ismail, Ulrike Schnaidt, Wieland Heuer, Maximilian Pichlmaier, Christian Kühn, Axel Haverich and Meike Stiesch

- **Background:** To test the hypothesis that the oral cavity is a potential source for implantable pacemaker and cardioverter defibrillator infections, the bacterial diversity on explanted rhythm heart management devices was investigated and compared to the oral microbiome.
- **Methods:** A metagenomic approach was used to analyze the bacterial diversity on the surfaces of non-infected and infected pacemakers. The DNA from surface swabs of 24 non-infected and 23 infected pacemakers was isolated and subjected to bacterial-specific DNA amplification, single strand conformation polymorphism- (SSCP) and sequencing analysis. Species-specific primer sets were used to analyze for any correlation between bacterial diversity on pacemakers and in the oral cavity.
- **Results:** DNA of bacterial origin was detected in 21 cases on infected pacemakers and assigned to the bacterial phylotypes *Staphylococcus epidermidis*, *Propionibacterium acnes*, *Staphylococcus aureus*, *Staphylococcus schleiferi* and *Staphylococcus*. In 17 cases bacterial DNA was found on pacemakers with no clinical signs of infections. On the basis of the obtained sequence data, the phylotypes *Propionibacterium acnes*, *Staphylococcus* and an uncultured bacterium were identified. *Propionibacterium acnes* and *Staphylococcus epidermidis* were the only bacteria detected in pacemaker (n = 25) and oral samples (n = 11).
- **Conclusions:** The frequency of the coincidental detection of bacteria on infected devices and in the oral cavity is low and the detected bacteria are highly abundant colonizers of non-oral human niches. The transmission of oral bacteria to the lead or device of implantable pacemaker or cardioverter defibrillators is unlikely relevant for the pathogenesis of pacemaker or cardioverter defibrillator infections.

Keywords: Biofilm, Infection, Pacemaker, Defibrillator, Oral cavity</formatted_text>
    <audio_inserts count="1">
      <insert timestamp="01:34:01" confidence="6" anchor="- **Conclusions:** The frequency of the coincidental detection of bacteria on in">

&gt; [!note] Lecturer — Device Prophylaxis
&gt; The presence of a pacemaker or implantable cardioverter defibrillator alone is not an indication for dental antibiotic prophylaxis.
&gt; 
&gt; - A patient with an implantable cardiac device may be better treated after the cardiac condition is controlled.
</insert>
    </audio_inserts>
    <images>
      <img order="0" bbox="46,514,89,569" bbox_format="xyxy_norm_1000" bbox_origin="top_left" bbox_space="page" type="clipart">
        <description>A simple black cross symbol (X mark) on a white background.</description>
      </img>
      <img order="1" bbox="46,637,89,694" bbox_format="xyxy_norm_1000" bbox_origin="top_left" bbox_space="page" type="clipart">
        <description>A simple black cross mark (X symbol).</description>
      </img>
    </images>
  </page>
  <page number="98">
    <text>Management of perioperative acute pain and infection (pus, swelling, cellulitis) needs to be a joint
decision between the dentist and the physicians caring for the patient planned for cardiothoracic

Original Contributions
Cover Story
Effect of dental treatment before cardiac
valve surgery
Systematic review and meta-analysis

Peter B. Lockhart, DDS, FDS RCPS; Hillary R. DeLong, JD; Ruth D. Lipman, PhD;
Elliot Abt, DDS, MS, MSc; Larry M. Baddour, MD; Monica Colvin, MD, MA;
Craig S. Miller, DMD, MS; Thomas Sollecito, DMD, FDS RCSEd; Kelly O’Brien, MUS;
Cameron G. Estrich, MPH; Marcelo W.B. Araujo, DDS, MS, PhD;
Alonso Carrasco-Labra, DDS, MSc

Check for updates
ADA CE Program
Supplemental material
is available online.

But
asymptomatic pathology?

Risks
Benefits may outweigh Risks

ABSTRACT
Background. The purpose of this systematic review was to determine the potential effect of dental
treatment before cardiac valve surgery (CVS) or left ventricular assist device (LVAD) implantation
on morbidity and mortality.
Types of Studies Reviewed. The authors included relevant studies from MEDLINE, Embase,
and the Cochrane Central Register of Controlled Trials, including randomized controlled trials and
cohort studies, published from 1998 through 2019 and involving adults who received dental
treatment before CVS or LVAD implantation. The authors assessed bias by using the Newcastle-
Ottawa Quality Assessment Scale and evidence certainty by using the Grading of Recommendations
Assessment, Development and Evaluation approach. The authors used a meta-analysis with a
random-effects model to estimate dichotomous and continuous outcomes, expressed as relative risk
(RR) and weighted mean difference.
Results. Six studies met the inclusion criteria for CVS but none for LVAD implantation. Very low
certainty in the evidence suggested uncertainty as to whether health outcomes for patients
undergoing dental treatment before CVS differed from those who did not. Postsurgical outcomes
included all-cause mortality (RR, 1.00; 95% confidence interval [CI], 0.53 to 1.91), infective
endocarditis (RR, 1.30; 95% CI, 0.51 to 3.35), postsurgical infection (RR, 1.01; 95% CI, 0.76 to
1.33), and length of stay in the hospital (weighted mean difference, 2.9; 95% CI, −2.3 to 8.1).
Conclusions and Practical Implications. From the available evidence, it is unclear whether
postoperative outcomes differ in patients receiving dental treatment before CVS compared with
outcomes in those who do not. Dentists and medical care professionals should collaborate on an
appropriate course of action for each patient, weighing any potentially relevant care considerations.
Key Words. Cardiac; pretreatment; medically complex; presurgical; dental clearance.
JADA 2019;150(9):739-747
https://doi.org/10.1016/j.adaj.2019.04.024

JADA
Dental Treatment
Before
Cardiac Valve
Surgery ??

Valvular disease
(eg. replacement, repairs, TAVI)

Infective endocarditis
(often leads to valvular surgery)

Heart transplant (heart failure)

Dr Jee-Yun Leung

![](L1 Cardiovascular Disease and Dentistry_figures/img_8872a2ddd68f8b1d.webp)</text>
    <formatted_text>Management of perioperative acute pain and infection (pus, swelling, cellulitis) needs to be a joint decision between the dentist and the physicians caring for the patient planned for cardiothoracic surgery.

**But when should we treat chronic, asymptomatic pathology?**

#### Risks Outweigh Benefits

#### Benefits May Outweigh Risks

- Valvular disease (eg. replacement, repairs, TAVI)
- Infective endocarditis (often leads to valvular surgery)
- Heart transplant (heart failure)

#### Supporting Evidence: Dental Treatment Before Cardiac Valve Surgery

*Lockhart PB, DeLong HR, Lipman RD, Abt E, Baddour LM, Colvin M, Miller CS, Sollecito T, O'Brien K, Estrich CG, Araujo MWB, Carrasco-Labra A. Effect of dental treatment before cardiac valve surgery: Systematic review and meta-analysis. JADA 2019;150(9):739-747. https://doi.org/10.1016/j.adaj.2019.04.024*

- **Background:** The purpose of this systematic review was to determine the potential effect of dental treatment before cardiac valve surgery (CVS) or left ventricular assist device (LVAD) implantation on morbidity and mortality.
- **Types of Studies Reviewed:** The authors included relevant studies from MEDLINE, Embase, and the Cochrane Central Register of Controlled Trials, including randomized controlled trials and cohort studies, published from 1998 through 2019 and involving adults who received dental treatment before CVS or LVAD implantation. The authors assessed bias by using the Newcastle-Ottawa Quality Assessment Scale and evidence certainty by using the Grading of Recommendations Assessment, Development and Evaluation approach. The authors used a meta-analysis with a random-effects model to estimate dichotomous and continuous outcomes, expressed as relative risk (RR) and weighted mean difference.
- **Results:** Six studies met the inclusion criteria for CVS but none for LVAD implantation. Very low certainty in the evidence suggested uncertainty as to whether health outcomes for patients undergoing dental treatment before CVS differed from those who did not. Postsurgical outcomes included all-cause mortality (RR, 1.00; 95% confidence interval [CI], 0.53 to 1.91), infective endocarditis (RR, 1.30; 95% CI, 0.51 to 3.35), postsurgical infection (RR, 1.01; 95% CI, 0.76 to 1.33), and length of stay in the hospital (weighted mean difference, 2.9; 95% CI, −2.3 to 8.1).
- **Conclusions and Practical Implications:** From the available evidence, it is unclear whether postoperative outcomes differ in patients receiving dental treatment before CVS compared with outcomes in those who do not. Dentists and medical care professionals should collaborate on an appropriate course of action for each patient, weighing any potentially relevant care considerations.

Key Words: Cardiac; pretreatment; medically complex; presurgical; dental clearance.</formatted_text>
    <audio_inserts count="1">
      <insert timestamp="01:55:39" confidence="6" anchor="- **Conclusions and Practical Implications:** From the available evidence, it is">

&gt; [!note] Lecturer — Valve Surgery Decisions
&gt; Cardiologists may be particularly concerned about infective endocarditis in patients undergoing valve surgery.
&gt; 
&gt; - Because infective endocarditis has substantial morbidity and mortality, dental treatment is often undertaken before valve surgery despite uncertainty in the evidence.
</insert>
    </audio_inserts>
    <images>
      <img order="0" bbox="460,649,541,792" bbox_format="xyxy_norm_1000" bbox_origin="top_left" bbox_space="page" type="figure" path="L1 Cardiovascular Disease and Dentistry_figures/img_8872a2ddd68f8b1d.webp">
        <description>Cover of the journal JADA (The Journal of the American Dental Association). The cover features an illustration combining a dental tooth, a stethoscope, and a heart to visually represent the theme of the issue's cover story.</description>
      </img>
    </images>
  </page>
  <page number="99">
    <text>Management of perioperative acute pain and infection (pus, swelling, cellulitis) needs to be a joint decision between the dentist and the physicians caring for the patient planned for cardiothoracic surgery.

Clin Oral Invest (1999) 3:79–83
© Springer-Verlag 1999

ORIGINAL ARTICLE

U. Meyer · D. Weingart · M.C. Deng · H.H. Scheld
U. Joos

Heart transplants – assessment of dental procedures

R
Received: 25 September 1998 / Accepted: 26 February 1999

Abstract The object of this study was to evaluate the effects of dental foci on survival rates and rejection episodes in heart transplant recipients. Therefore, in a retrospective longitudinal study we studied 74 heart transplant recipients at the Department of Maxillofacial Surgery and Department of Thoracic and Cardiovascular Surgery, University of Münster. Study patients were divided into groups: those in which dental foci had been verified (n=31) and those without dental foci (n=43). Statistical analysis was performed using the chi-square test, Kaplan-Meier life table analysis, and the log-rank test. Before heart transplantation, patients were screened clinically and radiographically to determine the extent of dental foci. Postoperatively, patients were evaluated dentally and medically to identify the impact of dental foci on the incidence of systemic and oral infections, frequency and severity of rejection episodes, mortality, and complications arising during dental treatment. By comparing the mortality, infection and rejection rates in the various groups no statistically significant differences (P&gt;0.05) were found between patients. Despite immunosuppression, extended inflammatory processes such as abscess formation or viral stomatitis were not found in the oral cavity. We therefore suggest that patients suffering from the symptoms of severe heart failure need not be subjected to rigorous preoperative dental treatment.

Key words Heart transplant · Dental treatment · Mortality

Introduction
The survival rate of patients after heart transplantation has improved due to recent advances in perioperative management and immunosuppression [7]. Preoperative evaluation includes assessment of dental foci and their subsequent eradication [13, 5, 8]. So far, no study has examined the need for such a radical approach.
Most microorganisms associated with bacteremia in patients with heart transplantation are commensal organisms of the oral cavity [9]. Systemic infections and rejection dramatically decrease the survival rate in patients subjected to heart transplantation. Since odontogenic inflammation may favor transplant rejection [6], cause bacterial endocarditis and may lead to life-threatening postoperative infections [2], all existing or potential sources of dental infection should be eliminated before heart transplantation. To our knowledge, specific guidelines specifying the extent of such dental procedures do not exist. The purpose of this study was to analyze the complication rates in patients in whom dental foci had been verified as compared with patients without dental foci so that the role of these foci on the postoperative outcome of heart transplantation could be determined. The influence of various dental foci on differences in survival and rejection probabilities of heart transplant recipients was investigated to reevaluate our dental treatment protocol.

**chronic, asymptomatic pathology?**

**Benefits may outweigh Risks**

? Valvular disease
(eg. replacement, repairs, TAVI)

? Infective endocarditis
(often leads to valvular surgery)

? Heart transplant (heart failure)

Dr Jee-Yun Leung

![](L1 Cardiovascular Disease and Dentistry_figures/img_e17743a95e2df4f6.webp)</text>
    <formatted_text>Management of perioperative acute pain and infection (pus, swelling, cellulitis) needs to be a joint decision between the dentist and the physicians caring for the patient planned for cardiothoracic surgery.

**But when should we treat chronic, asymptomatic pathology?**

#### Benefits May Outweigh Risks

- Valvular disease (eg. replacement, repairs, TAVI)
- Infective endocarditis (often leads to valvular surgery)
- Heart transplant (heart failure)

#### Supporting Evidence: Heart Transplants – Assessment of Dental Procedures

*Meyer U, Weingart D, Deng MC, Scheld HH, Joos U. Heart transplants – assessment of dental procedures. Clin Oral Invest (1999) 3:79–83. © Springer-Verlag 1999.*

- **Abstract:** The object of this study was to evaluate the effects of dental foci on survival rates and rejection episodes in heart transplant recipients. Therefore, in a retrospective longitudinal study we studied 74 heart transplant recipients at the Department of Maxillofacial Surgery and Department of Thoracic and Cardiovascular Surgery, University of Münster. Study patients were divided into groups: those in which dental foci had been verified (n=31) and those without dental foci (n=43). Statistical analysis was performed using the chi-square test, Kaplan-Meier life table analysis, and the log-rank test. Before heart transplantation, patients were screened clinically and radiographically to determine the extent of dental foci. Postoperatively, patients were evaluated dentally and medically to identify the impact of dental foci on the incidence of systemic and oral infections, frequency and severity of rejection episodes, mortality, and complications arising during dental treatment. By comparing the mortality, infection and rejection rates in the various groups no statistically significant differences (P&gt;0.05) were found between patients. Despite immunosuppression, extended inflammatory processes such as abscess formation or viral stomatitis were not found in the oral cavity. We therefore suggest that patients suffering from the symptoms of severe heart failure need not be subjected to rigorous preoperative dental treatment.

Key words: Heart transplant · Dental treatment · Mortality

- **Introduction:** The survival rate of patients after heart transplantation has improved due to recent advances in perioperative management and immunosuppression. Preoperative evaluation includes assessment of dental foci and their subsequent eradication. So far, no study has examined the need for such a radical approach. Most microorganisms associated with bacteremia in patients with heart transplantation are commensal organisms of the oral cavity. Systemic infections and rejection dramatically decrease the survival rate in patients subjected to heart transplantation. Since odontogenic inflammation may favor transplant rejection, cause bacterial endocarditis and may lead to life-threatening postoperative infections, all existing or potential sources of dental infection should be eliminated before heart transplantation. To our knowledge, specific guidelines specifying the extent of such dental procedures do not exist. The purpose of this study was to analyze the complication rates in patients in whom dental foci had been verified as compared with patients without dental foci so that the role of these foci on the postoperative outcome of heart transplantation could be determined. The influence of various dental foci on differences in survival and rejection probabilities of heart transplant recipients was investigated to reevaluate our dental treatment protocol.</formatted_text>
    <audio_inserts count="1">
      <insert timestamp="01:56:10" confidence="7" anchor="- **Introduction:** The survival rate of patients after heart transplantation ha">

&gt; [!note] Lecturer — Transplant Assessment
&gt; Evidence remains limited regarding whether dental treatment before heart transplantation reduces postoperative infection, mortality, or organ rejection.
&gt; 
&gt; - Patients become immunosuppressed after transplantation to prevent rejection, so infection is a concern.
&gt; - Patients may therefore benefit from dental assessment before transplantation.
</insert>
    </audio_inserts>
    <images>
      <img order="0" bbox="610,509,642,574" bbox_format="xyxy_norm_1000" bbox_origin="top_left" bbox_space="page" type="image" path="L1 Cardiovascular Disease and Dentistry_figures/img_e17743a95e2df4f6.webp"/>
    </images>
  </page>
  <page number="100">
    <text>TO PROCEED OR NOT TO PROCEED?

Dental treatment need

Severity of cardiac disease
(e.g. chest pain at rest, triggers/frequency, number of medications)

Assessing Risk

Type and magnitude of dental procedure

Stability and cardiopulmonary reserve
(functional capacity)

$\rightarrow$ Recommendation: integrated team decision based on individual situation of the patient (stable vs unstable condition)

Dr Jee-Yun Leung

![](L1 Cardiovascular Disease and Dentistry_figures/img_7e2f85c340dfd8a3.webp)</text>
    <formatted_text>#### Assessing Risk

- Dental treatment need
- Severity of cardiac disease (e.g. chest pain at rest, triggers/frequency, number of medications)
- Type and magnitude of dental procedure
- Stability and cardiopulmonary reserve (functional capacity)

→ **Recommendation:** integrated team decision based on individual situation of the patient (stable vs unstable condition)</formatted_text>
    <audio_inserts count="2">
      <insert timestamp="01:57:29" confidence="4" anchor="→ **Recommendation:** integrated team decision based on individual situation of ">

&gt; [!note] Lecturer — Risk Assessment
&gt; Assessment should include the symptoms caused by dental infection and the risk of systemic complications from dental disease.
&gt; 
&gt; - Also consider the treatment burden, the number and type of cardiac medications, and the patient’s functional capacity and cardiopulmonary reserve.
</insert>
      <insert timestamp="02:01:25" confidence="5" anchor="&gt; &quot;IF DENTAL PAIN OR INFECTION OCCURS WITHIN 6 MONTHS FOLLOWING THE EVENT, PROVI">

&gt; [!note] Lecturer — Future Proofing
&gt; Pre-operative dental treatment is not necessarily intended to provide comprehensive dental rehabilitation.
&gt; 
&gt; - Assess how long each dental problem is likely to remain stable and focus on conditions likely to cause problems while elective dental care is deferred.
&gt; - Early caries that is unlikely to cause a problem during the relevant six-month period may not require immediate treatment, because unnecessary treatment adds physiological stress.
</insert>
    </audio_inserts>
    <images>
      <img order="0" bbox="194,236,794,675" bbox_format="xyxy_norm_1000" bbox_origin="top_left" bbox_space="page" type="image" path="L1 Cardiovascular Disease and Dentistry_figures/img_7e2f85c340dfd8a3.webp"/>
    </images>
  </page>
  <page number="101">
    <text>&lt;h2&gt;How far ahead to future proof?&lt;/h2&gt;

“IN THE 12 MONTHS AFTER MYOCARDIAL INFARCTION, STENT PLACEMENT, CORONARY ARTERY BYPASS SURGERY, OR VALVE PROCEDURES (INCLUDING TRANSCATHETER AORTIC VALVE IMPLANTATION [TAVI]), PATIENTS ARE AT INCREASED RISK OF A MAJOR ADVERSE CARDIAC EVENT (EG SUDDEN DEATH).

DEFER ELECTIVE DENTAL TREATMENT FOR 6 MONTHS AFTER MYOCARDIAL INFARCTION, STENT PLACEMENT, CORONARY ARTERY BYPASS SURGERY OR VALVE PROCEDURE.

IF DENTAL PAIN OR INFECTION OCCURS WITHIN 6 MONTHS FOLLOWING THE EVENT, PROVIDE ADEQUATE EMERGENCY TREATMENT BUT AVOID THE USE OF ADRENALINE-CONTAINING LOCAL ANAESTHETICS. CONSIDER SEEKING SPECIALIST ADVICE ABOUT APPROPRIATE TREATMENT AND TIMING OF PROCEDURES.”

&lt;b&gt;Oral &amp; Dental Therapeutic Guidelines v4 2026&lt;/b&gt;

Dr Jee-Yun Leung</text>
    <formatted_text>#### How far ahead to future proof?

&gt; &quot;IN THE 12 MONTHS AFTER MYOCARDIAL INFARCTION, STENT PLACEMENT, CORONARY ARTERY BYPASS SURGERY, OR VALVE PROCEDURES (INCLUDING TRANSCATHETER AORTIC VALVE IMPLANTATION [TAVI]), PATIENTS ARE AT INCREASED RISK OF A MAJOR ADVERSE CARDIAC EVENT (EG SUDDEN DEATH).
&gt;
&gt; DEFER ELECTIVE DENTAL TREATMENT FOR 6 MONTHS AFTER MYOCARDIAL INFARCTION, STENT PLACEMENT, CORONARY ARTERY BYPASS SURGERY OR VALVE PROCEDURE.
&gt;
&gt; IF DENTAL PAIN OR INFECTION OCCURS WITHIN 6 MONTHS FOLLOWING THE EVENT, PROVIDE ADEQUATE EMERGENCY TREATMENT BUT AVOID THE USE OF ADRENALINE-CONTAINING LOCAL ANAESTHETICS. CONSIDER SEEKING SPECIALIST ADVICE ABOUT APPROPRIATE TREATMENT AND TIMING OF PROCEDURES.&quot;

*Oral &amp; Dental Therapeutic Guidelines v4 2026*</formatted_text>
    <audio_inserts count="1">
      <insert timestamp="02:01:07" confidence="6" anchor="*Oral &amp; Dental Therapeutic Guidelines v4 2026*">

&gt; [!note] Lecturer — Emergency Timing
&gt; The six-month deferral reflects historic concerns about reinfarction, mortality, healing of necrotic myocardium, and development of collateral circulation.
&gt; 
&gt; - Emergency treatment during this period may require specialist advice, a medically monitored hospital setting, ECG or pulse oximetry monitoring, and intravenous sedation or an anaesthetist where appropriate.
&gt; - Cardiac rehabilitation and exercise-tolerance testing may help determine recovery and the timing of later dental treatment.
</insert>
    </audio_inserts>
  </page>
  <page number="102">
    <text>THINKING IT THROUGH... CARDIAC SURGERY

**Rationale**
• Does need for dental treatment outweigh the cardiac risks?
• Direct effect on cardiac outcome = Endocarditis risk

**Medical, Dental and Social Considerations**
• Bacteraemia risk of dental pathology
• Amount of treatment patient can tolerate in one go vs risks of performing over multiple visits
• Anticoagulation / antiplatelet drugs (prophylactic vs therapeutic)
• Antibiotic prophylaxis
• Focus on preventive oral hygiene to ↓ daily bacteraemia

Entire or localised areas of the mouth
• Entire dentition

**Optimal Timeframes**
• Urgency for cardiac surgery
• Future-proof for next 6 months (i.e. optimise for the short-term)

**Treatment Approaches**
• Aggressive (e.g. typically insufficient time to assess periapical response to RCT)

Dr Jee-Yun Leung 2025</text>
    <formatted_text>#### Rationale

- Does need for dental treatment outweigh the cardiac risks?
- Direct effect on cardiac outcome = Endocarditis risk

#### Medical, Dental and Social Considerations

- Bacteraemia risk of dental pathology
- Amount of treatment patient can tolerate in one go vs risks of performing over multiple visits
- Anticoagulation / antiplatelet drugs (prophylactic vs therapeutic)
- Antibiotic prophylaxis
- Focus on preventive oral hygiene to ↓ daily bacteraemia
- Entire or localised areas of the mouth — entire dentition

#### Optimal Timeframes

- Urgency for cardiac surgery
- Future-proof for next 6 months (i.e. optimise for the short-term)

#### Treatment Approaches

- Aggressive (e.g. typically insufficient time to assess periapical response to RCT)</formatted_text>
    <audio_inserts count="3">
      <insert timestamp="02:02:21" confidence="3" anchor="- Focus on preventive oral hygiene to ↓ daily bacteraemia
- Entire or localised ">

&gt; [!note] Lecturer — Treatment Burden
&gt; If many teeth require removal, the patient may not tolerate complete treatment in one appointment.
&gt; 
&gt; - Spreading treatment across appointments may increase the number of episodes requiring antibiotic prophylaxis and anticoagulant considerations.
&gt; - The medical, dental, and social context should be considered together.
</insert>
      <insert timestamp="02:02:56" confidence="5" anchor="- Aggressive (e.g. typically insufficient time to assess periapical response to ">

&gt; [!note] Lecturer — Aggressive Treatment
&gt; For a tooth with infection, extraction may provide a more definitive treatment than root canal treatment when there is insufficient time to assess the periapical response.
&gt; 
&gt; - The aim is to address dental conditions most likely to cause problems while elective treatment will be deferred.
&gt; - Preventive care and oral hygiene remain important, but treatment should be proportionate to the cardiac situation and the patient’s capacity.
</insert>
      <insert timestamp="00:08:05" confidence="4" anchor="## **Questions**">

&gt; [!note] Lecturer — Clinical Framework
&gt; Study by applying a consistent framework rather than memorising every list or table.
&gt; 
&gt; - Use definition, aetiology and epidemiology, general manifestations and management, oral manifestations and management, risk assessment, and access, communication, consent, education, surgery, and spread.
&gt; - Clinical questions may use patient cases, so apply the framework to a scenario and consider what happens when a patient returns to general dental practice after hospital treatment.
</insert>
    </audio_inserts>
  </page>
  <page number="103">
    <text>**QUESTIONS?**

Jeeyun.leung@uwa.edu.au</text>
    <formatted_text>Jeeyun.leung@uwa.edu.au</formatted_text>
  </page>
  <footnotes>[^1]: Original PDF page 1: [[L1 Cardiovascular Disease and Dentistry.pdf#page=1|L1 Cardiovascular Disease and Dentistry, p.1]]
[^2]: Original PDF page 2: [[L1 Cardiovascular Disease and Dentistry.pdf#page=2|L1 Cardiovascular Disease and Dentistry, p.2]]
[^3]: Original PDF page 3: [[L1 Cardiovascular Disease and Dentistry.pdf#page=3|L1 Cardiovascular Disease and Dentistry, p.3]]
[^4]: Original PDF page 4: [[L1 Cardiovascular Disease and Dentistry.pdf#page=4|L1 Cardiovascular Disease and Dentistry, p.4]]
[^5]: Original PDF page 5: [[L1 Cardiovascular Disease and Dentistry.pdf#page=5|L1 Cardiovascular Disease and Dentistry, p.5]]
[^6]: Original PDF page 6: [[L1 Cardiovascular Disease and Dentistry.pdf#page=6|L1 Cardiovascular Disease and Dentistry, p.6]]
[^7]: Original PDF page 7: [[L1 Cardiovascular Disease and Dentistry.pdf#page=7|L1 Cardiovascular Disease and Dentistry, p.7]]
[^8]: Original PDF page 8: [[L1 Cardiovascular Disease and Dentistry.pdf#page=8|L1 Cardiovascular Disease and Dentistry, p.8]]
[^9]: Original PDF page 9: [[L1 Cardiovascular Disease and Dentistry.pdf#page=9|L1 Cardiovascular Disease and Dentistry, p.9]]
[^10]: Original PDF page 10: [[L1 Cardiovascular Disease and Dentistry.pdf#page=10|L1 Cardiovascular Disease and Dentistry, p.10]]
[^11]: Original PDF page 11: [[L1 Cardiovascular Disease and Dentistry.pdf#page=11|L1 Cardiovascular Disease and Dentistry, p.11]]
[^12]: Original PDF page 12: [[L1 Cardiovascular Disease and Dentistry.pdf#page=12|L1 Cardiovascular Disease and Dentistry, p.12]]
[^13]: Original PDF page 13: [[L1 Cardiovascular Disease and Dentistry.pdf#page=13|L1 Cardiovascular Disease and Dentistry, p.13]]
[^14]: Original PDF page 14: [[L1 Cardiovascular Disease and Dentistry.pdf#page=14|L1 Cardiovascular Disease and Dentistry, p.14]]
[^15]: Original PDF page 15: [[L1 Cardiovascular Disease and Dentistry.pdf#page=15|L1 Cardiovascular Disease and Dentistry, p.15]]
[^16]: Original PDF page 16: [[L1 Cardiovascular Disease and Dentistry.pdf#page=16|L1 Cardiovascular Disease and Dentistry, p.16]]
[^17]: Original PDF page 17: [[L1 Cardiovascular Disease and Dentistry.pdf#page=17|L1 Cardiovascular Disease and Dentistry, p.17]]
[^18]: Original PDF page 18: [[L1 Cardiovascular Disease and Dentistry.pdf#page=18|L1 Cardiovascular Disease and Dentistry, p.18]]
[^19]: Original PDF page 19: [[L1 Cardiovascular Disease and Dentistry.pdf#page=19|L1 Cardiovascular Disease and Dentistry, p.19]]
[^20]: Original PDF page 20: [[L1 Cardiovascular Disease and Dentistry.pdf#page=20|L1 Cardiovascular Disease and Dentistry, p.20]]
[^21]: Original PDF page 21: [[L1 Cardiovascular Disease and Dentistry.pdf#page=21|L1 Cardiovascular Disease and Dentistry, p.21]]
[^22]: Original PDF page 22: [[L1 Cardiovascular Disease and Dentistry.pdf#page=22|L1 Cardiovascular Disease and Dentistry, p.22]]
[^23]: Original PDF page 23: [[L1 Cardiovascular Disease and Dentistry.pdf#page=23|L1 Cardiovascular Disease and Dentistry, p.23]]
[^24]: Original PDF page 24: [[L1 Cardiovascular Disease and Dentistry.pdf#page=24|L1 Cardiovascular Disease and Dentistry, p.24]]
[^25]: Original PDF page 25: [[L1 Cardiovascular Disease and Dentistry.pdf#page=25|L1 Cardiovascular Disease and Dentistry, p.25]]
[^26]: Original PDF page 26: [[L1 Cardiovascular Disease and Dentistry.pdf#page=26|L1 Cardiovascular Disease and Dentistry, p.26]]
[^27]: Original PDF page 27: [[L1 Cardiovascular Disease and Dentistry.pdf#page=27|L1 Cardiovascular Disease and Dentistry, p.27]]
[^28]: Original PDF page 28: [[L1 Cardiovascular Disease and Dentistry.pdf#page=28|L1 Cardiovascular Disease and Dentistry, p.28]]
[^29]: Original PDF page 29: [[L1 Cardiovascular Disease and Dentistry.pdf#page=29|L1 Cardiovascular Disease and Dentistry, p.29]]
[^30]: Original PDF page 30: [[L1 Cardiovascular Disease and Dentistry.pdf#page=30|L1 Cardiovascular Disease and Dentistry, p.30]]
[^31]: Original PDF page 31: [[L1 Cardiovascular Disease and Dentistry.pdf#page=31|L1 Cardiovascular Disease and Dentistry, p.31]]
[^32]: Original PDF page 32: [[L1 Cardiovascular Disease and Dentistry.pdf#page=32|L1 Cardiovascular Disease and Dentistry, p.32]]
[^33]: Original PDF page 33: [[L1 Cardiovascular Disease and Dentistry.pdf#page=33|L1 Cardiovascular Disease and Dentistry, p.33]]
[^34]: Original PDF page 34: [[L1 Cardiovascular Disease and Dentistry.pdf#page=34|L1 Cardiovascular Disease and Dentistry, p.34]]
[^35]: Original PDF page 35: [[L1 Cardiovascular Disease and Dentistry.pdf#page=35|L1 Cardiovascular Disease and Dentistry, p.35]]
[^36]: Original PDF page 36: [[L1 Cardiovascular Disease and Dentistry.pdf#page=36|L1 Cardiovascular Disease and Dentistry, p.36]]
[^37]: Original PDF page 37: [[L1 Cardiovascular Disease and Dentistry.pdf#page=37|L1 Cardiovascular Disease and Dentistry, p.37]]
[^38]: Original PDF page 38: [[L1 Cardiovascular Disease and Dentistry.pdf#page=38|L1 Cardiovascular Disease and Dentistry, p.38]]
[^39]: Original PDF page 39: [[L1 Cardiovascular Disease and Dentistry.pdf#page=39|L1 Cardiovascular Disease and Dentistry, p.39]]
[^40]: Original PDF page 40: [[L1 Cardiovascular Disease and Dentistry.pdf#page=40|L1 Cardiovascular Disease and Dentistry, p.40]]
[^41]: Original PDF page 41: [[L1 Cardiovascular Disease and Dentistry.pdf#page=41|L1 Cardiovascular Disease and Dentistry, p.41]]
[^42]: Original PDF page 42: [[L1 Cardiovascular Disease and Dentistry.pdf#page=42|L1 Cardiovascular Disease and Dentistry, p.42]]
[^43]: Original PDF page 43: [[L1 Cardiovascular Disease and Dentistry.pdf#page=43|L1 Cardiovascular Disease and Dentistry, p.43]]
[^44]: Original PDF page 44: [[L1 Cardiovascular Disease and Dentistry.pdf#page=44|L1 Cardiovascular Disease and Dentistry, p.44]]
[^45]: Original PDF page 45: [[L1 Cardiovascular Disease and Dentistry.pdf#page=45|L1 Cardiovascular Disease and Dentistry, p.45]]
[^46]: Original PDF page 46: [[L1 Cardiovascular Disease and Dentistry.pdf#page=46|L1 Cardiovascular Disease and Dentistry, p.46]]
[^47]: Original PDF page 47: [[L1 Cardiovascular Disease and Dentistry.pdf#page=47|L1 Cardiovascular Disease and Dentistry, p.47]]
[^48]: Original PDF page 48: [[L1 Cardiovascular Disease and Dentistry.pdf#page=48|L1 Cardiovascular Disease and Dentistry, p.48]]
[^49]: Original PDF page 49: [[L1 Cardiovascular Disease and Dentistry.pdf#page=49|L1 Cardiovascular Disease and Dentistry, p.49]]
[^50]: Original PDF page 50: [[L1 Cardiovascular Disease and Dentistry.pdf#page=50|L1 Cardiovascular Disease and Dentistry, p.50]]
[^51]: Original PDF page 51: [[L1 Cardiovascular Disease and Dentistry.pdf#page=51|L1 Cardiovascular Disease and Dentistry, p.51]]
[^52]: Original PDF page 52: [[L1 Cardiovascular Disease and Dentistry.pdf#page=52|L1 Cardiovascular Disease and Dentistry, p.52]]
[^53]: Original PDF page 53: [[L1 Cardiovascular Disease and Dentistry.pdf#page=53|L1 Cardiovascular Disease and Dentistry, p.53]]
[^54]: Original PDF page 54: [[L1 Cardiovascular Disease and Dentistry.pdf#page=54|L1 Cardiovascular Disease and Dentistry, p.54]]
[^55]: Original PDF page 55: [[L1 Cardiovascular Disease and Dentistry.pdf#page=55|L1 Cardiovascular Disease and Dentistry, p.55]]
[^56]: Original PDF page 56: [[L1 Cardiovascular Disease and Dentistry.pdf#page=56|L1 Cardiovascular Disease and Dentistry, p.56]]
[^57]: Original PDF page 57: [[L1 Cardiovascular Disease and Dentistry.pdf#page=57|L1 Cardiovascular Disease and Dentistry, p.57]]
[^58]: Original PDF page 58: [[L1 Cardiovascular Disease and Dentistry.pdf#page=58|L1 Cardiovascular Disease and Dentistry, p.58]]
[^59]: Original PDF page 59: [[L1 Cardiovascular Disease and Dentistry.pdf#page=59|L1 Cardiovascular Disease and Dentistry, p.59]]
[^60]: Original PDF page 60: [[L1 Cardiovascular Disease and Dentistry.pdf#page=60|L1 Cardiovascular Disease and Dentistry, p.60]]
[^61]: Original PDF page 61: [[L1 Cardiovascular Disease and Dentistry.pdf#page=61|L1 Cardiovascular Disease and Dentistry, p.61]]
[^62]: Original PDF page 62: [[L1 Cardiovascular Disease and Dentistry.pdf#page=62|L1 Cardiovascular Disease and Dentistry, p.62]]
[^63]: Original PDF page 63: [[L1 Cardiovascular Disease and Dentistry.pdf#page=63|L1 Cardiovascular Disease and Dentistry, p.63]]
[^64]: Original PDF page 64: [[L1 Cardiovascular Disease and Dentistry.pdf#page=64|L1 Cardiovascular Disease and Dentistry, p.64]]
[^65]: Original PDF page 65: [[L1 Cardiovascular Disease and Dentistry.pdf#page=65|L1 Cardiovascular Disease and Dentistry, p.65]]
[^66]: Original PDF page 66: [[L1 Cardiovascular Disease and Dentistry.pdf#page=66|L1 Cardiovascular Disease and Dentistry, p.66]]
[^67]: Original PDF page 67: [[L1 Cardiovascular Disease and Dentistry.pdf#page=67|L1 Cardiovascular Disease and Dentistry, p.67]]
[^68]: Original PDF page 68: [[L1 Cardiovascular Disease and Dentistry.pdf#page=68|L1 Cardiovascular Disease and Dentistry, p.68]]
[^69]: Original PDF page 69: [[L1 Cardiovascular Disease and Dentistry.pdf#page=69|L1 Cardiovascular Disease and Dentistry, p.69]]
[^70]: Original PDF page 70: [[L1 Cardiovascular Disease and Dentistry.pdf#page=70|L1 Cardiovascular Disease and Dentistry, p.70]]
[^71]: Original PDF page 71: [[L1 Cardiovascular Disease and Dentistry.pdf#page=71|L1 Cardiovascular Disease and Dentistry, p.71]]
[^72]: Original PDF page 72: [[L1 Cardiovascular Disease and Dentistry.pdf#page=72|L1 Cardiovascular Disease and Dentistry, p.72]]
[^73]: Original PDF page 73: [[L1 Cardiovascular Disease and Dentistry.pdf#page=73|L1 Cardiovascular Disease and Dentistry, p.73]]
[^74]: Original PDF page 74: [[L1 Cardiovascular Disease and Dentistry.pdf#page=74|L1 Cardiovascular Disease and Dentistry, p.74]]
[^75]: Original PDF page 75: [[L1 Cardiovascular Disease and Dentistry.pdf#page=75|L1 Cardiovascular Disease and Dentistry, p.75]]
[^76]: Original PDF page 76: [[L1 Cardiovascular Disease and Dentistry.pdf#page=76|L1 Cardiovascular Disease and Dentistry, p.76]]
[^77]: Original PDF page 77: [[L1 Cardiovascular Disease and Dentistry.pdf#page=77|L1 Cardiovascular Disease and Dentistry, p.77]]
[^78]: Original PDF page 78: [[L1 Cardiovascular Disease and Dentistry.pdf#page=78|L1 Cardiovascular Disease and Dentistry, p.78]]
[^79]: Original PDF page 79: [[L1 Cardiovascular Disease and Dentistry.pdf#page=79|L1 Cardiovascular Disease and Dentistry, p.79]]
[^80]: Original PDF page 80: [[L1 Cardiovascular Disease and Dentistry.pdf#page=80|L1 Cardiovascular Disease and Dentistry, p.80]]
[^81]: Original PDF page 81: [[L1 Cardiovascular Disease and Dentistry.pdf#page=81|L1 Cardiovascular Disease and Dentistry, p.81]]
[^82]: Original PDF page 82: [[L1 Cardiovascular Disease and Dentistry.pdf#page=82|L1 Cardiovascular Disease and Dentistry, p.82]]
[^83]: Original PDF page 83: [[L1 Cardiovascular Disease and Dentistry.pdf#page=83|L1 Cardiovascular Disease and Dentistry, p.83]]
[^84]: Original PDF page 84: [[L1 Cardiovascular Disease and Dentistry.pdf#page=84|L1 Cardiovascular Disease and Dentistry, p.84]]
[^85]: Original PDF page 85: [[L1 Cardiovascular Disease and Dentistry.pdf#page=85|L1 Cardiovascular Disease and Dentistry, p.85]]
[^86]: Original PDF page 86: [[L1 Cardiovascular Disease and Dentistry.pdf#page=86|L1 Cardiovascular Disease and Dentistry, p.86]]
[^87]: Original PDF page 87: [[L1 Cardiovascular Disease and Dentistry.pdf#page=87|L1 Cardiovascular Disease and Dentistry, p.87]]
[^88]: Original PDF page 88: [[L1 Cardiovascular Disease and Dentistry.pdf#page=88|L1 Cardiovascular Disease and Dentistry, p.88]]
[^89]: Original PDF page 89: [[L1 Cardiovascular Disease and Dentistry.pdf#page=89|L1 Cardiovascular Disease and Dentistry, p.89]]
[^90]: Original PDF page 90: [[L1 Cardiovascular Disease and Dentistry.pdf#page=90|L1 Cardiovascular Disease and Dentistry, p.90]]
[^91]: Original PDF page 91: [[L1 Cardiovascular Disease and Dentistry.pdf#page=91|L1 Cardiovascular Disease and Dentistry, p.91]]
[^92]: Original PDF page 92: [[L1 Cardiovascular Disease and Dentistry.pdf#page=92|L1 Cardiovascular Disease and Dentistry, p.92]]
[^93]: Original PDF page 93: [[L1 Cardiovascular Disease and Dentistry.pdf#page=93|L1 Cardiovascular Disease and Dentistry, p.93]]
[^94]: Original PDF page 94: [[L1 Cardiovascular Disease and Dentistry.pdf#page=94|L1 Cardiovascular Disease and Dentistry, p.94]]
[^95]: Original PDF page 95: [[L1 Cardiovascular Disease and Dentistry.pdf#page=95|L1 Cardiovascular Disease and Dentistry, p.95]]
[^96]: Original PDF page 96: [[L1 Cardiovascular Disease and Dentistry.pdf#page=96|L1 Cardiovascular Disease and Dentistry, p.96]]
[^97]: Original PDF page 97: [[L1 Cardiovascular Disease and Dentistry.pdf#page=97|L1 Cardiovascular Disease and Dentistry, p.97]]
[^98]: Original PDF page 98: [[L1 Cardiovascular Disease and Dentistry.pdf#page=98|L1 Cardiovascular Disease and Dentistry, p.98]]
[^99]: Original PDF page 99: [[L1 Cardiovascular Disease and Dentistry.pdf#page=99|L1 Cardiovascular Disease and Dentistry, p.99]]
[^100]: Original PDF page 100: [[L1 Cardiovascular Disease and Dentistry.pdf#page=100|L1 Cardiovascular Disease and Dentistry, p.100]]
[^101]: Original PDF page 101: [[L1 Cardiovascular Disease and Dentistry.pdf#page=101|L1 Cardiovascular Disease and Dentistry, p.101]]
[^102]: Original PDF page 102: [[L1 Cardiovascular Disease and Dentistry.pdf#page=102|L1 Cardiovascular Disease and Dentistry, p.102]]
[^103]: Original PDF page 103: [[L1 Cardiovascular Disease and Dentistry.pdf#page=103|L1 Cardiovascular Disease and Dentistry, p.103]]</footnotes>
</document>
